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ABSTRACT 
 
Transmissible spongiform encephalopathies (TSEs) represent a unique category of 
diseases known as protein misfolding diseases.  Pathogenesis is dependent on the misfolding of 
normal cellular prion protein (PrPC), which is thought to occur following physical interaction 
with the infectious conformation PrPSc and a yet unknown cofactor molecule(s).  Most common 
immunotherapeutic strategies involve targeting an immune response against the PrPC protein 
since evidence has shown that functional membrane-expressed PrPC is an absolute requirement 
for the development of a prion infection.  As of yet, however, the true function of PrPC is not 
known, therefore, stimulating such an immune response against this widely-expressed cell 
membrane protein may have harmful consequences.  Targeting the PrPSc conformation avoids 
the potential initiation of an autoimmune response and may circumvent PrPC tolerance 
mechanisms allowing for a greater Ab mediated immune response; thus representing a safer, 
and more effective, immunotherapeutic strategy.             
 A weakly immunogenic PrPC epitope (YYR), which induces antibodies specific for the 
PrPSc conformation, was used as the starting point for the development of a prion vaccine.  By 
optimizing epitope design, as well as vaccine formulation and delivery, immunogenicity was 
enhanced while PrPSc-specificity was retained.  One epitope in particular, 
QVYYRPVDQYSNQN, when created as a genetic fusion with the leukotoxin carrier molecule, 
appeared to be an immunogenic vaccine candidate.  The immune response following two 
vaccinations with this construct induced a robust and sustained serum PrPSc-specific IgG 
antibody response.  Specific antibody was also detected in the nasal secretions and cerebral 
spinal fluid of vaccinated animals.  Allowing for the possibility that epitope spreading may 
occur, resulting in the production of auto-reactive anti-PrPC antibodies, both ELISA and 
immunoprecipitation experiments were performed and were unable to detect the presence of 
anti-PrPC antibodies.  Altogether the evidence suggests that this epitope may be a good 
candidate for the development of a TSE vaccine.   
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 1 
 
1.0   LITERATURE REVIEW 
 
Although trillions of dollars have been invested in the development of antibiotics, 
antivirals and vaccines, infectious diseases are still responsible for 22% of all human deaths 
(http://apps.who.int/tdr/svc/publications/tdr-research-publications/globalization-infectious-
diseases.  Traditionally, these infectious diseases were limited to the categories of bacterial, 
viral, fungal and parasitic.  Disease caused by each category of infectious agent reflects the 
unique biological interaction between the agent and the host.  In spite of these differences, these 
agents are all unified by the utilization of genetic material for protein expression and replication 
of the agent.  More recently, a novel infectious agent which lacks its own genome and is 
capable of causing devastating pathology in both humans and animals, has been identified.  
Specifically, following the efforts of anthropologists, pathologists and physicians in Papua New 
Guinea during the 1950’s, a unique neurological disease, Kuru, afflicting the indigenous Fore 
tribes, was discovered.  Initially described as being caused by a “slow” virus, further research in 
the 1970’s revealed that this new agent lacked the qualifying features (nucleic acid) necessary 
for its classification as a virus.  This was later termed by Stanley Prusiner as a proteinaceous 
infectious agent or “prion”.  Consequently, after much resistance from the scientific 
community, it was established that a new class of infectious agent had been discovered.              
  
1.1  Prions 
 
1.1.1  Prions as Infectious Agents 
 
 The discovery of Kuru stimulated research leading to the identification of a group of 
neurodegenerative disorders referred to as transmissible spongiform encephalopathies (TSEs).  
The concept of “slow viruses” was first described by Sigurdsson while researching  
neurodegenerative disease in sheep (Sigurdsson, 1954).  Later, in 1959, a veterinary pathologist 
Hadlow, hypothesized that Kuru and Scrapie were related disorders.  At the same time, similar 
assumptions about Kuru and another neurodegenerative disease that was called Creutzfeldt-
Jacob disease were made (Klatzo et al., 1959).  The work by Gajdusek’s group changed the 
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ideology regarding the cause of neurodegenerative disorders when they successfully transmitted 
Kuru to chimpanzees (Gajdusek et al., 1966).  This indicated that a transmissible agent was 
responsible for the disease (Gibbs et al., 1968).  
 Following the logic that the observed neurodegeneration was due to an infectious agent, 
an exhaustive search for the traditional signs of an infectious agent began.  Populations of T and 
B-cells were analyzed in both Scrapie-infected and control mice, but no differences between the 
experimental and control groups were detected (Garfin et al., 1978).  Experiments looking at 
the potential influence that B-cell maturation may have on Scrapie infections showed no 
difference in disease incubation or progression between infected wild-type mice and infected 
mice deficient in mature B-cells (Kasper et al., 1982).  Therefore, B-cell maturation did not 
appear to play a role in the Scrapie disease process.  Attempts to detect a Scrapie-induced 
humoral response by immunofluorescence, neutralization and precipitation all failed (Kasper et 
al., 1981).  What was determined, however, was that Scrapie infections appeared to involve the 
lymphoreticular system (Stites et al., 1979).  Independent of the site of inoculation, high 
Scrapie titers were detectable in the spleen and other lymphoid organs (Dickinson and Fraser, 
1969).   
While many researchers had shown Scrapie was a transmissible disease, extensive 
research was indicating that the Scrapie agent behaved in a fashion that was distinct from 
known infectious organisms.  With Scrapie infection studies producing perplexing results, 
Stanley Prusiner focused his work on characterizing the infectious component of these 
seemingly linked neurodegenerative disorders.  Sedimentation experiments demonstrated that 
the Scrapie agent aggregated with cellular components (Prusiner et al., 1980), and was stable in 
non-ionic and anionic detergents (Prusiner, 1982).  Other experiments revealed it to be a 
hydrophobic molecule, a characteristic that complicates purification procedures and allows for 
extreme heat stability (Prusiner et al., 1978).  Several key pieces of evidence indicated that one 
of the required components of infectivity was a protein; digestion with proteinase K or protein 
denaturation via sodium dodecyl sulfate (SDS), trypsin, phenol, urea and chaotropic salts all led 
to a loss of infectivity (Prusiner et al., 1981).  
Early attempts to identify the genetic component associated with the Scrapie agent 
began with pH stability studies.  Infectious material was inactivated at alkaline pH, whereas 
acidic treatments had no effect (Prusiner, 1982).  Because alkali conditions disrupt both 
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proteins and nucleic acid, the results were unable to rule out the presence of nucleic acids in 
association with the Scrapie agent (Prusiner, 1982).  Further experiments, in particular ones that 
determined the Scrapie agent was resistant to nuclease digestion and ultraviolet irradiation, 
suggested there was no nucleic acid content in the Scrapie agent (Prusiner, 1982).  Collectively, 
the extensive molecular analysis determined that the Scrapie agent was different from plasmids, 
viroids, and viruses.  Specifically, its resistance to nucleic acid degradation treatments, small 
size, and resistance to heat inactivation suggested the Scrapie agent to be a new type of 
infectious agent.  Prusiner labelled these agents as “prions” which he defined as “small 
proteinaceous infectious particles which are resistant to inactivation by most procedures that 
modify nucleic acids” (Prusiner, 1982).                 
 
1.1.2  Cellular PrP  
 
Human PrPC, a 253 amino acid protein, is encoded by the prion gene Prnp located on 
the short arm of chromosome 20.  In addition to regulatory regions such as heat shock elements, 
Prnp is composed of three exons (Haigh et al., 2007).  The discovery that the entire open 
reading frame is contained within a single exon (the third one) helped eliminate the possibility 
that PrPSc is produced by alternative RNA splicing (Basler et al., 1986).  Little is known 
regarding the regulation of this gene other than the entire first intron is required for full 
promoter activity (Inoue et al., 1997) and that the heat shock elements are responsible for up-
regulation of expression during periods of cellular stress (Shyu et al., 2000).  In 2007 it was 
shown that in the absence of intron 1, exon 1 decreased the activity of the promoter.  This 
suggested that different control mechanisms may be utilized based on the cellular requirements, 
and that targeting intron 1, to reduce PrPC expression in Scrapie infected animals, may help to 
slow disease progression (Haigh et al., 2007).       
 
1.1.2.1  PrPC Structure 
 
 The cellular prion protein (PrPC) is a membrane protein containing a 
glycosylphosphatidyl inositol (GPI) anchor and is highly conserved amongst mammalian 
species.  PrPC mRNA is constitutively expressed in many different tissues with the highest 
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levels of PrPC mRNA expression in the neurons (Kretzschmar et al., 1986) but there are also 
significant levels of expression in the heart (Brown et al., 1990), skeletal muscle (Bosque et al., 
2002; Brown et al., 1998), lymphoid tissue/white blood cells (Liu et al., 2001; Paltrinieri et al., 
2004), gut tissues (Morel et al., 2004), and reproductive tissues such as the testes and uterus 
(Tanji et al., 1995).  Before PrPC is delivered to the outer cell membrane, it is targeted to the 
endoplasmic reticulum (ER) where the N-terminal signal peptide is cleaved and a GPI anchor is 
added to the C-terminus at serine 231, creating a 209 amino acid protein (Hope et al., 1986).  
Once at the outer membrane, PrP associates with lipid rafts and is cycled between the cell 
surface and the endocytic compartment at approximately 60 minute intervals with 95% of the 
internalized protein getting recycled back to the cell surface (Shyng et al., 1993).  Nuclear 
magnetic resonance (NMR) studies have determined that PrPC has a flexible N-terminal 
unstructured domain which contains four octapeptide-repeat regions, and a globular C-terminal 
domain consisting of three α–helices and two anti-parallel β–sheet structures [Figure 1.1 a, 
b](Riek et al., 1996).  There is a hydrophobic sequence in the middle of the protein from amino 
acids 113-135 which some suggest may serve as a transmembrane domain in some prion 
isoforms (Bartz et al., 2000).  Additionally, there is a single disulphide bond between cysteine 
residues 179 and 214 and two N-glycosylation sites at asparagine residues 182 and 198 (Cappai 
and Collins, 2004).     
 Prion structural comparisons among species (human, Syrian hamster and bovine) 
indicate great similarity, which is anticipated with 90% sequence homology (Alonso et al., 
2002).  Cervid PrP, however, contains a unique and well defined rigid loop located between α-
helix 2 and the connecting β-strand (amino acids 166-175) [Figure 1.2 a, b].  This same region 
in other species is flexible and disordered.  Further investigations revealed that the rigidity of 
the loop in cervids is due to a two amino acid substitution S170N and N174T (Sigurdson and 
Aguzzi, 2007).  Structural differences in PrPC have been shown to influence species 
susceptibility to PrPSc.  Consequently, it has been hypothesized that the rigid loop structure in 
cervid PrP may be a contributing factor to the rapid horizontal CWD transmission observed in 
wild populations (Sigurdson and Aguzzi, 2007).        
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 a) 
   
 b)  
                 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Structural features of PrPC.  a) Representation of the primary structure of PrPC 
and its post-translational modifications.  The numbers indicate amino acid position within the 
protein.  OR (green) refers to the flexible octapeptide repeat region.  CC (pink) shows the 
charged cluster.  HC (green) is the hydrophobic core.  The approximate cutting sites of 
proteinase K (PK) are indicated by the black arrows.  Blue arrows represent the β-sheets while 
orange loops depict the α-helices.  GPI is the glycosyl phosphatidyl inositol anchor and MA is 
the membrane anchor.  b) Tertiary structure of PrPC based on NMR spectroscopy including 
unstructured N-terminal and globular C-terminal domains.  The α-helices are in red and the β-
sheets are in blue.  Adapted from references (Aguzzi and Heikenwalder, 2006).  Permission 
from the publisher was granted for use of this material.  
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Figure 2
Structural features and biochemical properties of the cellular prion protein. (a) Scheme of the primary
structure of the cellular prion protein and its posttranslational modifications. A secretory signal peptide
resides at the extreme N terminus. The numbers describe the positions of the respective amino acids.
The proteinase K (PK)-resistant core of PrPSc is depicted in gray; the approximate cutting site of PK
within PrPSc is i dicated by arrows. CC (pink), charged cluster; HC (green), hydrophobic core; S-S, single
disulfide bridge; MA, membrane anchor region; GPI, glycosyl phosphatidyl inositol; CHO, facultative
glycosylation sites; NMR nuclear magnetic resonance. (b) Tertiary structure of the cellular prion protein,
as deduced from NMR spectroscopy, inserted into a lipid bilayer, including the unstructured N-terminal
tail (gray) and the GPI anchor. The α-helices are indicated in red; the antiparallel β-sheets are shown in
turquoise. Sugar residues are shown as colored small circles. See figure for biochemical properties of
PrPC and PrPSc. Figure adapted with permission from References 24 and 25.
to mediate neurotoxicity of the pathological
prion protein in vitro (38).
In addition to the expression of PrPC in
the CNS, on circulating (e.g., T and B cells)
and resident cells of the immune system (e.g.,
FDCs), PrPC is also expressed on long-term
repopulating hematopoietic stem cells (39).
There it is believed to positively regulate the
proliferation of neural precursors during de-
velopmental and adult mammalian neuroge-
nesis (40). Whatever the function of PrPC is,
upon conversion to PrPSc it may be altered,
and this may constitute a plausible cause of
neurodegeneration (35).
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a)       b) 
                     
 
 
 
 
 
 
Figure 1.2: Cervid PrPC structure.  (a) NMR structure for elk prion protein.  HA, HB and HC 
indicate the location α-helix 1, 2 and 3 respectively.  Adapted from (Gossert et al., 2005) using 
iMol.  (b) Prion loop structural representations for both mice and elk corresponding to amino 
acids 165-174, a region between β-sheet 2 and α-helix 2.  In most species the loop region is 
entirely flexible, however in elk and deer the same region is rigid.  Adapted from (Aguzzi and 
Heikenwalder, 2006).  Permission from the publisher was granted for use of this material. 
 
 
 
 
 
 
 
 
 
 7 
1.1.2.2  PrPC Function 
 
 Despite the highly conserved sequence across species and ubiquitous expression within 
the body, little is known about the actual function of PrPC.  It has been hypothesized, however, 
that the prion protein may be involved in the following biological processes: copper 
metabolism, due to its binding affinity of copper; neuroprotective function due to its anti-
apoptotic activity (Bounhar et al., 2001; Diarra-Mehrpour et al., 2004); signal transduction 
(Koch et al., 1991; Mouillet-Richard et al., 2000); synapse formation/function (Aguzzi et al., 
2008a) and neuritogenesis (Graner et al., 2000). 
 Copper has an important physiological role in all organisms, functioning as a cofactor in 
processes such as oxidative stress protection, blood clotting, normal cell growth and 
development, respiration, and iron transport (Puig and Thiele, 2002).  Insufficient copper 
concentrations in humans have been linked to serious diseases which include Menkes syndrome 
(Harrison and Dameron, 1999), as well as various neurodegenerative disorders such as 
Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and transmissible spongiform 
encephalopathies (TSEs) (Waggoner et al., 1999).  Numerous studies have shown that the 
histidine-containing octapeptide repeat region of the PrPC protein is capable of binding up to 
four Cu2+ ions (Walter et al., 2006).  These copper ions stimulate a conformational change in 
PrPC, resulting in a structure that has some conserved characteristics similar to the infectious 
conformation, including a higher β–sheet content, increased protease resistance, a propensity 
for aggregation, but the structure is still distinct from the PrPSc isoform (Quaglio et al., 2001).  
It was also found that micromolar concentrations of copper induce endocytosis of cell-surface 
associated PrPC (Pauly and Harris, 1998).  Consequently, it has been suggested that PrPC has a 
role in copper uptake/efflux and may also serve as copper reservoir at the cell surface without 
stimulating endocytosis (Westergard et al., 2007). 
 One model which has been used to explain the pathogenesis of several 
neurodegenerative disorders is chronic oxidative stress.  Impairment of mitochondrial function, 
increased oxidative damage, defects in the ubiquitin-proteosome system, protein aggregation, 
altered iron metabolism, excitotoxicity and inflammation have all been linked to oxidative 
stress in the brain (Halliwell, 2006).  Studies of oxidative stress in neurons found that PrPC 
seems to protect against reactive oxygen species (ROS) (Milhavet and Lehmann, 2002).  
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Westergard et al. proposed three possible mechanisms by which this may occur.  One 
explanation is that the PrPC acts directly on the ROS via a copper-dependent superoxide 
dismutase (SOD) activity (Brown et al., 1999).  SOD’s are enzymes which remove reactive 
oxygen species by converting them into more stable molecules (H2O2) (Halliwell, 2006).  A 
second theory is that PrPC acts indirectly by up-regulating activities of molecules like Cu-Zn 
SOD (Westergard et al., 2007).  The last hypothesis posits that PrPC may prevent activation of 
ROS induced apoptosis (Halliwell, 2006).             
 In vitro signalling analysis and prion knockout (PrP0/0) studies indicate PrPC mediates 
the interaction between several signalling transduction pathways which include protein kinase 
A, Fyn, phosphatidylinositide 3-kinase (PI3K)/Akt, and mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) known to induce neuronal survival 
(Chiarini et al., 2002; Mouillet-Richard et al., 2000).  Through studies examining induced 
ischemic injuries in neuronal tissue of PrP0/0 and wild type (WT) mice, it was demonstrated that 
the absence of PrPC exacerbates ischemic brain injury.  The authors hypothesized this was due 
to reduced activation of the anti-apoptotic pathway PI3K/Akt which in turn resulted in 
increased caspase-3 activity (Weise et al., 2006).   
 Protein localization studies indicate the presence of PrPC in the pre-synaptic region of 
the axon terminus (Fournier et al., 1995).  This observation is supported by the pathological 
changes such as synapse loss, PrPSc accumulation at the synaptic terminal (Jeffrey et al., 2000), 
and abnormal electrophysiological recordings during prion disease progression (Barrow et al., 
1999).  In the terminal stages of disease, accumulation of PrPSc in synaptosomes was found to 
coincide with alterations in the gamma-aminobutyric acid (GABA) system which is involved in 
the inhibition of excitatory glutamatergic transmission (Bouzamondo-Bernstein et al., 2004).  
The synaptic involvement of PrPC may also be responsible for the altered circadian rhythms 
(Tobler et al., 1996) and impaired hippocampal-dependent spatial learning phenotype in PrP-
deficient mice (Criado et al., 2005).                        
 With evidence that PrPC function is linked to programmed cell death pathways 
(Kurschner and Morgan, 1995, 1996), it seems logical that studies have described a relationship 
between PrPC and numerous cancer pathways.  An important concept in tumorigenesis and the 
development of resistance to anti-cancer drugs is the ability of malignant cells to escape 
apoptotic death (Johnstone et al., 2002).  Consequently, cancer researchers have been 
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investigating strategies to overcome resistance and induce apoptotic death in cancer cells.  
While analysing genetic determinants of tumor cell resistance to the cytotoxic effects of tumor 
necrosis factor (TNF) in breast cell carcinoma cells, Diarra-Mehrpour et al. (2004) 
demonstrated that endogenous PrPC mRNA and protein levels were 17-fold and 10-fold higher 
in TNF-resistant cells compared to TNF-sensitive cells.  They further showed that ectopic 
expression of PrPC produced TNF-resistance in previously sensitive breast adenocarcinoma 
cells (MCF7) via an alteration in cytochrome c release from nuclear condensation and 
mitochondria.  This suggested that PrPC has a role in the development of tumor resistance 
(Diarra-Mehrpour et al., 2004).  In a follow-up study, the same authors showed that silencing 
PrPC in apoptotic resistant MCF7 cells activated the proapoptotic Bax by reducing Bcl-2 
expression and consequently sensitized the cells to TNF induced apoptosis (Meslin et al., 
2007).        
 
1.1.3  Infectious PrP 
 
 The infectious component of prion diseases appears to be an insoluble β–sheet-rich 
version of the normal non-pathogenic α–helical PrPC.  While the primary structures of the two 
isoforms are identical, differences in secondary and tertiary structure account for the unique 
properties of PrPSc (Zou and Cashman, 2002).  Unlike PrPC, the infectious isoform is resistant 
to proteinase K (PK) digestion and readily forms insoluble aggregates (Prusiner, 1998).  These 
aggregates are composed of hydrolyzed fragments of the PrPSc protein, referred to as PrP 27-30 
to reflect their molecular weights that range between 27 and 30 kDa.  While crystal and NMR 
structures have been determined for PrPC, the tendency for PrPSc to aggregate prevents the 
application of structural analysis.  Through techniques such as circular dichroism, which offer 
less specific structural information, it has been determined that there is an increase in β–sheet 
content from 3% to 42% as the conformation changes from PrPC to PrPSc (Pan et al., 1993). 
Although PrPSc is generally described as the infectious conformation, subtle variations 
exist which make identifying the exact infectious component more challenging.  One variation, 
referred to as PrPSensitive (PrPSen), is more susceptible to PK digestion than another variation, 
PrPResistant (PrPRes).  While most PrPSc infected tissues contain PrPRes, its presence in not an 
absolute requirement for infectivity (Bessen and Marsh, 1994; Lasmezas et al., 1997).  PrPSen 
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has also been identified in Scrapie-infected tissue, making it difficult to discern which version 
is truly responsible for infectivity (Caughey et al., 1995; Safar et al., 1998).  While data are 
inconclusive in this regard, there is evidence for the existence of multiple PrPSc isoforms, also 
referred to as strains, which possess unique infectivity, pathology, neurotropism and 
biophysical traits.  The concept of prion strains will be discussed later.  
 
1.1.3.1  Pathogenesis 
 
 The formation of PrPSc is thought to occur via interaction between PrPC and an 
infectious PrPSc particle whereby PrPSc induces refolding of PrPC to PrPSc.  PrPC is an absolute 
requirement for conversion and infection.  Infection of PrP deficient mice with PrPSc material 
produces no accumulation of infectious material or disease.  When PrPC expression was 
restored, typical prion disease pathology was observed (Mallucci et al., 2003).  Transgenic 
mice, engineered such that PrP is produced without the GPI anchor, resist clinical symptoms 
following inoculation with Scrapie.  Unlike PrP knock-out mice, however, the GPI anchor 
transgenic mice still produced PrPSc and amyloid plaque aggregation (Chesebro et al., 2005).  
This experiment illustrates the need for PrPC to be membrane-anchored for Scrapie pathology to 
develop.  
One research group investigated whether PrPC expression was necessary on all types of 
brain cells (neurons, astrocytes and oligodendrocytes) for susceptibility to prion disease, 
formation of PrPSc and transmission of infectivity.  Several transgenic mouse lines were created 
to selectively express PrPC.  Mice with exclusive neuronal PrP expression supported prion 
infection and development (Race et al., 1995) while mice with only oligodendrocyte expression 
lacked signs of prion disease (Prinz et al., 2004).  Mice with astrocyte PrP expression showed 
disease symptoms despite the lack of neuronal PrPC (Raeber et al., 1997).  It was suggested that 
deposition of PrPSc in close proximity to neurons and their processes was sufficient to induce 
pathology (Jeffrey et al., 2004).    
Because the definitive function of PrPC has yet to be determined, the pathological 
mechanisms of PrPSc are also uncertain.  One argument offers that PrPSc causes a ‘gain of 
function’ whereby the presence of the misfolded protein adds a neurotoxic function.  The 
opposing argument hypothesises that PrPSc causes a “loss of function”.  This is derived from the 
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belief that PrPC has a neuroprotective effect and as prion pathogenesis progresses, PrPSc 
converts more and more of the cellular isoform into the infectious conformation resulting in 
reduced neuroprotection.  Some research has also shown that PrPSc itself is not neurotoxic due 
to the lack of correlation between PrPSc deposition and disease severity.  It has been suggested 
instead that the conversion from PrPC to PrPSc is the key component in pathogenesis rather than 
its accumulation (Trevitt and Collinge, 2006).  
 There are two main theories to explain the mechanism by which PrPSc induces the 
misfolding of PrPC: the template-directed refolding model and the nucleated polymerization 
model [Figure 1.3].  The first model postulates that incoming PrPSc starts a catalytic cascade 
using PrPC, or a PrP intermediate, as a substrate for conformational conversion into a new β–
sheet-rich protein.  This new PrPSc protein then serves to convert the next PrPC molecule as the 
cycle continues.  The re-folding mechanism is kinetically controlled by a high activation energy 
barrier which prevents spontaneous conversion at detectable rates.  It is thought that this energy 
barrier is lowered by the formation of an intermediate PrPC-PrPSc heterodimer complex which 
facilitates the full conversion of PrPC, with the help of a chaperone molecule, into the new PrPSc 
conformation (Aguzzi et al., 2008b).   
 The second model is based on a thermodynamically controlled nucleated polymerization 
reaction.  This is a non-catalytic event whereby conversion of PrPC to PrPSc is technically a 
reversible process.  At equilibrium however, the natural cellular PrP isoform is highly favoured.  
The isoform conversion only occurs when a native PrP protein monomer comes into contact 
with an already formed PrPSc crystal seed or aggregate.  Successful refolding into the PrPSc 
isoform is stabilized once the new protein adds onto the preformed seed.  This model therefore, 
implies that infectivity requires the presence of PrPSc in oligomer form and that monomers 
consequently are not infectious (Aguzzi et al., 2008b). 
 
1.1.3.1.1  Peripheral Amplification 
 
 TSE infections are usually established following oral ingestion of infectious PrPSc 
material.  Once in the digestive tract, it is proposed that PrPSc crosses the mucosal barrier via 
three potential mechanisms.  The first utilizes a specific subset of intestinal epithelial cells  
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Figure 1.3: Two Models for the Conversion of PrPC into the PrPSc isoform.  a) The template 
directed model suggests the interaction between an exogenous PrPSc and endogenous PrPC are 
required to facilitate the conversion.  The spontaneous formation of PrPSc from PrPC is 
prevented by high activation barrier.  b) The seeded nucleation postulates that PrPC and PrPSc 
are in equilibrium such that the PrPC conformation is favoured.  In the PrPSc conformation, 
monomers can act as seeds for the accumulation of other PrPSc proteins leading to the formation 
of amyloids and other infectious seeds.  Figure adapted from (Aguzzi and Heppner, 2000). 
Permission from the publisher was granted for use of this material 
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called microfold cells or M-cells.  These cells consist of a thin apical membrane made up of 
mircofolds, and an invaginated basal membrane which houses various immune cells.  The thin 
membrane allows for the transport of many types of bacteria, viruses, and proteins including 
prions, across the epithelial layer where they encounter lymphocytes and dendritic cells 
(Neutra, 1999).  This interaction between the immune cells and pathogenic antigen serves to 
stimulate a mucosal immune response.  While the M-cells facilitate uptake and transfer of Ag to 
the immune system, they may also serve as a portal of entry for pathogens like prions which do 
not stimulate an immune response and are left to continue on their route of infection [Figure 
1.4]. 
 While in the intestinal lumen, PrPSc can be degraded by digestive enzymes into smaller 
protease resistant fragments.  These fragments may form complexes with ferritin which are 
transported across the intestinal epithelium by a ferritin-dependent endocytosis mechanism 
(Mishra et al., 2004).   
A third mechanism of uptake has been proposed based on observations made during 
bacterial research and has yet to be directly linked to TSE transport.  This involves direct 
sampling of prion Ag by migratory bone marrow-derived dendritic cells which can travel from 
the blood vessels to the inner surface of the intestinal wall.  From here, the trapped Ag is 
transported to the lymphoreticular system which includes the mesenteric lymph nodes (Huang 
et al., 2002). 
Immunohistochemistry revealed that once across the mucosal barrier, PrPSc 
accumulation occurs in lymphoid tissues of the palatine tonsils, spleen, lymph nodes and 
Peyer’s patches (Andreoletti et al., 2000).  More specifically, it is within the tingible body 
macrophages of the B-cell follicles and later on the plasmalemma of the follicular dendritic 
cells (FDC) that PrPSc replication and accumulation occurs (van Keulen et al., 1996).  This 
amplification phase, particularly within the Peyer’s patches, is important for transfer of PrPSc to 
the nervous system. 
Kitamota et al. (1991) were instrumental in establishing the relationship between B-
cells, FDCs and prion disease progression.  B-cell deficient mice were successfully infected 
with prion material via intra-cranial (IC) challenge, but failed to show any signs of disease 
following intra-peritoneal (i.p.) challenge.  Further investigation of the i.p. inoculated mice  
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Figure 1.4: Representation of possible ways exogenous PrPSc could cross the intestinal 
epithelium and invade the enteric nervous system.  M and dendritic cells are able to sample 
antigens and transport them to the lymphoid follicles (LF) of the Peyer’s patches underlying the 
follicular-associated epithelium (FAE) where PrPSc then accumulates on follicular dendritic 
cells and follicular macrophages within the lymphoid follicles.  An additional method of uptake 
may exist with ferritin-dependent trans-epithelial transportation pathway.  Once PrPSc had 
crossed the epithelial layer, contact with the enteric nervous system leads to neural invasion.  
Figure from (van Keulen et al., 2008).  Permission from the publisher is granted for use of this 
material.         
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Figure 1. Schematic representation of the possible ways of intestinal epithelial crossing and subsequent
invasion of the ENS. After ingestion, PrPSc can be taken up by M-cells or dendritic cells and transported
to the lymphoid follicles (LF) of the Peyer’s patches underlying the follicle-associated epithelium (FAE).
Within the lymphoid follicles PrPSc accumulates on follicular dendritic cells and is taken up by follicular
macrophages. This accumulation of PrPSc could facilitate infection of the neighbouring submucosal plexus
of the ENS. Alternatively, PrPSc could be taken up as a complex with ferritin and transcytosed by intestinal
epithelial cells through the ferritin pathway. Once the epithelium is crossed, the mucosal plexus of the ENS
can get infected followed by neural spread to the submucosal plexus.
gut-associated lymphoid tissues (GALT) of
the tonsil and the Peyer’s patches in the in-
testines [2, 23, 68]. This initial accumulation
in the GALT strongly fav rs the hypothesis of
transport of TSE agents through M-cells be-
cause antigens that have been transcytosed by
M-cells are actively transported from the basal
side of the M-cells to the underlying GALT by
either dendritic cells or macrophages.
The first immunohistochemical evidence
of PrPSc in the GALT consists of the in-
tracellular accumulation within the tingible
body macrophages (TBM) in the B-cell fol-
licles. At a later stage, PrPSc is also found
on the plasmalemma of the follicular dendritic
cells (FDC) in the germinal centres of the
B-cell follicles [2, 35, 65, 67]. The replication
of the TSE agents in the GALT is thought
to be crucial to the further neuro-invasion as
disease susceptibility is reduced in experimen-
tal animal models in which FDC function is
impaired [10, 42]. However, absence of agent
eplication in the GALT does not fully preve t
neuro-invasion. For instance in sheep of the
VRQ/ARR PrP genotype (carrying both the
VRQ allele associated with high scrapie sus-
ceptibility and the ARR allele associated with
high scrapie resistance) there is minimal or no
involvement of the lymphoid tissues in agent
replication [65]. However, these sheep do get
natural scrapie, albeit at an older age [7]. In
addition, they can be experimentally infected
when the oral dose of scrapie agent is high
enough1.
In cattle, replication of the BSE agent in
the lymphoid tissues is minimal to absent.
1 O. Andréoletti, Personal communication.
(page number not for citation purpose) Page 3 of 12
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revealed that PrPSc failed to accumulate in the spleen and brain despite having normal levels of 
FDCs (Kitamoto et al., 1991).  Based on previous studies which illustrated that FDC 
development was a B-cell dependent process, the Kitamoto group concluded that by removing 
the B-cell population they prevented maturation of the present FDC population which, as it 
became evident, are essential for prion replication and disease progression.  They were able to 
verify this by reconstituting B-cells in B-cell deficient mice, which had been given prion 
material i.p., which restored susceptibility to prion disease. 
Following the linkage of FDCs and prion replication, studies discovered a link between 
the inflammatory process (involving FDCs, B-cells, macrophages and other immune cells 
associated with germinal centers) and accumulation of PrPSc.  In the presence of inflammation, 
the upregulation of FDC cytokines such as lymphotoxin resulted in an ectopic induction of 
PrPC-expressing FDCs (Aguzzi and Calella, 2009).  As a result, non-lymphoid organs 
undergoing inflammation, such as nephritis, hepatitis or pancreatitis showed signs of prion 
accumulation.  In contrast, they are prion-free under normal conditions (Heikenwalder et al., 
2005).  Experiments have shown that in symptomatic and asymptomatic Scrapie-infected mice, 
with nephritis, prion infectivity was detectable in the urine (Seeger et al., 2005).  Similar 
experiments in sheep with mastitis showed that infectivity was shed in the colostrum and milk 
(Aguzzi and Calella, 2009).  This is problematic in the context of wild/farmed animal 
populations where PrPSc-infected individuals suffering from inflammatory processes in 
excretory organs may shed PrPSc material into the environment and increase disease 
transmission.     
 
1.1.3.1.2  Neuroinvasion 
 
 The mechanism by which PrPSc travels from lymphoid tissue to the nervous system is 
not well understood.  Experimental conditions that either remove or increase lymphoid 
innervation show that increased lymphoid innervation correlates with faster neuroinvasion 
(Glatzel et al., 2001).  The proximity of PrPSc expressing FDC’s to the sympathetic nerve 
endings has also been shown to influence rates of neuroinvasion.  Whether there is passive 
diffusion of infectious PrP molecules or some sort of facilitated transport system from the 
FDCs to nerve endings is not known (Aguzzi, 2006). 
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The enteric nervous system (ENS) has been identified as the first neural tissue to be 
invaded by PrPSc following the amplification phase (Andreoletti et al., 2000).  The ENS, a 
member of the autonomic nervous system, innervates the gut and is made up of two main 
networks, Meissner’s plexus, located in the gut submucosa, and Auerbach’s plexus which runs 
between the circular and longitudinal muscle layer extending from the esophagus to the rectum 
(van Keulen et al., 2008).  As a component of the autonomic nervous system, the ENS is 
directed by the sympathetic and parasympathetic input from the central nervous system via 
efferent nerves which connect to the enteric plexi (van Keulen et al., 2008).  Following 
infection of the ENS, PrPSc travels to the brain using mainly the sympathetic pathway via the 
Vagus nerve to the dorsal motor nucleus in the medulla oblongata, or the parasympathetic 
pathway via the Splanchnicus nerve to the intermediolateral column of the spinal cord (van 
Keulen et al., 2000). 
 
1.1.3.1.3  Neurodegeneration 
 
 The mechanisms for prion-related neurodegeneration are closely related to the proposed 
functions of PrPC.  This is to be expected as the TSE disease process is essentially the 
conversion of PrPC to PrPSc which leads to a reduction in the number of functioning cellular 
prion proteins, thus sparking the debate about whether prion pathology is due to a gain of a 
neurotoxic function or the loss of a neuroprotective function.  Hur et al. proposed five 
mechanisms of prion neurodegeneration: increased oxidative stress and mitochondrial 
dysfunction; disruption of iron metabolism; altered calcium metabolism; increased 
inflammatory activity of cytokines, chemokines and nuclear factor-kappa; and finally apoptosis 
(Hur et al., 2002). 
 It has been observed in TSE-infected animals that there is reduced activity of 
Manganese-SOD.  This mitochondrial enzyme is responsible for converting superoxide anions 
into less reactive species.  The resulting accumulation of ROS leads to ischemic cell injury and 
subsequently apoptosis or necrosis.  Additional mitochondrial deficits, such as decreased 
cytochrome-c oxidase and ATPase activity, increased lipid peroxidation, and structural 
abnormalities, have been detected in hippocampal and cerebral cortical neurons of TSE infected 
hamsters (Choi et al., 1998). 
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 Increased iron metabolism within the brain (favouring a redox state of Fe+3), as a result 
of a TSE infection, is involved in exacerbating ROS injury by converting harmful free radicals 
such as a superoxide anion into an even more highly reactive hydroxyl radical (Hur et al., 
2002).  Hur et al. found that this change in iron content is linked to increased expression of two 
iron regulating proteins, IRP1 and IRP2, which play an instrumental role in iron metabolism.  
The abnormal IRP expression was particularly evident in the reactive astrocytes of the cerebral 
cortex and hippocampus. 
 Proper calcium regulation is essential for the normal functioning of the CNS.  
Variations in intracellular calcium concentrations facilitate the coordination of electrochemical 
signals, neurite growth, synaptogenesis, synaptic transmission, cell survival and plasticity 
(Sorgato and Bertoli, 2009).  In vitro experiments showed that in PrPSc infected cells, there was 
a down-regulation of N-type voltage-gated Ca2+ channels resulting in reduced cytosolic Ca2+ 
(Sandberg et al., 2004).  PrPSc aggregates that accumulate in the synaptic cleft may physically 
interrupt synaptic transmission of electric potentials created by Ca2+-activated potassium 
channels, or compromise the stability of newly formed synapses (Sorgato and Bertoli, 2009).  
This can result in excitotoxocity (Khosravani et al., 2008), and ischemic brain damage (Spudich 
et al., 2005).  The interference with the development of long term potentiation also has negative 
effects on processes such as learning and memory (Sorgato and Bertoli, 2009).  
 
1.1.3.2  Transmission of Infectious PrP 
 
 Natural transmission of TSEs likely occurs following ingestion of contaminated 
material such as skin, dirt, decomposed carcasses, urine, contaminated placentas, and faecal 
matter (Kruger et al., 2009) or by direct contact between animals.  These diseases can also be 
experimentally induced via intracerebral injection, a method that establishes neurdegenerative 
symptoms and pathology more quickly than either experimental oral or peripheral inoculation.  
Transmission of prion diseases between different species has been shown to be much less 
efficient than within the same species.  This suggests TSEs are limited by a species barrier.  
Further trans-species experiments have demonstrated that transmission does occur but that 
incubation times may be greatly extended so that clinical disease may or may not occur during 
the natural lifespan of the affected animal (Race et al., 2001).  The concept of prion strains 
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complicates the understanding of TSE transmission in that certain strains of PrPSc, derived and 
transmitted within the same species, can result in the either the development of an 
asymptomatic carrier or the onset of clinical disease (Weissmann, 2004).  
 
1.1.3.2.1  Strains 
 
 The term “strain”, when used in the context of prion disease, refers to phenotypic 
differences such as variations in the pattern of aggregate deposition, incubation times, neuronal 
tissue tropism and pathological morphology (Falsig et al., 2008).  These differences are thought 
to result from the conformational flexibility of the PrPSc structure, which leads to exposure of 
distinct cleavage sites, differing stability in the presence of denaturing compounds (Peretz et 
al., 2001a), and altered ratios of di-, mono- and unglycosylated forms (Aguzzi et al., 2008b).  
The strain of an incoming infectious PrPSc molecule appears to be imprinted in all of the 
subsequent PrPSc proteins that are produced during the conversion of the host’s cellular PrP 
(Aguzzi and Polymenidou, 2004).            
 Strains within traditional pathogens such as bacteria and viruses are determined by 
nucleic acid sequences in their genome.  The mechanism of strain formation in prions is not 
attributable to differences in the primary PrP structure.  It has been demonstrated that different 
strains can be passaged serially through inbred mice that have identical PrP gene sequences 
(Collinge and Clarke, 2007).  Strains have also been be re-isolated in mice following passage 
through other species with differing PrP primary structures (Bruce et al., 1994).   
 It has been shown that prion strain characteristics play a role in the establishment of a 
species barrier.  Species barrier is a concept whereby the transmission of prion diseases 
between different species is much less efficient than within species (Collinge and Clarke, 
2007).  When species B is infected with prion from species A, the infectivity rate is low and the 
disease progression, in successfully infected animals, is slow and unpredictable.  In contrast, 
when species A is infected with prions from species A, infection rates are high and progression 
is quick with a very similar disease course in each animal.  Interestingly, following the passage 
of prion from species A to B, subsequent passages of the same prion to another B animal now 
has the same disease progression as if the prion had originated from a species B animal.  The 
type of strain influences how easily this species barrier is broken.  For example, the prion strain 
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responsible for the BSE crisis in England was very easily transmitted to a variety of species, 
including humans (Bruce et al., 1994).   
 
 
1.1.3.3  Prion Diseases 
 
 Since the earliest observation (around 1730) of a chronic neurodegenerative disease in 
Western Europe, several analogous neurodegenerative diseases have been identified in different 
species [Table 1].  In most cases, it was initially assumed that the causative agent was some 
sort of slow virus.  It was not until Stanley Prusiner’s work in the late 1970s and early 80s that 
these diseases were found to be caused by a misfolded prion protein.  Different names were 
attributed to each of the diseases based on species: Scrapie in sheep, Creutzfeldt-Jacob disease 
(CJD) in humans, Bovine Spongiform Encephalopathy (BSE) in cattle, and Chronic Wasting 
Disease (CWD) in cervids. 
  In sheep and cattle, prion disease symptoms are very similar.  The symptomatic phase 
of the disease initially presents with rubbing of the head, flanks and buttocks, a symptom which 
may last well into the later stages of the disease.  Also evident at the early stages is the nibbling 
of hair on the lower legs.  General weakness follows which progresses to the inability to rise.  
Wasting symptoms appear, such as a loss in body weight despite normal food and water intake.  
Neurological motor deficits affecting gait include wide-based stance of hind limbs and high 
stepping motions in the front limbs, which in severe cases makes the animals appear 
intoxicated.  Further neurological changes include body tremors and personality/behavioural 
alterations which may manifest as uncooperativeness, excitability and extreme distress.  Once 
an animal is symptomatic, Scrapie and BSE are slowly progressive and lethal within 2 to 6 
months (Beghi et al., 2004; Parry, 1962).   
 Sheep possess a unique attribute with regards to TSE transmission.  Their susceptibility 
is influenced by polymorphisms at three different codons (136, 154 and 171) within the PrP 
sequence (Houston et al., 2003).  It has been observed that susceptibility to Scrapie strongly 
correlates with valine (V) at position 136, arginine (R) at 154 and glutamine (Q) at 171 (VRQ) 
(Goldmann et al., 1994), whereas resistance is attributed to alanine (A) at 136, with R at 154 
and 171 (ARR) (van Keulen et al., 1996).  Prion disease is rare in heterozygous ARR animals  
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Table 1.1: Summary of dates for when specific TSEs were first described.  Adapted from 
(Vana et al., 2007). 
 
TSE	   First	  Described	   Reference	  
Creutzfeldt-­‐Jakob	  disease	   1920	   (Creutzfeldt,	  1989)	  
Sporadic	  Creutzfeldt-­‐Jakob	  disease	   1921	   (Jakob,	  1921)	  
Familial	  Creutzfeldt-­‐Jakob	  disease	   1924	   (Kirschbaum,	  1924)	  
Gerstmann-­‐Straussler-­‐Scheinker	  
syndrome	  
1928	   (Gerstmann	  et	  al.,	  1936)	  
	   	   Kuru	   1957	   (Gajdusek	  and	  Zigas,	  1957)	  
Chronic	  Wasting	  Disease	   1967	   (Williams,	  2005)	  
Iatrogenic	  Creutzfeldt-­‐Jakob	  disease	   1974	   (Duffy	  et	  al.,	  1974)	  
New	  Variant	  Creutzfeldt-­‐Jakob	  disease	   	   	   1996	   (Will	  et	  al.,	  1996)	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and virtually undetected in animals homozygous for ARR (Ikeda et al., 1995).  Knowledge of 
this led to a breeding strategy in Europe where sheep flocks were bred to attain the ARR 
genotype in an attempt to eradicate the transmission of Scrapie amongst their herds (Kao et al., 
2002). 
 
1.1.3.3.1  Scrapie 
 
Although Scrapie belongs to a group of diseases that were only recently classified, 
historical descriptions of Scrapie have been traced back to 1732.  Some sources claim there is 
evidence, although less convincing, that corresponds to the Roman era (Schneider et al., 2008).  
The term “Scrapie” was first seen in a manuscript from 1750 but a more common term for it at 
the time was “distemper” (Comber, 1772).  The majority of written accounts were not produced 
by scientist or veterinarians, but by farmers, shepherds and government employees.  The latter 
individuals were the ones immediately involved with the infected animals and actually went to 
great efforts to cover up the outbreaks because of the monetary/economic implications that 
would result (Schneider et al., 2008).  Similar to current management strategies, 
acknowledgment of a Scrapie infected animal meant the entire herd would be culled and 
pasture land quarantined indefinitely (Turner, 1795).  This behaviour indicated a basic 
understanding of Scrapie as an infectious entity.     
While historical descriptions of Scrapie symptoms were accurate, the beliefs of what 
caused the disease varied greatly.  The range of hypotheses included: thunder, extreme 
atmospheric conditions, food/nutritional insufficiency, parasites, humidity in the sheep pen, tail 
docking, age during mating, cross-breeding and inbreeding (Schneider et al., 2008).  The 
method of transmission was equally debated with ideas ranging from sexual transmission 
(Comber, 1772), sporadic occurrence, and genetic inheritance.  After 100 years of failed 
attempts to experimentally demonstrate Scrapie transmissibility, two French scientists, Cuille 
and Chelle in 1936, successfully infected sheep and goats intracerebrally, intraocularly, 
epidurally, and subcutaneously using brain and spinal cord suspensions from Scrapie-infected 
sheep (Cuille and Chelle, 1936).  Their experiment was important for several reasons.  First, 
they confirmed that Scrapie was indeed infectious; second, that the course of infection required 
a very long (18 month) incubation period; and third, that the incubation period was affected by 
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species.  The infected sheep demonstrated a quicker symptom onset (11-22 months) than the 
goats (25-26 months) (Cuille and Chelle, 1938).  Speculation as to what transmissible agent 
actually caused Scrapie evolved over the next 50 years, gaining momentum as human related 
prion diseases (CJD and Kuru) were identified in the 50’s and 60’s by Sigurdsson and 
Gajdusek.  
                        
1.1.3.3.2  Chronic Wasting Disease 
 
 CWD was first identified at a research station in Fort Collins, Colorado in 1967 
(Williams, 2005).  It was not until 1978 that the relationship between CWD and other TSEs was 
recognized following comparative analysis of neuronal lesions (Williams and Young, 1980) 
and accumulation of PrP aggregates (Browning et al., 2004).  During the 1970’s and 80’s, 
CWD existed primarily in the Colorado Rocky Mountains and an area extending along the river 
valleys to Wyoming (Miller et al., 2000).  In 1996, however, the disease was also detected in 
the Canadian prairies on an elk farm (Sigurdson and Aguzzi, 2007). 
Strategies for containing CWD are extremely problematic because the afflicted animals 
primarily consist of wild, free-ranging populations.  Other complicating factors are the 
scavenging of contaminated deer carcases by predators ranging from mountain lions to vultures, 
and a poor understanding of the natural routes of disease transmission (Sigurdson and Aguzzi, 
2007).  Although oral cross-species infection has not been directly observed, there have been 
suspicion in a few cases, which was later disproved, that human patients suffering from CJD 
may have contracted it from CWD infected deer meat (Belay et al., 2004).  CWD, being one of 
the most contagious of the TSEs, can reach a prevalence of 30% in wild populations and as 
high as 100% in captive cervids (Williams, 2005).  This has created concern that infected wild 
populations of deer may serve as a reservoir leading to the transmission of CWD to farmed deer 
and cattle. 
Symptoms of CWD are subtle and hard to detect in the early stages of disease.  They 
include: weight loss, excessive drinking and urination as well as regurgitation.  The motor 
deficits common to Scrapie and BSE are often absent in CWD cases (Sigurdson and Aguzzi, 
2007).  Despite the lack of easily observable symptoms, post-mortem histopathological 
examinations reveal neurological lesions similar to Scrapie, BSE and human prion diseases 
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(Williams and Young, 1993).  It takes anywhere from several weeks to many months for the 
infected animal to succumb to the disease once it has spread to the nervous system. 
 
1.1.3.3.3  Bovine Spongiform Encephalopathy 
 
 Since the first BSE diagnosis in 1986, more than 179,000 positive cases have been 
identified in Great Britain (Wells et al., 1987).  While the recycling of BSE-infected material 
into feed for cattle was likely the main factor of transmission, the actual source of the original 
BSE agent is still unknown (Baron and Biacabe, 2006).  It has been suggested that BSE 
developed spontaneously in cattle via a somatic or germ-line mutation of PrP or that cattle may 
have been infected by another species such as sheep (Konold et al., 2006).  Twenty years of 
rigorous surveillance following the first BSE outbreak have indicated that disease transmission 
is under control in most of Europe (Editorial-team, 2007).  Mass screening of bovine tissues as 
part of the surveillance initiatives has identified the presence of two new BSE strains, L-Type 
and H-Type which are distinct from the classic BSE (Cappai and Collins, 2004).  These strains 
are more rare than classic BSE and are usually detected in older animals, thus representing a 
possible sporadic form of TSE in cattle (Biacabe et al., 2008).  Both strains are infectious, 
maintaining their original molecular phenotype upon transmission and cause distinct 
neuropathology.  In mouse infection studies, the L-type has been observed to be more virulent, 
replicating faster than both classical BSE and the H-type strain (Cappai and Collins, 2004). 
 
1.1.3.3.4  Creutzfeldt-Jacob Disease 
 
 In the 1950s, an epidemic spreading amongst the Fore people of Papua New Guinea 
gained the attention of health officials.  At the peak of the epidemic, as many as 10% of the 
local Fore population was infected (Gajdusek and Zigas, 1957).  The disease appeared to affect 
the central nervous system and displayed symptoms such as progressive ataxia or loss of  motor 
coordination (Collinge, 2001).  Derived from the appearance of these symptoms, the disease 
was given  the name Kuru, which in the Fore language means “to shiver” (Collins et al., 2004).  
William Hadlow, a veterinary pathologist specialising in TSEs, made the connection in 1959 
between Scrapie and Kuru.  He noted that epidemiologically, clinically and pathologically, the 
 24 
two diseases were remarkably similar (Hadlow, 1959).  This led to further investigations by 
Gajdusek who was able to prove Kuru to be transmissible after he successfully infected 
chimpanzees (Gajdusek et al., 1966). 
 Epidemiological studies suggested that Kuru was transmitted by the cannibalistic Fore 
funeral rituals (Gajdusek, 1977).  These ceremonies involved the children and women 
consuming nervous tissue from the deceased relative while men ingested tissue like muscle, 
which was much less likely than the nervous tissue to contain PrPSc material, although at that 
time the nature of the infectious agent was unknown (Klitzman et al., 1984).  The number of 
Kuru cases declined steadily following the discontinuation of the funeral ceremonies.  
However, complete eradication of Kuru has taken much longer than anticipated due to 
incubation periods lasting as long as four decades (Collins et al., 2004).  
 The most common form of prion disease in humans in sporadic CJD (sCJD) with a 
frequency of approximately 0.5-1 case per million people (Coulthart and Cashman, 2001).  
Unlike the familial forms of CJD, which are caused by autosomal dominant traits linked to 
mutations on the Prnp gene (Hsiao et al., 1989), it is unknown whether sCJD is caused by 
endogenous or exogenous factors (Aguzzi, 2006).  Countries with active surveillance programs 
often report higher CJD incidence rates, such as Switzerland with 3 cases per million people 
(Glatzel et al., 2003).  Most of those cases, however, are due to iatrogenic spread rather than 
exposure to infected material (Aguzzi and Calella, 2009).  Symptoms in sporadic cases usually 
appear around the age of seventy and are lethal within weeks or months.  Symptoms often 
include rapidly progressing dementia, ataxia, muscle twitching and uncoordinated speech 
(Coulthart and Cashman, 2001).   
 Following the BSE crisis in the United Kingdom in the 1980s, a novel form of CJD 
emerged.  Given the name “variant CJD” (vCJD), this new form of prion disease appeared to be 
linked to the consumption of BSE-contaminated meat products.  The two main differences 
between sporadic and vCJD are the dramatic decrease in age at onset of symptoms (29 years), 
and increased duration of symptoms (16 months) prior to death (Will, 1999).  Some additional 
symptoms, that are typically rare in sporadic CJD, like involuntary movements and sensory 
symptoms have been observed in 100% and 50% of symptomatic vCJD patients, respectively 
(Zeidler et al., 1997).   
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 As of 2003, the number of autopsy confirmed cases of vCJD was 153 and currently the 
number is estimated at 200 (http://www.bseinfo.org).  While these numbers are low, the number 
of people actually infected with vCJD and not showing symptoms is likely much higher.  Due 
to incubation times that can last decades, there may be a population of people that are 
harbouring the infectious PrP without a manifestation of observable symptoms.  These people 
are often referred to as ‘asymptomatic carriers’.  Without accepted pre-mortem diagnostic tests, 
health professionals are not able to identify these asymptomatic individuals via routine 
screening.  This creates a dangerous situation because researchers have found evidence that 
vCJD can be transmitted via contaminated blood products (Peden et al., 2004), infectious 
cadaveric tissues, and contaminated surgical instruments (Brown et al., 2000).    
    
1.1.3.4  Prion Diagnostics 
 
 With the lack of accepted pre-mortem diagnostic tests available, health professionals 
have to rely on clinical examinations for the identification of TSE’s (Soto, 2004).  Definitive 
confirmation however, can only be made by post-mortem histological or biochemical analysis 
of brain (Ingrosso et al., 2002).  While histological assays are accurate, they are time-
consuming, labour-intensive and low-throughput.  Development of new biochemical tests has 
allowed multiple samples to be processed in a few hours.  The majority of the tests have 
detection limits ranging from 0.5 pmol to 20 pmol and utilize immunodetection of the PrPSc 
isoform or proteolysis to distinguish PrPC from the infectious conformation (Soto, 2004).   
 To enable the detection of preclinical peripheral PrPSc, Sabotio et al. developed a 
method of PrPSc amplification called protein misfolding cyclic amplification (PMCA) (Saborio 
et al., 2001).  Similar to the polymerase chain reaction method used to amplify DNA, PrPC of 
the same species is added to a sample containing small quantities of PrPSc and incubated to 
allow for the expansion of PrPSc aggregates.  These new aggregates are broken up using 
sonication to form more PrPSc seed molecules and are re-incubated in the presence of added 
PrPC.  After several amplification cycles, the amount of PrPSc has been shown to be several 
million fold higher than in the original sample (Saa et al., 2006), allowing detection using 
standard molecular techniques like Western blots.  Concerns were raised regarding the 
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specificity of this technique after it was shown that PrPSc can be generated from samples 
lacking PrPSc (Deleault et al., 2007) which limits the usefulness of PMCA as a diagnostic test.           
 The discovery of PrPSc infectivity in blood from vCJD patients (Deleault et al., 2007; 
Llewelyn et al., 2004) created a great need for the development of a blood test for prions.  The 
first detection system was developed in 1996 and consisted of capillary electrophoresis and a 
competitive immunoassay which detected a PK resistant C-terminal sequence of PrP (Schmerr 
et al., 1998; Schmerr et al., 1996; Schmerr and Jenny, 1998).  Despite several revisions and 
improvements, the method  was not suitable for routine testing (Everest et al., 2007).  More 
recent initiatives involve the use of a 15B3 prion antibody developed by Prionics (Korth et al., 
1999; Nazor et al., 2005) and a Seprion resin manufactured by Microsense.  Both systems 
concentrate PrPSc so it is detectable by ELISA and flow cytometry.  One other group designed 
fluorescent labelled peptides to discriminate PrPC from PrPSc.  When the labelled peptide binds 
to PrPSc, a shift in conformation modifies the fluorescent properties of the label (Grosset et al., 
2005).  Despite the advances in blood diagnostics, the strict guidelines governing diagnostic 
requirements prevent their acceptance for use in an official capacity.    
 
1.2  Historical Approach to Prion Therapy 
 
 For the last fifty years there have been ongoing efforts to identify effective prion 
therapeutic agents.  Typically these agents have targeted PrPC, PrPSc or the conversion process.  
Research in this area increased dramatically with the emergence of vCJD in the 1990’s and the 
discovery that prion infectivity can be transmitted via blood, surgical instruments and transplant 
tissues from asymptomatic carriers (Collinge, 1999).  Investigations of potential therapies have 
been conducted primarily in three experimental systems which include cell-free in vitro 
conversion assays, cell-based models or animal models (Trevitt and Collinge, 2006).  The cell-
free method involves the addition of a PrPSc seed molecule to a PrPC substrate in the presence 
of a potential therapeutic agent.  Therapeutic potential is evaluated based on the ability of the 
molecule to interfere with the isoform conversion process.  Cell-based research utilizes cell 
lines such as N2a (mouse neuroblastoma cells) to assess the ability of given therapeutic agent to 
either prevent prion infection of the cells, or clear a chronically prion infected cell line like 
ScN2a of PrPSc.  These cell models allow for the analysis of some very basic aspects of prion 
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pathogenesis such as isoform conversion, cytotoxicity, apoptosis and abnormal cell signalling.  
Animal models make up the third type of commonly used experimental system.  This tends to 
be the most expensive and complicated model, but it also has the potential to be the most 
informative.  Many different aspects of an anti-prion therapeutic’s potential can be analyzed 
such as its ability to influence incubation phase of infection, severity of symptoms, pathology, 
immune response, as well as survival time and rate.  Several difficulties, however, exist within 
this type of model.  Issues such as genetic variability between species such as sheep and mice, 
and inconsistent models of infection and lengthy incubation periods, are examples of the 
challenges facing researchers who utilize in vivo systems.  
 Dating back as far as the 1960’s, the main area of research was focused on 
chemotherapeutic agents (Trevitt and Collinge, 2006).  As it was initially thought that prion 
diseases were the result of a slow virus, this biased the nature of the therapeutic agents which 
were investigated.  Typical TSE targets/goals for chemotherapeutic agents have been:  
sterilization of sources of infection; prion prophylaxis; interruption of PrPC conversion during 
peripheral amplification; prevention of neuroinvasion; and reduction of PrPSc accumulation 
(Cashman and Caughey, 2004).  Countless agents have been tested ranging in class from: 
polysulphated polyanionic compounds, glycosaminoglycans, sulphonated dyes, quinacrines, 
metal chelators, tetrapyrroles, polylene antibiotics, tetracyclic compounds and β–sheet breaker 
peptides (Cashman and Caughey, 2004; Trevitt and Collinge, 2006).  Very few have shown 
significant success within an in vivo system, especially after symptoms have developed 
(Dormont, 2003).  The blood-brain barrier serves as a substantial obstacle for most therapeutic 
agents.  Due to the large size of most chemotherapeutic agents, they are unable to reach the 
CNS and consequently fail to interfere with prion related pathogenesis.  Even compounds like 
curmunin, quinacrine, quinolones and polylene antibiotics, which are able to penetrate the CNS, 
fail to improve symptoms of late stage TSE disease (Cashman and Caughey, 2004). 
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1.2.1  Immunotherapy 
 
1.2.1.1  In vitro Immune Therapy 
 
 The conversion of PrPC to PrPSc occurs at or near the cell surface (Borchelt et al., 1990; 
Caughey and Raymond, 1991).  This provides an opportunity for antibodies to bind and prevent 
the interaction and conversion of PrPC by PrPSc.  Such a strategy might be used as 
immunoprophylaxis to prevent infection of animals exposed to PrPSc or as therapy to treat 
infected animals, helping to slow or stop the progression of disease and minimize the shedding 
of infectious PrPSc into the environment.  The challenge with this approach is that PrPC is a 
ubiquitously-expressed endogenous protein, making it very difficult to stimulate an immune 
response.  This is the result of an immunological phenomenon known as tolerance.  Tolerance 
occurs when the immune system recognizes a protein as being “self”.  Consequently, immune 
cells such as T and B-cells, which have receptors specific to a particular protein, are deleted or 
prevented from initiating an immune response towards that particular protein (Zinkernagel and 
Hengartner, 2001).  This is a safety mechanism that ensures that the body’s adaptive immune 
system does not attack itself.  Situations where there is a malfunction in the process of self 
recognition result in autoimmune disorders such as rheumatoid arthritis, diabetes, and lupus.  
Overcoming tolerance to PrPC remains one of the biggest challenges in prion vaccine research 
(Heppner and Aguzzi, 2004). 
 Early immunologic protection experiments in 1988 demonstrated that ex vivo incubation 
of a prion inoculum with anti-PrPC polyclonal antibody, prior to inoculation, resulted in a 2-log 
reduction in infectivity (Gabizon et al., 1988).  Further work was done to identify the region of 
PrP involved in the interaction with PrPSc resulting in isoform conversion.  This was done using 
mAb 3F4 (specific for amino acids 109-113) (Kascsak et al., 1987) and polyclonal sera to 
peptides (corresponding to amino acids 23-33, 90-104, 143-156 and 219-232) to try and prevent 
PrPRes formation in a cell free conversion system (Gabizon et al., 1988).  Abs to the region 219-
232 were found to disrupt the formation of new PrPRes.  The same effect was not observed 
during incubation with PrPRes seed.  Furthermore, when PrPSen Abs and peptide 219-232 were 
co-incubated, the Ab bound to the peptide, allowing for the uninterrupted formation of PrPRes.  
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This illustrated that the inhibition of PrPRes formation was due to the direct binding of the Ab to 
the 219-232 region (Horiuchi and Caughey, 1999).   
 Preliminary immunotherapy research in 2001 showed that culturing ScN2a cells with 
mAb 6H4 (specific for amino acids 144-152 on the prion protein) continuously for 6 weeks 
resulted in the complete clearance of PrPSc (Enari et al., 2001).  In the absence of 6H4, 
however, the cells became susceptible to prion infection.  This study, and similar in vitro 
investigations, offered evidence that anti-PrP Abs have the potential to interfere with the prion 
disease process.  That same year Heppner et al. created transgenic mice that expressed 6H4 as a 
single chain Ab.  To circumvent the issue of PrP tolerance, the mice used contained a 
heterozygous prion knockout (Prnp +/-), thus allowing for the accumulation of high anti-PrP 
titers.  The mice were infected with Rocky Mountain Laboratory (RML) strain of mouse 
adapted Scrapie via an intraperitoneal challenge and monitored for prion disease.  The mice 
expressing 6H4 survived 120 days longer than the control mice (Heppner et al., 2001).  
 That same year, Peretz et al. used recombinant antibody antigen-binding fragments 
(Fabs) to prevent PrPC conversion in ScN2a cells infected with PrPSc.  They observed a direct 
relationship between the amount of antibody binding to surface PrPC and its inhibition of PrPSc 
formation.  Their most effective Fab, D18, not only stopped PrPSc formation but also cleared 
pre-existing PrPSc.  In challenge experiments, mice infected with Scrapie cells pre-incubated 
with the antibodies, survived more than three months longer than those that received untreated 
cells.  The success of D18 had been attributed to its ability to bind to its specific epitope (132-
156) as well as recognizing/binding to cell surface PrPC molecules (Peretz et al., 2001b). 
 In 2004, two antibodies, SAF34 (specific for the octarepeat PrPC region) and SAF61 
(specific for 144-152 of both PrPC and PrPSc), were studied in neuroblastoma cells over-
expressing PrPC with and without PrPSc infection (Perrier et al., 2004).  When used 
independently, both antibodies decreased the levels of PrPC in uninfected and PrPSc infected 
cells, however, SAF61 was more effective.  When used cooperatively, they had a synergistic 
effect.  The authors suggested that SAF61’s mechanism of action was its quick clearance of 
PrPC, which removes the substrate required for PrPSc production.  Although treatment with 
SAF34 had a similar end result to SAF61, its mechanism is different.  SAF34 was unable to 
clear PrPC so it was hypothesized that it prevented interaction between PrPC and PrPSc, as 
suggested by previous work (Enari et al., 2001; Peretz et al., 2001b).  The epitopes recognized 
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by both SAF34 and SAF61 correspond to a region of PrP thought to be involved in an 
interaction with the laminin receptor (Hundt et al., 2001).  Consequently, the binding of SAF 
antibodies to PrP may interfere with this process (Perrier et al., 2004). 
 Using PrP-/- mice, Kim et al. produced a panel of antibodies to either recombinant PrP or 
PrPSc (Kim et al., 2004b).  They then tested the ability of the antibodies to protect ScN2a cells 
from infection.  From the results, they concluded that the criterium required for protection by 
antibody was not in the specificity of the epitope, but in the capacity of the antibody to bind cell 
surface PrPC (Kim et al., 2004a).  At the end of its natural cycle, surface-expressed PrPC 
becomes internalized via clarithrin vesicles and then enters the degradation pathway (Peters et 
al., 2003; Shyng et al., 1994).  It is during this internalization process, at the level of the cell 
membrane, that the conversion from PrPC to PrPSc is thought to occur (Borchelt et al., 1992; 
Caughey and Raymond, 1991).  Consequently, the authors suggested that the binding of mAb to 
surface PrPC prevents internalization and thereby inhibits the conversion process (Kim et al., 
2004a). 
 In contrast to targeting of surface PrP, Cardinale et al. developed anti-prion single chain 
antibody fragments (scFv) with an endoplasmic reticulum (ER) retention signal KDEL to target 
intracellular PrP.  Stable expression of these scFvs in nerve growth factor differentiating PC12 
cells inhibited PrPC translocation from the ER to the cell surface and prevented PrPSc 
accumulation (Cardinale et al., 2005).  They later applied this concept to an in vivo model.  
Lysates from wild-type and scFv (8H4)-expressing PC12 cells was injected intracerebrally into 
C57BL mice, 35 days after exposure to Scrapie.  Mice that received wild-type PC12 cell lysate 
succumbed to prion disease whereas only 2/10 mice in the scFv (8H4) group were infected.  At 
300 days post-infection, the eight mice in the experimental group remained symptom free with 
no detectable histopathology (Vetrugno et al., 2005).      
 
1.2.1.2  In vivo Immunization     
 
 The necessity for extracerebral PrPSc to undergo amplification in the periphery prior to 
neuroinvasion provides an opportunity for prophylaxis.  However, due to immunological 
tolerance to PrPC, attempts to stimulate humoral responses against prion proteins in vivo has 
proven challenging.  It was demonstrated in 1993 that it is possible to raise antibodies to PrP in 
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Prnp-/- mice (Prusiner et al., 1993).  Heppner et al. (2001) speculated that the use of genes 
encoding high-affinity anti-PrP antibodies produced in Prnp-/- mice might be able to redirect B-
cell responses in mice expressing PrPC.  They took Prnp-/- and Prnp+/- populations of mice and 
transgenically introduced genetic sequences which encoded for the heavy and light chains of 
6H4, a mAb specific for PrPC.  By four weeks of age, the Prnp-/- mice all produced consistently 
high anti-PrP titers.  Mice expressing PrP (Prnp+/-) developed anti-PrP antibodies more slowly 
than the control mice.  Unresponsiveness of B-cells likely corresponds to the level of self-
antigen presented (Adelstein et al., 1991) and B-cell receptor avidity/affinity (Tiegs et al., 
1993).  Therefore, the delay in production of anti-PrP in Prnp+/- mice may be due to negative 
selection of B-cells expressing 6H4 epitopes with high-avidity for PrPC  (Heppner et al., 2001).  
Consequently, the 6H4 produced by Prnp+/- mice may have different binding properties than 
6H4 produced by the Prnp-/- mice.  All mice were inoculated i.p. with RML Scrapie.  Following 
inoculation, spleen and brain were analyzed for the presence of PrPSc.  Spleens from the 
nontransgenic Prnp+/- group showed PrPSc accumulation while the Prnp+/--6H4 group did not.  
Brain samples, used to assess the ability of PrPSc to spread to the CNS, showed identical results 
to that of the spleen.  To rule out unintended mechanisms of PrPSc protection, the authors used 
Western blots to determine whether the presence of 6H4 was causing reduced expression of 
PrPC.  Equal levels of PrPC protein in both the transgenic and nontransgenic Prnp+/- mice 
indicated this was not the case.  It appeared that protection was mainly occurring via masking, 
by 6H4, of PrPC sites critical for interaction with PrPSc.  Because PrPC is an abundant self 
protein the risk of inducing autoimmunity is always a concern, however, no obvious signs of 
autoimmune disease were detected in this study (Heppner et al., 2001).                                         
While the presence of anti-PrP antibodies in the peripheral compartments does not 
appear to have any negative consequences, Solforosi et al. (2004) investigated the effect of 
anti-PrPC antibodies on neuronal cells in vivo.  PrPC D13 mAbs (1 mg/mL) were injected into 
the hippocampus of C57BL/10 mice.  Within 24 hrs, cross-linking of cell-surface PrPC by the 
antibodies resulted in rapid and extensive apoptosis of neurons in the hippocampal and 
cerebellar regions.  Further investigation revealed that the administration of monovalent Fab 
fragments from D13, via the same methods, produced apoptosis at a much reduced rate.  This 
suggested that the cross-linking event was most likely the cause of apoptosis.  In contrast to the 
previous results, experiments with a D18 mAb specific for a region involved in PrPC-PrPSc 
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interaction did not trigger apoptotic cell death.  This may be because D18 was ineffective at 
cross-linking PrPC or it obscured the region of PrPC which binds to a cofactor molecule 
necessary for apoptosis signalling (Solforosi et al., 2004).  
 
1.2.1.2.1  Passive Immunization 
 
 Further enthusiasm for anti-prion immunotherapy developed following the experiments 
of White et al. in 2003.  They were able to show that the passive transfer of anti-PrP IgG 
antibodies to wild type mice, which were subsequently i.p. challenged with PrPSc, resulted in a 
significant delay in prion symptoms (White et al., 2003).  The effects were most noticeable 
when a high antibody dose was administered biweekly during the splenic amplification phase.  
The treatment decreased splenic PrPSc at 60 days post-infection, and by 250 days, PrPSc was 
still undetectable in the brain.  An unfortunate limitation, however, was the inability of the anti-
PrP antibodies to effectively cross the blood-brain barrier which restricted protection by passive 
vaccination to the extraneural compartments.  This conclusion was inferred from results 
showing that passive antibody transfer had no effect on prion disease progression following 
intracranial challenge. 
 Also in 2003, the ability of mAbs 8B4 (residues 34-52), 8H4 (175-185), and 8F9 (205-
233) were tested to see if they provided passive protection against PrPSc challenge.  Mice were 
inoculated intraperitoneally with Scrapie at either a 10-fold or 1000-fold dilution.  Immediately 
after challenge, mice were injected with one of the three mAbs.  Antibody treatment was 
repeated each week until death.  In the group receiving the 1:10 diluted challenge material, both 
8H4 and 8B4 provided a 10% incubation prolongation; with the 1000-fold dilution, disease 
prevention was observed in 10% of mice treated with 8B4.  The ineffective response to 8F9 was 
likely due to its lower affinity for both PrPC and PrPSc.  While injected antibodies are rapidly 
cleared from the circulation, this experiment suggested further promise for antibody-based 
strategies (Sigurdsson et al., 2003).       
 It appears that the effectiveness of passive immunization was restricted to the peripheral 
compartments, likely by the blood brain barrier, as several experiments have shown 
development of prion disease following intracerebral inoculation despite peripheral treatment 
with anti-PrP antibodies.  There is, however, some potential application of antibody for 
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treatment of individuals accidentally exposed to prions.  Although anti-PrP antibodies are 
rapidly cleared from the blood, their brief presence does not seem to stimulate any detectable 
autoimmune reaction.  Whether this remains true for active vaccination strategies, where anti-
PrP antibodies are present for much longer periods of time, is a question that needs to be 
addressed.   
        
1.2.1.2.2  Active Immunization 
 
 Overcoming tolerance to PrPC is one of the greatest challenges for active PrP 
immunization.  Numerous investigations of different carrier systems [keyhole limpet 
hemocyanin (Hanan et al., 2001a), bacterial heatshock protein DnaK (Koller et al., 2002), 
multiple antigen peptide display (Sigurdsson et al., 2002)] and adjuvants [CpG ODN (Rosset et 
al., 2004), Freund’s complete or incomplete adjuvant (Hanan et al., 2001b; Polymenidou et al., 
2004), Montanide (Schwarz et al., 2003), TitreMax (Gilch et al., 2003)], have been employed 
as a way to compensate for the inherent lack of PrPC immunogenicity.  While many of the 
experiments use potent adjuvants, most are not suitable for use in humans or animals due to 
toxicity issues (Li et al., 2010).  Despite limitations posed by tolerance to PrPC, experiments 
have shown a relationship between antibody titers and protection from disease, therefore 
exhibiting the potential benefit of immunotherapeutic approaches. 
 The first group to show a delay in prion disease onset following active immunization 
with recombinant PrPC (residues 23-230) was Sigurdsson et al..  The results were modest with 
only a 10% increase in the incubation time in mice vaccinated (s.c.) at two week intervals 
starting 14 weeks prior to inoculation (i.p.).  Despite a delay in symptom onset, all mice died as 
a result of disease progression.  Those that were vaccinated at the time of inoculation did not 
benefit from the treatment.  The authors noted that high titers corresponded to prolonged 
incubation times, but following disease onset, there was no discernable histopathological 
difference between groups (Sigurdsson et al., 2002).        
 Other studies, which immunized against different regions of PrPC, demonstrated that 
different epitopes of the protein may have unique therapeutic value (Li et al., 2010).  
Experiments by Schwarz et al. (2003) compared the effectiveness of vaccinating with a short 
synthetic peptide (residue 105-125) to recombinant mouse PrP90-230 covalently linked to 
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keyhole limpet hemocyanine.  Immunization with PrP105-125 significantly prolonged survival 
by an average of 23 days over the adjuvant control animals.  Monoclonal antibodies with the 
same specificity had previously been shown to bind both PrPC and PrPSc.  They also prevented 
amyloid aggregation and dissolved preformed aggregates (Hanan et al., 2001a; Hanan et al., 
2001b).  In contrast to the previous work by Sigurdsson et al. with PrP23-230, the recombinant 
PrP90-230 immunization was not successful in delaying or preventing disease (Schwarz et al., 
2003).  They followed up with epitope mapping experiments to determine which epitopes, 
within PrP90-230 produced antibodies with the highest reactivity.  Antibodies to the region 
between 159-211 were the most highly detected by ELISA.  The authors suggested that only 
antibodies specific for residues 105-125 and 144-152 were effective in preventing prion disease 
(Schwarz et al., 2003).      
 
1.2.1.2.3  Mucosal Immunization 
 
 The majority of TSEs are transmitted orally; consequently, mucosal immunization may 
be an effective immunotherapeutic strategy.  Mucosal immunity is generally humoral and non-
inflammatory in nature.  Therefore, it is typically a safer alternative to subcutaneous or 
intramuscular immunization (Goni et al., 2005).  Immunological issues, such as those observed 
in a clinical trial of an Alzheimer’s vaccine (AN1792), illustrate a potential complication for the 
use of systemic vaccine delivery for neurological protein misfolding diseases.  The AN1792 
vaccine stimulates an immune response to the misfolded Aβ protein found in amyloid plaques 
which are thought to be responsible for causing Alzheimer’s disease symptoms/pathology.  The 
case report published by Nicoll et al. described a patient in the trial who rapidly declined and 
died six weeks following her last vaccination.  Post-mortem analysis revealed CD4+ 
lymphocytic meningoencephalitis accompanied by extensive macrophage infiltration of the 
cerebral white matter, indicative of a significant cell-mediated (Th1) inflammatory response 
(Nicoll et al., 2003).  While only one patient died, 6% of participants experienced serious side-
effects sufficient to bring the trial to a close.  Experts suggested that the vaccine may have 
stimulated too strong an immune response which weakened the barriers that normally protect 
the CNS from bacterial or viral attack, or that T-cell and microglial overactivation may have 
induced neuroinflammation (Solomon, 2004).              
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 Progress towards stimulating prion mucosal immunity was demonstrated by in vivo 
protection of mice following mucosal vaccination with PrP expressing Salmonella typhimurium 
(Goni et al., 2008).  The vaccination schedule consisted of weekly administration of four oral 
vaccinations using a live Salmonella construct followed by two injections of the same dead 
Salmonella construct.  Seven weeks after the first vaccination, mice were exposed, via oral 
gavage, to 139A Scrapie strain.  They found that 100% of mice expressing high IgA and IgG 
titers, and 33% of mice with high IgG and low IgA, were symptom-free 400 days after 
inoculation.  Histological and Western blot analysis verified a lack of PrPSc in the brains of 
asymptomatic animals (Goni et al., 2008).  It was anticipated that the level of protection would 
be directly linked to the magnitude of IgA production, but the 33% survival rate observed in the 
low IgA/high IgG group suggested other factors may also be important in determining vaccine 
efficacy (Goni et al., 2008).  They concluded that anti-PrP IgA is likely important in preventing 
prion uptake in the gut while systemic anti-PrP IgG interferes with the isoform conversion 
process.  One advantage of this system is the ability of Salmonella to target the key sites of 
prion uptake within the digestive tract, the M-cells (Li et al., 2010).  At the same time, the 
variation in Salmonella intra-gut survival, PrP expression, and level of gut penetration, pose 
significant challenges for stimulating the desired immunological response in each vaccinated 
animal (Goni et al., 2008).  Despite having only been tested in mice and not a larger animal 
model, the authors have provided insight into the type of immune response (non-inflammatory 
Th2) which may be necessary for providing protection against oral prion infections.                                              
 
1.2.1.2.4  Immunization Using Plasmid and Viral Vectors 
 
 Tolerance is likely the greatest challenge for immunotherapeutic strategies targeting 
PrPC.  Despite anergy or deletion of most B and T-cell expressing receptors specific for PrPC, 
experts believe it is possible to stimulate the limited anti-PrPC antibody repertoire using potent 
immunogenic delivery systems (Gregoire et al., 2005; Li et al., 2010).  Nikles et al. 
hypothesized that recombinant virus-like particles would function as more efficient B-cell 
immunogens than monovalent recombinant proteins, and consequently developed a retrovirus 
(murine leukemia virus) based PrP vaccine construct expressing residues 121-231 (PrP111) 
(Nikles et al., 2005).  Using three different groups of C57BL/6 mice with PrP genotypes, (Prnp 
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-/-, -/+, +/+) vaccination with PrP111 produced PrPC-specific responses with titers inversely 
proportional to the number of PrP alleles expressed.  The authors were surprised, however, by 
the similarity of IgM titers between the three genotypes in the early time points.  While class 
switching of PrPC-specific IgM to IgG antibodies was less pronounced in wild type animals 
compared to Prnp-/-, use of the murine leukemia virus delivery system appeared to provide 
antigenic T-helper determinants allowing for class switching to occur in the wild-type animals 
despite tolerance to PrP (Nikles et al., 2005).  Whether the level of antibodies produced by this 
construct are sufficient to be of therapeutic value remains to be determined.   
 In 2007, Kirnbaur’s group incorporated a PrPC B-cell epitope (144-152) into a capsid 
protein component of the bovine papillomavirus type 1 which was expressed by recombinant 
baculovirus technology.  Advantages of this carrier system are its ability to self-assemble into 
pentamers which further multimerize into virus-like particles and display the inserted PrP 
epitope at a density up to 360 copies per particle.  Additionally, virus-like particle vaccines that 
continuously induce anti-PrP antibody result in a more constant antibody concentration over 
time, consequently, fewer vaccinations may be required (Handisurya et al., 2007; Kirnbauer et 
al., 1992). The epitope, also recognized by mAb 6H4 and other commercial antibodies, was 
selected based on previous studies linking that region with PrPSc induced conformational 
changes (Handisurya et al., 2007).  Rabbits and rats were vaccinated with the virus particles, 
along with either Freund’s incomplete adjuvant or CpG, four times at 2-4 week intervals.  Anti-
PrP IgG antibodies were detected in both species two weeks after the last boost.  In vitro 
experiments using ScN2a and rabbit anti-PrP IgG demonstrated the ability of the antibodies to 
prevent de novo formation of PrPSc.      
Rosset et al. (2004) compared a plasmid expressing PrP as a vaccine in wild type and 
Prnp-/- C57BL/6 mice.  On its own, PrP plasmid DNA stimulated anti-PrP antibodies directed 
against the N-terminal region in the knock-out mice but failed to induce a response in the wild-
type animals.  The addition of CpG oligodeoxynucleotides, an adjuvant that helps stimulate 
dendritic cells (Krug et al., 2001) and B-cells (Krieg et al., 1995), to the PrP plasmid DNA 
formulation helped to successfully induce anti-PrP antibodies in the wild-type mice (Rosset et 
al., 2004).  The epitopes recognized by these antibodies were unique to those produced in Prnp-
/- mice and specific for the C-terminal portion of PrP.  Another difference was that antibodies in 
Prnp-/- mice recognized membrane bound PrPC whereas none of the antibodies from wild-type 
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animals did.  The authors suggested that antibodies were specific for different locations on PrP 
despite identical immunizations because B-cells specific for native PrPC epitopes are strongly 
tolerated (Gregoire et al., 2005).  It was also observed that Prnp-/- antibodies were primarily of 
the IgG1 isotype whereas antibodies from wild-type mice were mainly IgG2b, an indication 
that the immune response in wild-type animals was skewied toward a Th1 cell-mediated 
response.  The authors concluded that antibodies stimulated by PrP plasmid DNA + CpG, while 
unable to bind PrPC, might be effective in blocking PrPSc replication by targeting regions 
uniquely exposed in the PrPSc conformation (Gregoire et al., 2005).   
 More recently it was suggested that the use of xenogenic antigens may be effective in 
circumventing tolerance to autoantigens such as PrPC.  Although 90% of the prion amino acid 
sequence is conserved among mammals, it was demonstrated that vaccination of mice with 
bovine PrP stimulated the production of anti-PrP antibodies (Ishibashi et al., 2007).  Tang et al. 
implemented xenogenic prion (human) expression via an adenovirus vector system which had 
been shown previously, in cancer studies, to be a potent generator of antibody (CD4+) and cell-
mediated (CD8+) responses to both the viral capsid proteins as well as the transgene (Tang et 
al., 2004).  In C57BL/6 wild-type mice, the authors compared dendritic cell mediated delivery 
with direct administration of the adenovirus vector.  The dendritic cell mediated treatment, 
only, was able to break B-cell tolerance against murine PrP, producing antibodies which 
increased the survival of prion-infected mice by an average of 37 days (n=5) without 
stimulating T-cell directed autoimmunity (Rosset et al., 2009).   
 
1.2.1.2.5  PrPSc-specific Immunotherapy    
 
 The understanding about the physiological function of the PrPC is still limited.  For this 
reason, it may not be the safest strategy to target an immune response towards such a 
commonly expressed protein.  It has previously been demonstrated that antibodies which 
crosslink PrPC in neural tissue cause apoptosis (Solforosi et al., 2004).  The systemic presence 
of autoreactive PrPC antibodies may also lead to an impairment of the natural function of PrPC, 
inappropriate cell signal activation, or stimulation of suppressor T-cell lymphocytes (Li et al., 
2010).  An alternative immunotherapeutic strategy is to stimulate an immune response specific 
for the PrPSc conformation.  While this approach is challenged by the lack of PrPSc structural 
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information, it may present a more viable method for circumventing the body’s tolerance 
mechanisms to PrPC and avoid induction of autoimmunity.    
 In 2007, Pilon et al. (2007) created three peptide vaccine constructs ranging in length 
from 13 to 29 amino acids.  One construct contained a tyrosine-tyrosine-arginine motif on α-
helix 1 which was one of the two regions predicted by Paramithiotis et al. (2003) to be 
selectively exposed on the PrPSc conformation.  Results from vaccination trials showed all three 
constructs to be moderately immunogenic, with the α-helix 1 group displaying higher median 
titers than the other two groups.  In a Scrapie challenge experiment, the best result observed 
was a 20 day increase in survival when compared to the control group.  There was, however, a 
lack of correlation between the longest surviving group and the group with the highest median 
titers.  The authors concluded that a successful vaccine would need to address two main issues; 
overcoming self-tolerance and stimulating antibodies with high affinity for the PrPSc 
conformation (Pilon et al., 2007).        
 One strategy for establishing an immune response to the infectious prion conformation 
would be to identity a cryptic epitope specifically exposed in the PrPSc conformation.  In an 
attempt to address this issue, it was found that during the refolding process from PrPC to PrPSc, 
there is increased solvent exposure of tyrosine (Y) side chains (Paramithiotis et al., 2003).  The 
majority of these residues are located in the structured C-terminal domain, a region linked to 
infectivity and protease resistance (Riek et al., 1996).  Of the 11 residues in the structured 
region, 6 are present in bi-tyrosine pairs, a motif that is conserved in human, sheep, mouse, 
hamster, cattle and deer [Figure 1.5].  Two pairs are in conjunction with a C-terminal arginine 
(R), one of which is located on α–helix 1 and the other on β-strand 2.  It was hypothesized by 
Paramithiotis et al. that a YY-motif located on a β–sheet may present an epitope specific for the 
PrPSc conformation.  Testing of this hypothesis resulted in the production of rabbit antiserum 
that selectively immunoprecipitated (IP) PrPSc from infected mouse brain and not PrPC from 
uninfected brains (Paramithiotis et al., 2003).  These results indicate that the YYR epitope on 
β2–sheet may represent a strong vaccine target for the stimulation of a specific PrPSc immune 
response.  Despite use of an aggressive vaccination protocol which utilises the commonly used 
vaccine carrier molecule KLH and potent adjuvants such as Freund’s Complete, this strategy  
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Figure 1.5: Conserved Tyr-Tyr-X motifs in aligned amino-acid sequences of sheep, 
bovine, human, mouse, elk, mule deer and whitetail deer PrP. 
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has been limited by poor immunogenicity where IgM was the only antibody isotype detected 
(Paramithiotis et al., 2003). 
 
1.2.1.2.5.1  Peptide-Based Vaccine Design 
 
 Traditional vaccines are often designed using attenuated live or inactivated 
microorganisms.  Culturing these organisms can be difficult and even the safest attenuated 
vaccine systems can produce harmful immune responses.  For diseases such as cancer, and 
protein misfolding diseases like TSEs, Parkinson’s, Alzheimer’s and Huntington’s disease, 
pathology is linked to altered self-proteins.  As a result, normal vaccine strategies are not 
applicable due to robust tolerance mechanisms.  Extensive research has determined that short 
peptide fragments derived from residues found on the much larger self-proteins, can stimulate 
very specific immune responses (Purcell et al., 2007).  The ability to target only the ‘rogue’ self  
proteins may serve as a powerful tool in preventing the transmission of these diseases or 
progression of symptoms/pathology in already sick individuals, without stimulating 
autoimmunity. 
 Peptide vaccine technology offers advantages in terms of safety and ease of production.  
Peptide preparations can be freeze-dried, making their transportation and storage much easier 
than those vaccines requiring refrigeration.  Their safety is derived from the ability to create an 
immune response without the requirement of infectious material such as that required for 
attenuated vaccines.  Also, the absence of genetic material eliminates the risk of genetic 
integration or recombination with the patient’s genome, a concern posed by DNA vaccines.  
Furthermore, large scale production of peptides is economical, and purity is easily analyzed 
using liquid chromatography and mass spectrometry (Purcell et al., 2007). 
 Vaccinating with an exogenously administered peptide can be challenging because the 
exact pathway by which the peptide is processed and then presented to immune cells is thought 
to be different than for traditional antigens and not well understood (Purcell et al., 2007).  To 
successfully activate B-cells specific for a certain target, the peptide fragment has to represent 
the appropriate conformation.  For this to be achieved, structural knowledge of the native 
antigen is very beneficial (Purcell et al., 2003).  Consequently, peptide vaccine design for TSEs 
is made more challenging due to the lack of structural data for the misfolded prion protein. 
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An additional challenge for peptide vaccine design is overcoming the weaker 
immunogenicity of the peptide fragments, a drawback attributed to their small size.  This is 
particularly true of the cryptic YYR epitope identified by Paramithiotis et al. (2003) as a 
potential peptide target for prion immunotherapy.  This three amino acid motif, due to its size, 
has the immunological characteristics of a hapten.  A hapten is an antigen which on its own 
lacks sufficient immunogenicity to stimulate an immune response.  Consequently, haptens are 
usually coupled to a larger immunogenic carrier molecule such as tetanus toxoid or KLH.  
When such an immunogenic complex is presented to the immune system, antibodies to the 
carrier, hapten and junction between the hapten and carrier, are produced.  Successful activation 
of the humoral branch of the immune system against a given antigen “A” requires two 
components.  The first is the activation of the T-helper (Th) CD4+ cell which occurs via 
interaction with an antigen presenting cell (APC) (usually a macrophage, dendritic cell or B-
cell) displaying the antigen A in the context of a surface MHC II molecule (Mond et al., 1995).  
One of the main functions of an APC is to phagocytose cellular debris, degrade it into peptide 
fragments which attach to MHC II molecules and are translocated to the cell surface for 
presentation to the immune system (while both endogenous and exogenous peptide processing 
occurs, this discussion will focus on the exogenous component).  If a Th-cell recognizes antigen 
A, it binds to it (producing signal #1) and receives a costimulatory signal (signal #2) from the 
APC, completing the activation requirements of the Th-cell.  The second component requires a 
B-cell that has an Ig receptor on its surface specific for antigen A.  This interaction alone is not 
sufficient to activate the B-cell.  It needs authorization from a Th-cell with the same specificity 
to antigen A.  Once this occurs, the B-cell becomes activated and produces Abs specific for 
antigen A (Purcell et al., 2007).  Therefore, the goal of a successful vaccine carrier molecule is 
to provide Th epitopes which will help activate a robust B-cell response to the poorly 
immunogenic hapten.  By specifically testing for these different groups of antibodies using 
peptide-specific ELISAs it is possible to determine the effectiveness of the vaccine construct. 
 
1.2.1.2.5.2  GnRH as a Model for Vaccine Design Against Endogenous Peptides. 
 
There was a significant amount of work done in the 1990’s on a vaccine strategy for 
targeting the gonadotropin-releasing hormone (GnRH).  GnRH is an important hormone which 
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helps regulate the release of pituitary gonadotropins (Schally et al., 1973).  Immunological 
neutralization of GnRH has the potential for use in treatment of sex hormone-related 
malignancies (Meloen et al., 1995) without the side effects caused by castration (Meloen et al., 
1994).  Issues such as carrier molecule selection and antigen presentation were addressed to 
compensate for the weak immunogenicity of the GnRH peptide.  
In an effort to find a effective carrier molecule, Manns et al. (1997) found they could 
stimulate significant GnRH peptide-specific responses using the carrier molecule Leukotoxin 
(Lkt), a truncated 96 kDa multiple repeat toxin containing many Th-cell epitopes derived from 
Pasteurella haemolytica.  Typically, the strategy used for coupling vaccine carrier molecules to 
weakly immunogenic peptides is through a chemical conjugation using carbodi-imide (Fraser et 
al., 1974).  This method, however, is labour intensive when used to produce a highly purified 
and homogenous protein and is not cost effective for use in a commercial vaccine (Manns et al., 
1997).  Furthermore, this process can interfere with the biological activity of the carrier 
molecule by physically obstructing immunogenic epitopes.  Consequently, a genetic construct 
was utilised, within a highly regulated bacterial expression system, to produce large amounts of 
identical chimeric Lkt-GnRH proteins (Manns et al., 1997). 
 Antigen presentation is an important variable affecting the immunogenicity of an 
endogenous peptide.  While trying to figure out how to alter the GnRH peptide to increase its 
immunogenicity, one research group speculated that creating tandem repeats of the original 10 
amino acid sequence may help reduce the appearance of “self”.  Their experiments showed that 
all animals vaccinated with the tandem repeat responded to the treatment whereas only two out 
of five responded to vaccination with the non-repeated construct (Meloen et al., 1994).  
Another group of researchers investigated the effect of epitope orientation on immunogenicity.  
Results indicated that the synthesis of an inverted repeat yielded an increase in immunogenicity 
similar to that seen in the repeated versus non-repeated constructs (Ghosh and Jackson, 1999).  
An example of an inverted repeat versus a linear repeat for a given hypothetical three residue 
epitope would be XYZZYX and XYZXYZ, respectively. 
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1.3  Importance of a TSE Vaccine     
            
 Discovering the link between BSE and the vCJD outbreak of 1996 brought TSEs to the 
attention of the public and health professionals.  As many as 180,000 BSE cases were 
identified, triggering the culling of 750,000 animals (Donnelly et al., 2002; Wilesmith et al., 
1988).  Experts suggested that as many as 3 million BSE-infected animals entered the human 
and animal food chains undetected (Donnelly et al., 2002).  While confirmed cases of vCJD are 
only at 188 worldwide (Collee et al., 2006), the potential spread via contaminated blood or 
tissue products taken from asymptomatic carriers is of great concern. 
 CWD is the most contagious of the TSE’s and presents a significant threat to both wild 
and farmed deer populations with rates of infectivity as high as 30% and 100%, respectively 
(Williams, 2005).  The possibility for cross-species infectivity with humans and farmed 
animals, as well as its ability to persist in the environment for years, and a poor understanding 
of CWD transmission, make containment using current resources unattainable (Sigurdson and 
Aguzzi, 2007).   
 As a group, TSE’s have had undeniable economical impact, leaving many countries 
with billions of dollars in lost revenue due to border closures and weakened consumer 
confidence.  While key historical TSE events have provided the momentum for research 
initiatives aimed at understanding PrPC function, PrPSc infectivity and designing effective pre-
mortem diagnostics and therapeutic strategies, definitive answers in these areas remain elusive.  
Despite the research initiatives that have been underway for a few decades, there are still large 
deficits in key areas of understanding such as PrPC function and pre-mortem diagnostics. 
Identifying a disease-specific epitope may have significant applications in more than one of 
these TSE research areas.  These events have provided the momentum for research initiatives 
aimed at understanding PrPC function, PrPSc infectivity and designing effective diagnostic tests 
and therapeutic strategies.   
 
1.4  Other Protein Misfolding Diseases 
 
 The development of a successful vaccine strategy for prion disease, using cryptic 
epitopes, may shed light on how similar approaches can be used in the battle against other 
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protein misfolding diseases such as ALS, Alzheimer’s, and Parkinson’s.  ALS is a 
neurodegenerative disease most commonly associated with pathology within the upper and 
lower motor neurons of the spinal cord (Bruijn et al., 2004).  Pathogenesis has been linked to 
the intracellular accumulation of aggregates consisting of a misfolded version of the 
endogenous protein superoxide dismutase (SOD1) (Nordlund and Oliveberg, 2008).  Non-
pathogenic SOD1 is a soluble homo-dimer expressed in neurons which helps to reduce 
oxidative damage from free radical species (Rakhit et al., 2006).  The mechanism causing the 
misfolding of SOD1 is not well understood but is hypothesized to be a result of mutations in the 
SOD1 gene (Shaw and Valentine, 2007).  Research on identifying a conformational epitope 
specific for the pathological conformation began in 2006 when Rakhit et al. reported that they 
identified an epitope on misfolded SOD1 monomers that is normally buried in native SOD1 
dimers.   
Like TSEs, Alzheimer’s is a neurodegenerative disease and typically causes dementia in 
the form of memory loss, and impairment of language, reasoning, and judgment in the elderly 
population (Hooper and Turner, 2008).  Alzheimer’s disease, however, has a much higher 
prevalence rate with 29.3 million people worldwide currently suffering from the disease (Wimo 
et al., 2007) and no acceptable therapeutic agents are currently available (Roberson and Mucke, 
2006).  Symptoms are caused by the deposition of neuronal plaques consisting primarily of 
insoluble amyloid-β (Aβ) peptides that are 40-42 amino acids in length (Mattson, 2004).  
Unlike the pathological misfolding of PrPC to produce PrPSc, the formation of Aβ results from 
the proteolytic cleavage of the amyloid precursor protein (APP) by the enzyme β-secretase 
(Hooper and Turner, 2008).  Normally, APP is cleaved by α-secretase to produce a soluble 
isomer called sAβ which is readily detectable in serum and cerebrospinal fluid (Walsh and 
Selkoe, 2007).  Analysis of the proteolytic pathway producing Aβ has shown it to have a 
physiologic function that responds to neurological activity.  Increased activity results in 
increased Aβ formation which reduces excitatory synaptic transmission.  In the diseased state, 
overproduction of Aβ peptide and/or failure of the degradation enzymes leads to 
oligomerization and aggregation which over time results in senile plaque formation 
(extracellular amyloid deposits) and symptom development (Ghochikyan, 2009).  
Parkinson disease (PD) is a neurodegenerative disorder that typically affects movement.  
Symptoms result from a tropic loss of dopaminergic neurons located in the substantia nigra, an 
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area responsible for the initiation of intentional movements (Kazantsev and Kolchinsky, 2008), 
and the formation of cytoplasmic inclusions referred to as Lewy bodies (Emadi et al., 2009).  
The main therapeutic strategy is dopamine replacement using a dopamine precursor molecule 
called levodopa; however, after prolonged use this strategy becomes ineffective (Kazantsev and 
Kolchinsky, 2008).  Research has shown that PD-associated neuronal damage results from an 
accumulation of misfolded α-synuclein, which forms neurotoxic aggregates.  The presence of 
these aggregates interfere with cytoskeleton components as well as mitochondrial and cellular 
membranes (Kazantsev and Kolchinsky, 2008).  They have also been detected in extracellular 
compartments such as plasma and cerebrospinal fluid of PD patients (El-Agnaf et al., 2006).  
Non-pathogenic α-synuclein is 14 kDa and is most often found in the presynaptic terminals of 
neurons (Iwai et al., 1995).  Existing normally as an unfolded protein, α-synuclein can adopt 
many different conformations such as fibrils, oligomers, small aggregates, spherical and linear 
protofibrils (Conway et al., 1998; Serpell et al., 2000).  The oligomeric conformation has been 
linked to the neurodegenerative effects seen in PD (Volles and Lansbury, 2003; Volles et al., 
2001).  Work by Emadi et al. has shown it is possible to detect the different morphological 
conformations of α-synuclein using single chain variable domain antibody fragments.  This 
allows for the possibility that the stimulation of a conformation specific immune response may 
be a realistic therapeutic strategy (Emadi et al., 2009).  
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1.5  Hypothesis and Objectives 
 
Using the YYR epitope, unique to the infectious conformation of the prion protein, it is 
hypothesized that through epitope optimization, significant antibody responses can be 
stimulated in mice, cows and cervids as a result of sequence homology between species.  
  The objectives of this project were to:   
1)  Design a series of vaccine constructs based on different lengths of YYR 
motif to test their capacity to stimulate specific Ab responses in vivo (using 
sheep and mice).  
2)  Develop enzyme-linked immunoabsorbent assays (ELISA) to assess epitope-
specific Ab titres.  
3)  Determine what vaccine dose is most immunogenic for each species being 
used in the vaccine trials.  
4)  Determine if there is an immunological advantage to increasing the number 
and orientation of the YYR repeats incorporated into the vaccine construct. 
5)  Evaluate the specificity of the antibody responses for PrPC and PrPSc 
6)  Evaluate vaccine immunogenicity in cervid species.   
7)  Assess safety of the vaccine by screening for antibodies which may cross 
react with PrPC.  
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2.0  MATERIALS AND METHODS  
 
2.1  Animals 
 
 Mice were obtained from Charles River (Wilmington, MA) and housed in the animal 
care facilities at the Vaccine and Infectious Disease Organization (VIDO).  Mice were typically 
four to six weeks of age at the start of each experiment. 
 Sheep were obtained from the University of Saskatchewan breeding program associated 
with the Animal Science Department.  Sheep have genetic polymorphisms within the PrP gene 
(at codons 136, 154 and 171) which influence susceptibility to prion disease.  The most 
common phenotypes in the order of susceptible to resistant are: valine, arginine, glutamine 
(VRQ); alanine, arginine, glutamine (ARQ) and alanine, arginine, arginine (ARR).  Of the 
prion susceptible phenotypes, VRQ is very rare.  The majority of sheep used in these studies 
were bred from ARQ homozygous breeding pairs.  The lambs typically consisted of mixed sex 
and breed (Suffolk and Arcott) and ranged from 1-6 months in age at the beginning of a trial.  
For each trial, however, the groups of animals being used were aged matched, to allow for 
better comparison among experimental groups.  Sheep were housed in outdoor pens, fed a 
standard ration at VIDO, and all experimental procedures were performed by VIDO Animal 
Care technicians during trials. 
 Sheep used in the Norwegian Scrapie challenge trial were from the Rygia breed and 
ranged in age from 0-7 years of age.  Animals were housed in dedicated Scrapie isolation pens 
at the Sheep and Goat Research Station in Sandes, Norway.  Experimental procedures were 
supervised by Dr. Martha Ulvund, and sheep were handled by the Animal Care staff at the 
research station in Sandes.     
Elk and Whitetail deer were puchased by the University of Saskatchewan and housed at 
the Goodale Research farm located 9 miles South East of Saskatoon.  The animals ranged in 
age from 1-5 years of age.  Experimental procedures were supervised by Dr. Trent Bollinger, 
Western College of Veterinary Medicine, and the deer were handled by the Goodale staff.   
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2.2  Epitope Design and Construction 
 
2.2.1  Peptide Synthesis for ELISA 
 
 To detect peptide-specific antibody responses, peptides of the same sequence as the 
epitopes were chemically synthesized on a Pioneer solid-phase peptide synthesizer (PerSeptive 
Biosystems, Foster City, CA) using Fmoc (9-fluorenylmethoxy carbonyl) chemistry. The 
peptide chains were synthesized from the carboxyl terminus to the amino terminus onto [5-(4-
Fmoc-aminomethyl-3,5-dimethyloxyphenoxy) valeric acid]-polyethylene glycol-polystyrene 
(PAL-PEG-PS) resin. Fmoc-protecting groups at the amino terminus were deprotected with 
piperidine.  The peptides were cleaved from the resin with concurrent deprotection of the side 
chain-protecting groups by treating the resin-bound peptide with trifluoroacetic acid (TFA) (9.3 
parts) in the presence of scavengers (anisole-ethyl-methyl sulfide-1, 2-ethanedithiol [3:3:1]), for 
7 h.  The crude peptides were filtered from the resin, and the TFA was evaporated.  Diethyl 
ether was added to the residues to precipitate the crude peptide.  The peptides were isolated and 
purified by high-performance liquid chromatography (HPLC) on Vydac protein C4 columns 
(1.0 by 25 cm) eluting with a linear gradient of 10% buffer A (H2O-0.1% TFA)-90% buffer B 
(acetonitrile-H2O [90/10]-0.01% TFA) for 40 min at a flow rate of 3 mL/min.  The purity and 
molecular weight of the respective peptides were confirmed by matrix-assisted laser desorption 
ionization (MALDI)-time of flight mass spectrometry on a PE Biosystems Voyager system 
4068 (National Research Council, Plant Biotechnology Institute, Saskatoon, Canada). 
 
2.2.2  Recombinant Lkt-YYR Constructs 
 
Genes corresponding to the desired epitopes were synthesized with flanking BamHI and 
NcoI restriction sites by Codon Devices (Cambridge, MA) and BioBasic (Markham, ON) to 
facilitate their insertion into the Lkt expression vector pAA352 (Potter AA and Manns JG, 
2000).  The appropriate fragments were sub-cloned, via NcoI and BamHI restriction sites, into 
pAA352 [Figure 2.1] which contains a gene encoding a 96 kDa version of the Lkt protein such 
that the antigens are expressed as C-terminal fusions.  A series of plasmid constructs were  
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Figure 2.1: Map of pAA352 Lkt expression vector.  The plasmid contains an ampicillin 
(Amp) resistance gene to allow for plasmid screening.  YYR constructs were inserted at the C-
terminal end of the Lkt gene using the restriction sites BamHI and NcoI.  Leukotoxin 
expression is under regulations of a hybrid trp::lac promoter from E.coli. 
 
 
 
 
 
 
 
!
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created representing different expansions of the YYR epitope as well as different presentations 
(either linear or inverted repeats) [Table 2.1].  All plasmids were sequenced verified in-house 
using the Beckman Coultier CEQ 2000XL DNA Analysis System and manufacturer’s 
specifications for the CEQ Dye Terminator Cycle Sequencing with Quick Start Kit (Beckman 
Coulter).  
 
2.2.2.1  Growth and Induction of Lkt expression Vectors 
 
Eschericia coli DH5αF5 cells were transformed with chimeric Lkt expression vectors 
and incubated overnight at in 10 mL of Luira-Bertani (LB) broth with 100 µg of ampicillin 
shaking at 220 rpm at 37 °C.  The overnight culture was used to inoculate 500 mL of pre-
warmed LB broth containing ampicillin.  Incubation at 37 °C with shaking was continued until 
an OD600 of 0.6 was achieved.  Cells were then induced using sterile isopropyl beta-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM and incubated for 3 h at 37 °C.  
Cells were harvested by centrifugation at 10,000 x g for 15 minutes at 4 °C.  The supernatant 
was discarded and cell pellets were re-suspended in 25% sucrose, 50 mM Tris pH 8.0 (4 mL/L 
of culture) and then frozen at -80 °C.   
 
2.2.2.2  Lysis and Purification/Solubilization of Lkt fusion proteins 
 
Cells were thawed at room temperature and 1 mL of lysozyme (10 mg/mL) was added 
per 4 mL of re-suspended pellet.  This solution was mixed, set on ice for 15 minutes before 
adding 20 mL RIPA:TET buffer (5:4; RIPA containing 20 mM Tris-HCl pH 8.0, 200 mM NaCl 
and 2% sodium deoxycholate; TET containing 100 mM Tris-HCl 8.0, 50 mM EDTA and 2% 
Triton X-100), inverted quickly, vortexed for 20 seconds, and then placed on ice for 20 
minutes.  The cell mix was then sonicated three times with a 3/4 inch probe at 50% for 20 
seconds.  Cells were centrifuged at 25,000 x g for 20 minutes, the supernatant discarded and 
tubes were inverted on tissue to drain supernatant off the pellet.  The pellet was resuspended in 
1 mL of 4 M guanidine-HCl per 30 mg pellet and then stored at 4 °C overnight.  Particulates 
were removed by centrifugation at 1,300 x g for 10 minutes and the supernatant was decanted.  
Protein purity and quantity in the supernatant was determined using electrophoresis in SDS  
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Table 2.1: PrP Peptide Sequences and Presentations.  Constructs were created, based on the 
ovine PrP sequence, as C-terminal fusion to the Lkt protein.  Nomenclature indicates YYR 
from alpha helix 1 (α1) or beta sheet 2 (β2), the direction and magnitude of epitope expansion 
and the presentation as either linear (L) or inverted (I) epitopes represented graphically by the 
arrows in the “Presentation” column.   
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PAGE with Coomassie Blue staining and compared relative to BSA standards.  The isolated 
protein was determined to be greater than 85% pure. 
 
2.2.3  Recombinant Lkt-PrPC  
 
 Recombinant Lkt-PrPC constructs were synthesized using the same protocol as the Lkt-
YYR constructs but with the following modifications: full-length ovine PrPC was synthesized 
with flanking restrictions sites by BioBasic to facilitate its insertion into pAA352 at the C-
terminal end as a non-repeated, linear sequence. 
 
2.2.4  Bacterial Strains 
 
 Competent DH5αF5 E. coli cells (VIDO) were transformed by our pAA352 Lkt-YYR 
based constructs. 
 
2.2.4.1  Competent Cells 
 
   Competent E. coli DH5αF5 cells were prepared by treating a log phase culture that had 
been centrifuged at 5,000 x g for 5 minutes at 4 ºC with sterile 0.1 M CaCl2 and cooling on ice 
for 20 minutes.  Cells were centrifuged again as above and resuspended in chilled 0.1 M CaCl2 
with 17.5% glycerol on ice for 20 minutes and then stored at -80 ºC (Sambrook and Russell, 
2001).  
 
2.2.5  Bacterial Growth Media 
 
 To facilitate growth of E. coli bacteria containing specific plasmids for mini-preps, 
cultures were inoculated into LB broth (BD Biosciences) which consists of 10 g tryptone, 5 g 
yeast, and 10 g NaCl for every 1 L of water.  Once necessary ingredients are added the medium 
is sterilized in the autoclave at 121 ºC for 15 minutes.  Once cooled, ampicillin was added to 
make a final concentration of 100 µg/mL (LB-amp100) which allowed for selection of bacteria 
containing plasmid DNA following transformation.      
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2.2.6  Vectors 
 
Three different vectors were used throughout this project.  The majority of the 
molecular experiments involved the use pAA352 which was made at VIDO.  Epitope constructs 
synthesized by BioBasic were sent in generic pUC57 vectors allowing for the extraction of the 
sequence of interest using restriction digestion with BamHI and NcoI for the Lkt fusion 
constructs.  Double digestions were carried out for the pAA352 and pUC57 vectors as follows: 
10 Units (U) of NcoI and 20 U of BamHI were added to 1 µL of plasmid, 5 µL of NEbuffer 3, 
0.5 µL BSA, 1 µL RNase and 36 µL ddH20.  The reaction mix was incubated at 37 ºC for 60 
minutes and then heat inactivated at 65 ºC for 20 minutes.  Samples (pUC57) were run on an 
agarose gel to visualize and excise the portion of the gel containing the fragments of interest, 
which was then processed with the Wizard SV gel and PCR cleanup system (Promega) 
according to manufacturers specifications.  For ligation, 30 µL of insert was added to: 2 µL of 
pAA352 (the ratio of insert to plasmid, 15:1, was established by the difference in the number of 
base pairs between the two), 3 U of T4 DNA ligase and 3.5 µL ligase buffer.  Samples were 
incubated at room temperature for 10 minutes and then inactivated at 65 ºC for 10 minutes.  A 
description of the amino acid and nucleic acid sequence for the β2(YYR)L construct is 
provided in Table 2.2 with the rest of the construct descriptions are included in the Appendix 
A.  
 
2.2.7  Transformation 
 
 Competent cells were thawed on ice for 30 minutes.  Plasmid DNA (2 µg) was added to 
20 µL of cells and placed on ice for 30 min.  The culture was heat-shocked at 42 ºC for 90 
seconds and put on ice for 2 minutes.  Pre-warmed LB broth (100 µL) was added and incubated 
at 37 ºC for one hour.  Cells were then plated on LB-amp100 plates overnight at 37 ºC and 
screened for viable colonies. 
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Table 2.2: The amino acid and nucleic acid sequence of the β2(YYR)L construct 
(Sequences for all the other constructs used in this project have been included in 
Appendix A). 
 
 
 
Construct β2(YYR)L 
 
Amino Acid 
Sequence 
GSYYRSGSYYRGSSYYRSGSYYRGSSYYRSGSYYRGSSYYR
SGSYYRGSSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC TAC TAT CGT AGC GGT TCT TAC TAT CGC GGC 
TCT AGC TAC TAT CGT AGC GGT AGC TAC TAT CGC AGC 
GGT TCT TAC TAT CGT GGC TCT AGC TAC TAT CGC AGC 
GGT TCT TAC TAT CGT AGC GGT TCT TAC TAT CGC GGC 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
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2.2.8  SDS-PAGE Analysis 
 
Samples were loaded with 5x SDS loading dye onto a 10% acrylamide gel with a pre-
stained low range molecular weight marker (Biorad).  Gels were run in SDS-PAGE buffer at 
100 V for 2 hours or until the dye beyond the end of the gel.  Gels were then stained for 30 
minutes with Coomassie blue and then de-stained overnight.   
 
2.2.9  Western Blot 
 
Lkt-YYR chimera proteins were resolved through a 10% SDS-PAGE gel.  Following 
electrophoresis, the proteins were transblotted onto polyvinylidene difluoride membranes 
(PolyScreen; Perkin Elmer Life Sciences).  The membranes were blocked with 3% molecular 
grade fat-free skim milk powder in phosphate-buffered saline containing 0.02% Tween 20.  
Primary and secondary washes were carried out using this sample buffer.  The 6H4 mAb was 
used to detect prion protein. 
 
2.2.10  Mini-prep Isolation of Plasmid DNA 
 
 Following transformation, individual colonies were selected from the LB-amp100 
overnight plates and inoculated into 5 mL of fresh LB-amp100 broth for overnight incubation in 
a 37 ºC shaker.  The cultures were centrifuged at 18,000 x g for 5 minutes and then DNA was 
isolated using the Wizard Plus SV Miniprep DNA Purification System by Promega.  Pellets 
were resuspended in 250 µL of the provided solution (50 mM Tris-HCl (pH 7.5), 10 mM 
EDTA and 100 µg/mL of RNase A) and vortexed.  Cell lysis solution (250 µL) containing 0.2 
M NaOH and 1% SDS was added and gently mixed using tube inversion followed by a 5 
minute incubation at room temperature.  10 µL of alkaline phosphatase was added and mixed 
by inversion 4 times and then incubated for 5 minutes.  Neutralization solution (350 µL) 
containing 4.09 M guanidine hydrochloride, 0.759 M potassium acetate and 2.12 M glacial 
acetic acid was added and mixed by inversion.  Samples were centrifuged at 18,000 x g for 10 
minutes at room temperature.  The supernatant was transferred to a spin column and centrifuged 
at maximum speed for one minute.  The column was transferred to a new tube and washed with 
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750 µL of 60 mM potassium acetate, 8.3 mM Tris-HCl (pH 7.5), 0.04 mM EDTA (pH 8.0) and 
60% Ethanol.  Following a second centrifugation, another 250 µL of column wash solution was 
added.  Samples were centrifuged at 18,000 g for two minutes and the column was transferred 
to a new tube where 50 µL of Nuclease-Free Water was added and incubated for one minute 
and then centrifuged for one minute as above.  The DNA in the bottom of the microcentrifuge 
tube was then ready to be run on an agarose gel for visualisation.    
 
2.2.11  Agarose Gel Electrophoresis 
 
 Plasmids were analysed for the presence of an insert using 1% agarose gel 
electrophoresis and a DNA supercoiled ladder to identify the molecular weight of the plasmid 
DNA.  Gels were run at 100 V for 30-45 minutes in 1x TAE buffer (40 mM Tris, 20 mM acetic 
acid, 1 mM EDTA).     
 
2.3  Immunization 
 
2.3.1  Mice 
 
Balb/c and C57BL/6 mice were immunized subcutaneously with 10 µl of Lkt 
recombinant fusions prepared in 60 µl of PBS (0.188 M Na2HPO4, 0.012 M NaH2PO4, 0.137 M 
NaCl, pH 7.8) and 30 µl of Emulsigen-D (MVP Technologies) for a final injection volume of 
100 µl/ vaccine dose.  Emulsigen-D contains the immunostimulant dimethyl dioctadecyl 
ammonium bromide.  Vaccines were administered at three-week intervals by the Animal Care 
staff at VIDO.  Initial vaccination experiments, demonstrated that vaccination at three-week 
intervals was the minimum amount of time required between boost to stimulate maximal 
antibody responses.   
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2.3.2  Deer/Elk 
 
 Deer and elk were immunized subcutaneously with 50 µl of the Lkt recombinant fusions 
prepared in 650 µl of PBS (0.188M Na2HPO4, 0.012M NaH2PO4, 1.8% NaCl, pH 7.8) and 300 
µL Emulsigen-D for a final injection volume of 1 mL/vaccine dose.  Vaccines were 
administered at six-week intervals by Dr. Trent Bollinger and the Goodale farm staff. 
 
2.3.3  Sheep 
 
2.3.3.1  University of Saskatchewan 
 
 Sheep of mixed sex and breed (Suffolk and Arcott) were immunized subcutaneously 
with 50 µg of the Lkt recombinant fusions prepared in 650 µl of PBS (0.188M Na2HPO4, 
0.012M NaH2PO4, 1.8% NaCl, pH 7.8) and 300 µL Emulsigen-D for a final injection volume of 
1 mL/vaccine dose.  Vaccines were administered at six-week intervals (with the exception of 
the dose titration study which used four week intervals) by the Animal Care staff at VIDO.  
Although the ideal vaccination interval was determined to be six weeks, it was felt that the four-
week interval used in the dose titration study was sufficient to answer our specific objective for 
that experiment.   
 
2.3.3.2  Norwegian School of Veterinary Science  
 
 Pregnant female ewes were used for the Scrapie challenge experiment. They were 
immunized SC at 6 weeks and 3 weeks prior to delivery of their lambs.  Vaccinations, 
inoculations and sample collections were conducted by the Animal Care staff at the Sheep and 
Goat Research division of the Norwegian School of Veterinary Science in Sandnes, Norway.   
     
2.4  Characterization of Antibody Immune Response 
 
2.4.1  Sample Collection 
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2.4.1.1  Serum 
 
 Serum samples were collected from the jugular vein in 10 mL SST vacutainer tubes 
(BD) and centrifuged at 1,000 x g for 10 minutes.  Serum was then archived at -80 ºC for 
ELISA testing.   
 
2.4.1.2  Nasal Secretions 
 
 Nasal secretions were collected using cotton tampons as described by (Raggo et al., 
2000). 
 
2.4.1.3  Cerebrospinal Fluid  
 
 The cerebrospinal fluids (CSF) were collected from the subarachnoid space (cisterna 
magna) between the arachnoid and pia mater layers of the meninges surrounding the brainstem 
at the level of the atlanto-occipital joint. For this study, the sheep were placed in sternal 
recumbency and the neck fully flexed immediately following euthanasia.  At the centre of the 
triangle formed by the caudal aspect of the occipital protuberance and the wings of the atlas 
(C1), a 1 1/2 inch 19 gauge needle was slowly advanced along a plane parallel to the horizontal 
ramus of the mandible. The needle was passed through the skin, subcutis, nuchal ligament, dura 
mater and finally the arachnoid mater.  It was possible to aspirate 2 to 10 mL/sheep.  Samples 
were visually inspected for contamination by blood.   
 
2.4.2  ELISAs 
 
PrP epitope, Lkt and PrPC-specific antibody responses were quantified by ELISA. The 
96-well Immulon 2HB polystyrene microtiter plates (Thermo Fisher) were coated overnight 
with either 0.5 µg per well of synthetic peptide, 0.125 µg per well of PrP-Pure, a recombinant 
protein (Allprion) or 0.1 µg per well of purified 96 kDa Lkt protein diluted to the proper 
concentration in coating buffer (0.05 M carbonate-bicarbonate, pH 9.6).  Plates were washed 
six times with distilled water (dH20) then blocked with 200 µL per well of TBST (TBS: Tris-
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buffered saline, 10 mmol/L Tris, 150 mmol/L NaCl, 0.05% Tween 20) and 1% skim milk. 
Plates were incubated for one hour at room temperature then washed 6 times with dH20. Serum 
samples were diluted 1:10 in TBST with 1% skim milk and then serially diluted 1:4 in TBST 
plus 1% skim milk.  Plates were incubated for 2 h then washed 6 times with dH20. 100 µL of 
alkaline phosphatase (AP)-conjugated rabbit anti-sheep immunoglobulin gamma (IgG) or AP-
conjugated goat anti-mouse IgG (Kirkgaard and Perry Laboratories; 1:2500) were added to 
each well to detect bound ovine and murine antibodies, respectively.  [For the IgG subtype 
ELISAs AP-conjugated goat anti-mouse IgG1, IgG2a or IgG2b was used instead.  (Kirkgaard 
and Perry Laboratories; 1:2000).]  After a 1 h incubation, plates were washed 6 times with dH20 
then 100 µL p-nitrophenyl phosphate (PNNP) (Sigma) was added to each well for 2 h. ELISA 
titers were expressed as the reciprocal of the highest serum dilution resulting in a reading 
exceeding two standard deviations above the negative control.   
 
2.4.3  Immunoglobulin Purification 
 
 IgG antibody was purified from sera on protein A-Sepharose columns which bind to the 
Fc portion of IgG molecules (Amersham Pharmacia). 
 
2.4.4  Brain Homogenate Preparation 
 
2.4.4.1  Immunoprecipitation Experiments at University of British Columbia 
 
 Brain homogenates containing either Scrapie-infected or uninfected hamster brains were 
produced as described by Paramithiotis et al. (2003). 
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2.4.4.2  Scrapie Challenge Trial at the Norwegian School of Veterinary Science  
 
 Brain homogenates containing Scrapie-infected sheep brains were produced by 
suspending 1 g of frozen sheep brain tissue (-20 C; transverse section of cerebrum anterior to 
hippocampus) in 4 mL of PBS solution (pH 7.4) and mixed in a stomacher (Heggebo et al., 
2000).  The 4 mL preparations were administered to the newborn lambs via a stomach tube 
immediately after birth, prior to their first colostrum feed.  
  
2.4.5  Coupling of YYR Antibody to Dynabeads for Immunoprecipitation 
 
Tosylactivated Dynabeads (Invitrogen) beads (175 µL) were added to PBS (pH 7.4) to 
make a volume of 1 mL.  The beads were washed with 1 mL 2x PBS and 50 µg of purified 
sheep YYR monoclonal antibody along with PBS up to 1 mL in a 2 mL cylindrical tube was 
added.  Tubes were rotated for 20 h at 37°C and then washed with 1 mL 2x 0.1% BSA/PBS.  1 
1 mL of blocking buffer: 0.2 M Tris-HCl, pH 8.5/0.1% BSA was added.  Samples were rotated 
for 4 h at 37°C, washed with 1 mL 2x PBS/0.1% BSA and then store at 4°C in 1 mL PBS. 
 
2.4.6  Immunoprecipitation 
 
Sera from immunized sheep were evaluated for a specific interaction with PrPSc and 
PrPC.  Prior to running the immunoprecipitation experiment, immunoglobulin was separated 
from the serum using column-affinity purification to reduce background. To 10 µL of mAb-
beads, 89 µL of binding buffer (3% Tween 20 and 3% NP40 in PBS) was added with 1 µL of 
10% (w/v) brain homogenate (RML/WT CD1).  Samples were rotated for 3 h at RT and washed 
with PBS (2% Tween20, 2% NP40) 3x.  After the last wash, 80 µL was removed, vortexed, and 
spun for 30 sec.  Tubes were placed in a magnet rack where all remaining liquid was removed 
and 20 µL of 2x loading buffer was added.  Samples were vortexed before heating for 5 min at 
95°C, spun down and placed in a magnet rack for the loading of the supernatants onto gels.  
(All experiments described in section 2.4.3 – 2.4.6 were performed by the laboratory staff of 
Dr. Neil Cashman, our collaborator, at the University of British Columbia) 
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2.5  Genotyping of the University of Saskatchewan Sheep Flock 
 
 Genotype analysis was conducted by the DNA Sequencing and Gene Synthesis 
department at the Plant Biotechnology Instutute.   
 
2.6  Chemicals and Reagents 
 
A list of the chemicals and enzymes used in this project are listed in Table 2.3. 
  
2.7  Statistics 
 
Data presented were non-parametric in their distribution.  Comparisons between 
treatment groups were conducted using Mann-Whitney analysis (GraphPad Prism 5.0 software, 
CA, USA).  P values less than 0.05 were considered significant.   
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Table 2.3: List of chemicals, enzymes and proteins used and the suppliers’ addresses. 
 
Chemical	  	   	   Supplier	  
Acrylamide	   Sigma-­‐Aldrich	  
Ampicillin	   Shelton	  Scientific	  
Agarose	   EMD	  
BSA	   New	  England	  Biolabs	  
Coomassie-­‐Brilliant	  blue	  R250	   Biorad	  
Diethanolamine	   Sigma	  
Emulsigen-­‐D	   MVP	  Laboratories	  
Ethidium	  bromide	   Pharmacia	  Biotech	  
Glycerol	   EMD	  
LB	  broth	   Difco	  
LB	  agar	   Difco	  
Magnesium	  chloride	   Sigma-­‐Aldrich	  
Methanol	   EMD	  
PNPP	  (4-­‐Nitrophenyl	  phosphate	  di(tris)	  salt	   Sigma-­‐Aldrich	  
Skim	  milk	  powder	   Difco	  
Sodium	  acetate	   Sigma-­‐Aldrich	  
Sodium	  dodecyl	  sulfate	   EMD	  
Tween	  20	   Biorad	  
	   	  
Enzymes	   Suppliers	  
BamHI	   New	  England	  Biolabs	  
NcoI	   New	  England	  Biolabs	  
T4	  DNA	  Ligase	   USB	  
	   	  
Antibodies	   Supplier	  
Goat	  anti-­‐mouse	  IgG	  (H+L)	  Alkaline	  
Phosphatase	  (AP)	  conjugated	  
Kirkgaard	  &	  Perry	  Laboratories	  
Rabbit	  anti-­‐sheep	  IgG	  (H+L)	  AP	  conjugated	   Kirkgaard	  &	  Perry	  Laboratories	  
Rabbit	  anti-­‐deer	  IgG	  (H+L)	  	  AP	  conjugated	   Kirkgaard	  &	  Perry	  Laboratories	  
6H4	  mAb	   Prionics	  
Tosylactivated	  Dynabeads	  M-­‐280	   Invitrogen	  
	   	  
Supplier	   Address	  
Allprion	   Allprion	  AG	  Schlieren,	  Switzerland.	  
Amersham	  Pharmacia	   Amersham	  Biosciences,	  Pittsburgh,	  PA,	  	  
USA.	  
BD	  Biosciences	   BD	  Bioscience,	  Mississauga,	  ON,	  Canada.	  
Beckman	  Coulter	   Beckman	  Coulter	  Canada	  Inc.,	  
Mississauga,	  ON,	  Canada	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Biorad	   Bio-­‐Rad	  Laboratories	  Ltd.,	  Mississauga,	  	  
ON,	  Canada	  
EMD	  Bioscience	   VWR	  Canlab,	  Mississauga,	  ON,	  Canada.	  
Eppendorf	   Eppendorf	  Canada,	  Mississauga,	  ON,	  
Canada.	  
Invitrogen	   Invitrogen	  Canada,	  Inc.,	  Burlington,	  ON,	  	  
Canada.	  
Kirkgaard	  &	  Perry	  Laboratories	   KPL,	  Inc.,	  Gaithersburg,	  MD,	  USA.	  
MVP	  Laboratories	   MVP	  Laboratories,	  Omaha,	  NE,	  USA.	  
New	  England	  Laboratories	   NEB	  Ltd.,	  Pickering,	  ON,	  Canada.	  
PerkinElmer	  	  Life	  Sciences	   PerkinElmer,	  Waltham,	  MA,	  USA.	  
PerSeptive	  Biosystems	   Global	  Medical	  Instruments	  Inc.,	  Ramsay,	  
MN,	  USA.	  
Prionics	   Prionics	  AG,	  Schlieren-­‐Zurich,	  Switzerland.	  
Promega	   Fisher	  Scientific,	  Ltd.,	  Nepean,	  ON,	  	  
Canada.	  
Sigma-­‐Aldrich	   Sigma-­‐Aldrich	  Canada	  Ltd.,	  Oakville,	  ON,	  	  
Canada.	  
Shelton	  Scientific	   VWR	  Canlab,	  Mississauga,	  ON,	  Canada.	  
Thermo	  Scientific	   Thermo	  Fisher	  Scientific,	  Waltham,	  MA,	  
USA.	  
usb	   GE	  Healthcare	  Bio-­‐Sciences,	  Baie	  d’Urfe,	  
Quebec,	  Canada.	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3.0  RESULTS 
 
3.1  Sheep Genotyping 
 
One of the risks during vaccine development is that the test vaccine, if not properly 
designed, may induce immunopathology.  This has been observed previously with traditional 
vaccines such as the live-attenuated viruses or inactivated bacteria, rather than for peptide 
vaccines.  From a safety perspective, it was essential that we investigated the possibility that the 
PrP constructs might induce prion disease or immunopathology.  Due to the existence of several 
prion genoptypes (VRQ, ARQ and ARR) within sheep, each with a distinct Scrapie phenotype, 
it was important to know the genotype of sheep used in our studies.  Clinical manifestation of 
prion disease can either be observable as in the VRQ and ARQ genotypes or be asymptomatic 
as in the ARR genotype.  Consequently, sheep in the University of Saskatchewan flock were 
genotyped and only animals of the ARQ genotype were used for vaccine trials.  Although VRQ 
would have been the ideal genotype, it is very rare and none of the local sheep contained those 
particular residues within Prnp [Table 3.1].  Of the 55 sheep genotyped, two of the four rams 
were homozygous for the ARQ genotype with the other two being heterozygous ARQ/ARR.  
Of the ewes, 28 were homozygous for ARQ, 4 were homozygous for ARR and the remaining 
19 were heterozygous ARQ/ARR.  Only animals of the ARQ/ARQ genotype were bred to 
produce the sheep used in the vaccine trials for this project.       
 
3.2  Analysis of Carrier Molecules KLH and Lkt 
 
 Previous studies in mice demonstrated the limited immunogenicity of the YYR epitope 
when chemically coupled to the KLH carrier molecule (Paramithiotis et al., 2003).  Due to the 
published success using the Lkt carrier protein with the GnRH peptide, it was hypothesized that 
Lkt may be an effective carrier for the YYR peptide.  To address this, four experimental groups 
of mice (n=10) were vaccinated SC at week 0. 3 and 6.  One group was vaccinated with 100 µg 
of KLH chemically coupled to the β2(YYR)L peptide.  The other three groups received either 
1, 10, or 100 µg of the Lkt-β2(YYR)L chimera because immunogenicity of Lkt has been shown  
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Table 3.1: Genotyping of the Prnp gene for the University of Saskatchewan sheep flock.  
 
 
 
	  
#	  of	  
Animals	  
Sex	   Codon	  136	   Codon	  154	   Codon	  171	   Phenotype	  
2	   M	   AA	   RR	   QQ	   ARQ	  
2	   M	   AA	   RR	   RQ	   ARR/ARQ	  
25	   F	   AA	   RR	   QQ	   ARQ	  
20	   F	   AA	   RR	   RQ	   ARR/ARQ	  
5	   F	   AA	   RR	   RR	   ARR	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to be dose-dependent (Potter and Manns, 2000).  The vaccine formulation contained 10 µL of 
the adjuvant Emulsigen-D in each dose to enhance immunogenicity of the constructs. 
 Within 24 hours of the primary vaccination, all of the mice in the group receiving 100 
µg Lkt-β2(YYR)L chimera had died.  Possible explanations for this acute death may be the 
amount of guanidine toxicity, or Lkt over-stimulation of the murine immune system causing 
systemic shock and consequently death.  Over the course of the experiment, 2 animals in the 
KLH group and 1 animal in the Lkt 1 µg group also died.  Results for the KLH group showed a 
maximum β2(YYR)L-specific titer of 1,000 reached at week eight with the exception of two 
animals which achieved titers of 3,000 and 3,500 [Figure 3.1a].  The β2(YYR)L-specific titers 
for the Lkt 10 µg group reached peak titers between 3,000-4,200 at week eight [Figure 3.1b].  
The lowest concentration of Lkt-β2(YYR)L chimera created a broader range of titers following 
each vaccination at week 0, 3 and 6 [Figure 3.1c].  As observed in the previous two groups, 
peak titers were achieved at week eight and ranged between 1,000 to 3,300 following the third 
vaccination.  Both the KLH 100 µg and Lkt 10 µg groups displayed a drop in titers by week 10 
following the peak titers at week eight.  The similar reduction in titers was not observed in the 
Lkt 1 µg group where titers remained relatively constant between week eight to ten.  A 
comparison of median titers for each group at week eight revealed that the β2(YYR)L-specific 
antibody response for the Lkt 10 µg group was significantly higher than both the KLH (p < 
0.0018) and Lkt 1 µg  groups (p < 0.0006) [Figure 3.2].  
 
3.3  Antibody Response to the Lkt-β2(YYR)L Chimeric protein in Sheep 
 
 After determining that the Lkt carrier protein significantly improved β2(YYR)L-specific 
antibody responses relative to the KLH carrier in mice, we then tested the Lkt carrier system in 
sheep, a relevant species for TSE.  Seven sheep were immunized with 50 µg of Lkt-β2(YYR)L 
formulated in 30% Emulsigen-D and 0.1 M PBS solution.  The sheep were immunized three 
times at 6 week intervals.   
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Figure 3.1: Peptide-specific murine serum Ab titers for KLH-β2(YYR)L and three 
different doses of Lkt--β2(YYR)L. a) Mice (n=8) were vaccinated with 100 µg of KLH 
chemically coupled to the β2(YYR)L epitope. b) Mice (n=9) were vaccinated with 10 µg Lkt-
β2(YYR)L produced as a genetic fusion to the β2(YYR)L epitope. c) Mice (n=10) were 
vaccinated with 1 µg Lkt-β2(YYR)L produced as a genetic fusion to the β2(YYR)L epitope 
Vaccines were formulated with 10% Emulsigen-D and administered SC at weeks 0, 3 and 6.  
Antibodies were detected using peptide-specific ELISAs and data presented represents 
individual animals.  Arrows indicate immunization intervals. 
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Figure 3.2: Comparison of week 8 β2(YYR)L peptide-specific serum Ab titers among all 
three groups of mice.  Mice were vaccinated SC at 0, 3, and 6 with the indicated carrier 
protein conjugated with β2(YYR)L peptide and formulated in 10% Emulsigen-D.  Each dot 
represents the titer of individual mice within each group and the horizontal bars indicate group 
median values.  The Lkt 10 µg group was significantly higher than both the KLH (p < 0.0018) 
and Lkt 1 µg  groups (p < 0.0006). 
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 ELISA analysis of peptide-specific titers revealed no detectable antibody response 
following all three vaccinations in all animals [Figure 3.3].  To determine if the absence of an 
antibody response was the result of ineffective vaccine delivery, an ELISA was performed to 
analyze antibody responses to the LKT carrier.  Lkt-specific antibody titers increased following 
each vaccination which confirmed effective delivery of the carrier protein [Figure 3.3].  
Therefore, we concluded there may be species variability in recognition of the β2(YYR)L 
epitope and that epitope modifications may be required to improve antibody responses. 
 
3.4  Symmetrical Expansion of the β2(YYR) Epitope to β2(1+YYR+1) in Linear and 
Inverted Presentations 
 
We postulated that increasing the length of the YYR epitope to include more of the 
naturally surrounding residues from the PrP protein might enhance B-cell recognition of the 
peptide.  It has also been reported that epitope orientation and the number of epitope tandem  
repeats can influence antibody production (Jinshu et al., 2004).  Consequently the original YYR 
was expanded to VYYRP (β2(1+YYR+1)) and synthesized as both linear and inverted repeats 
and presented as C-terminal fusions on Lkt.  Each construct was expressed in E. coli, purified, 
and formulated with 30% Emulsigen-D in a 0.1 M PBS solution.  Four groups of sheep were 
injected SC with each vaccine formulation [β2(YYR)L, n=5; β2(YYR)I, n=7; β2(1+YYR+1)L, 
n=5; β2(1+YYR+1)I, n=7] and the vaccine was injected three times at six week intervals.  Due 
to constraints of animal availability, the linear and inverted YYR constructs were tested in 
separate trials.   
 Results for both presentations of the YYR epitope reflected the previous YYR study 
with no detectable increase in antibody following any of the three vaccinations [Figure 3.4 and 
3.5].  Furthermore, the inverted peptide orientation provided no increase in immunogenicity 
when compared to the linear form. This suggested that the limited immunogenicity of the three 
amino acid motif was not altered by orientation within the recombinant protein. 
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Figure 3.3: Immunogenicity of Lkt-β2(YYR)L in sheep.  Sheep (n=7) were vaccinated with 
50 µg of Lkt produced as a genetic fusion to the β2(YYR)L epitope.  Vaccines were formulated 
with 30% Emulsigen-D and administered SC at week 0, 6 and 12.  Antibodies to Lkt and YYR 
were detected using peptide-specific ELISAs and data are presented as median values.  Arrows 
indicate immunization intervals. 
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Figure 3.4: β2(YYR)L-specific Ab titers in sheep serum following immunization with 
recombinant Lkt-β2(YYR)L.  Sheep (n=4) were vaccinated with 50 µg Lkt produced as a 
genetic fusion to the β2(YYR)L epitope.  Vaccines were formulated with 30% Emulsigen-D 
and administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
 
 
 
 
 
 
 
 
 
 
 
0 5 10 15
0.1
1
10
100
1000
10000
100000
1000000
Weeks
Pe
pt
id
e 
sp
ec
ifi
c 
se
ru
m
 A
b 
Ti
te
r
 72 
 
 
Figure 3.5: β2(YYR)I-specific Ab titers in sheep serum following immunization with 
recombinant Lkt-β2(YYR)I.  Sheep (n=7) were vaccinated with 50 µg Lkt produced as a 
genetic fusion to the β2(YYR)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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The addition of a single amino acid to the C- and N-terminal portions of the tandemly 
repeated YYR epitope in its linear orientation had no significant effect on immunogenicity.  
Two sheep showed a response with titers of 6,000 at week 6, with an additional two animals 
responding by week 12 with titers of 5,300 [Figure 3.6].  The two animals which responded 
significantly after the initial vaccination at week 0 displayed a drop in titer following the 
vaccination at week 6.  One animal had peptide-specific antibody titers which were detectable 
prior to vaccination.  That same animal failed to respond to any of the subsequent vaccinations.    
The inverted presentation of the expanded epitope produced consistent and sustained 
antibody responses in 6 of 7 animals throughout the experiment, with peak titers ranging 
between 1,000 to 18,000 by week 16 [Figure 3.7].  Unlike the linear version of this construct, 
titer increases followed booster vaccinations time points and no decrease in titers was observed 
until week 15 following the third vaccination.  Analysis of median titers at week 16 showed 
β2(1+YYR+1)I to be significantly more immunogenic than the inverted form of the basic YYR 
construct (p < 0.0106) [Figure 3.8].    
 
3.5  Vaccine Dose Titration with Lkt-β2(1+YYR+1)I 
 
The effectiveness of the Lkt carrier is dose-dependent in a species-specific manner 
(Potter AA and Manns JG, 2000).  Having designed a chimeric Lkt construct which stimulates 
detectable PrP peptide-specific antibody responses in sheep, the next step in the project was to 
identify a carrier protein dose which optimized β2(1+YYR+1)I-specific antibody responses in 
sheep.  Five doses (12.5, 25, 50, 100 and 200 µg) of the Lkt-β2(1+YYR+1)I construct were 
formulated with 30% Emulsigen-D and administered SC to 5 groups of sheep (n=5) at four 
week intervals. 
Using a β2(1+YYR+1)I-specific titer of 1,000 as a cut-off to define a positive Ab 
response, the lowest dose of Lkt-peptide induced a positive antibody response in only two 
animals by week twelve [Figure 3.9a].  Doubling the Lkt-peptide dose to 25 µg induced a 
minimum positive antibody response in 4/5 animals with one animal achieving an antibody titer 
of 5,300 at week 6 and another animal achieving a titer of 19,000 by week 10 [Figure 3.9b].  
At 50 µg, all five animals exceeded Ab titers of 1,000 with one animal achieving a peak titer of  
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Figure 3.6: β2(1+YYR+1)L-specific Ab titers in sheep serum following immunization with 
recombinant β2(1+YYR+1)L.  Sheep (n=5) were vaccinated with 50 µg Lkt produced as a 
genetic fusion to the β2(1+YYR+)L epitope.  Vaccines were formulated with 30% Emulsigen-
D and administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.7: β2(1+YYR+1)I-specific Ab titers in sheep serum following immunization with 
recombinant Lkt-β2(1+YYR+1)I.  Sheep (n=5) were vaccinated with 50 µg Lkt produced as a 
genetic fusion to the β2(1+YYR+)I epitope.  Vaccines were formulated with 30% Emulsigen-D 
and administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.8: Comparison of week 16 β2(YYR) and β2(1+YYR+1) peptide-specific serum 
Ab titers in their linear and inverted orientations.  Sheep were vaccinated SC at 0, 6, and 12 
weeks with 50 µg of the indicated Lkt chimeric protein and formulated in 30% Emulsigen-D.  
Each dot represents the titer of individual sheep within each group and the horizontal bars 
indicate group median values.  The median β2(1+YYR+1)I titers were significantly greater than 
that of β2(YYR)I and β2(YYR)L (p < 0.011).  Arrows indicate immunization intervals. 
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Figure 3.9: Peptide-specific sheep serum Ab titers for five different Lkt-β2(1+YYR+1)I 
doses. a) Sheep (n=5) were vaccinated with 12.5 µg Lkt-β2(1+YYR+)I. b) Sheep (n=5) were 
vaccinated with 25 µg Lkt-β2(1+YYR+)I. c) Sheep (n=5) were vaccinated with 50 µg Lkt-
β2(1+YYR+)I. d) Sheep (n=5) were vaccinated with 100 µg Lkt-β2(1+YYR+)I. e) Sheep (n=5) 
were vaccinated with 200 µg Lkt-β2(1+YYR+)I.  Vaccines were formulated with 30% 
Emulsigen-D and administered SC at weeks 0, 4 and 8.  Antibodies were detected using 
peptide-specific ELISAs and data presented represents individual animals.  Arrows indicate 
immunization intervals. 
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26,000 and another had a peak titer of 31,000 [Figure 3.9c].  All animals in the 100 µg group 
surpassed a titer of 1,000, with two animals developing titers of 5,000 and one animal had an 
antibody titer of another 37,000 [Figure 3.9d].  Further increasing the Lkt-peptide dose to 200 
µg resulted in decreased peptide-specific antibody responses, with all five animals attaining 
titers less than 500 [Figure 3.9e].  
Therefore, the magnitude of the peptide-specific antibody response was dependent on 
the dose of the carrier protein, with the highest and lowest doses of the carrier protein inducing 
the weakest peptide-specific antibody titers.  A comparison of median peptide-specific titers at 
week 10 revealed no statistically significant difference among the three intermediate Lkt doses 
of 25, 50 and 100 µg [Figure 3.10].  There was, however, a significant difference when 
comparing the 100 µg and 200 µg Lkt groups ( p <0.0079) but no significant difference when 
comparing the 12.5 µg and 25 µg Lkt groups (p < 0.095).  At weeks 6 and 10, there was a 
significant difference between 50 µg and 12.5 µg Lkt groups (p < 0.032), and at 6 and 8 weeks 
there was a significant difference between 50 µg and 200 µg Lkt groups (p < 0.032 and p < 
0.0079, respectively).  While the 100 µg Lkt dose stimulated a marginally higher median 
antibody titer than the 50 µg dose, the difference was outweighed by the economical 
advantages of the lower dose.   
 
3.6  The Effect of Epitope Tandem Repeat Number [β2(1+YYR+1)I x 4] 
 
In an effort to further enhance the immunogenicity of the β2(1+YYR+1)I, we 
hypothesized that increasing the physical size of the construct through the addition of more 
tandem repeats may improve immunogenicity based on the concept of T-cell independent (TI) 
activation.  Typically, antibody responses require Th-cells for the activation of an Ag-specific 
B-cell, however, there is an alternative method of B-cell activation which is much quicker and 
can occur in the absence of Th-cells (Mond et al., 1995).  TI inducing Ags are usually large, 
multivalent molecules present on bacteria, viruses and fungal pathogens.  It is the multivalency 
of these proteins which enable them to induce multiple domains of highly cross-linked 
membrane Ig and consequently produce high levels of B-cell activation (Humphrey, 1981).  
Due to the enhanced membrane Ig cross-linking, low TI Ag concentrations are sufficient to 
achieve the threshold level of activation required for B-cell induction.  These low TI Ag  
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Figure 3.10: Comparison of week 10 β2(1+YYR+1)I peptide-specific sheep serum Ab 
titers among the 12.5, 25, 50, 100 and 200 µg Lkt groups.  Sheep were vaccinated SC at 0, 4, 
and 8 weeks with the different indicated doses of Lkt-β2(1+YYR+1)I protein formulated in 
30% Emulsigen-D.  Each dot represents the titer of individual sheep within each group and the 
horizontal bars indicate group median values.  There was a significant difference in the median 
titers between the 100 µg and 200 µg groups (p < 0.0079).   
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concentrations minimize the degree of modulation and disappearance of Ig from the surface of 
Ag-specific B-cells, allowing for prolonged contact between the Ag and membrane Ig resulting 
in persistent B-cell signalling (Brunswick et al., 1988).  With the concept of TI activation in 
mind, a β2(1+YYR+1)I gene was created with a combination of restriction sites that facilitated 
the insertion of multiple repeats into the pAA352 vector.  Fusing four copies of the gene 
produced a total of 48 β2(1+YYR+1)I epitopes and sequence analysis confirmed all the inserts 
were in-frame. 
Two groups of sheep (n=7) were injected SC with 50 µg of either the Lkt-
[β2(1+YYR+1)I x 4] or the regular β2(1+YYR+1)I construct formulated in 30% Emulsigen-D.  
The sheep were immunized at 6 week intervals.  The antibody response to the β2(1+YYR+1)I 
construct were similar to the previous experiments [Figure 3.3 and 3.11] with the antibody 
response at week 14 ranging between a titer of 300 to 6,500.  Six of 7 animals had peptide-
specific titers exceeding 1,000.  At week 14, in the [β2(1+YYR+1)I x 4] group, titers ranged 
from 0 to 5,000 with 5/7 animals exceeding 1,000 [Figure 3.12].  A comparison of median 
titers at week 14 indicated, however, that doubling the number of peptide epitopes in the Lkt 
chimeric protein did not significantly enhance peptide-specific antibody responses (p < 0.073) 
[Figure 3.13].  There was actually a decrease in the median titers of the [β2(1+YYR+1)I x 4] 
group compared to the β2(1+YYR+1)I group.   
 
3.7  Further expanding the PrP epitope from β2(1+YYR+1) to β2(2+YYR+2) and 
β2(3+YYR+1) 
 
Having observed an increase in immunogenicity following the symmetrical addition of a 
single amino acid to the YYR epitope, four more constructs were designed to further expand 
the YYR epitope.  Building on results from the previous symmetrical expansion, where 
increased immunogenicity was observed, an additional symmetrical construct β2(2+YYR+2) in 
both linear and inverted presentation was synthesized.  Another construct consisted of a non-
symmetrical expansion towards the N-terminus [β2(3+YYR+1)] in both linear and inverted 
forms.  Based on PrPC structural data (Riek et al., 1996), expansion of the YYR epitope in the 
N-terminal direction incorporates residues postulated to be contained within the PrPSc cryptic  
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Figure 3.11: β2(1+YYR+1)I peptide-specific sheep serum Ab titers for the 50 µg Lkt-
β2(1+YYR+1)I group.  Sheep (n=7) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(1+YYR+)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.12: [β2(1+YYR+1)I x 4] peptide-specific sheep serum Ab titers for the 50 µg Lkt-
[β2(1+YYR+1)I x 4] group.  Sheep (n=7) were vaccinated with 50 µg Lkt produced as a 
genetic fusion to the [β2(1+YYR+1)I x 4] epitope.  Vaccines were formulated with 30% 
Emulsigen-D and administered SC at weeks 0, 6 and 12.  Antibodies were detected using 
peptide-specific ELISAs and data presented represents individual animals.  Arrows indicate 
immunization intervals. 
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Figure 3.13: Comparison of week 14 β2(1+YYR+1)I and [β2(1+YYR+1)I x4] peptide-
specific serum Ab titers for the two groups of sheep.  Sheep were vaccinated SC at 0, 6, and 
12 weeks with 50 µg of the indicated Lkt chimeric protein formulated in 30% Emulsigen-D.  
Each dot represents the titer of individual sheep within each group and the horizontal bars 
indicate group median values. 
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epitope.  Expansions in the C-terminal direction would contain residues that may be surface-
exposed and risk induction of antibodies that could cross-react with PrPC.  Four groups of sheep 
(n=7) were injected SC three times at 6 week intervals with the four constructs formulated in 
30% Emulsigen-D.  All groups had 7 animals with the exception of the β2(3+YYR+1)L group 
which had 5.  Six of the 7 animals in the β2(2+YYR+2)L group developed peptide-specific 
titers exceeding 1,000; 5 animals had titers exceeding 5,000 and two animals had titers greater 
than 100,000 [Figure 3.14].   
This was the first trial in which peptide-specific antibody responses exceeded 100,000.  
The inverted orientation of β2(2+YYR+2) induced antibody responses which peaked at 15,000 
by week 16.  As with the linear construct, 5 animals had titers exceeding 5,000 [Figure 3.15].  
Three of 5 animals in the linear version of the non-symmetrical expansion β2(3+YYR+1)L also 
achieved titers of 5,000, with responses at week 16 ranging between 800 to 6,800 [Figure 
3.16].  Despite a smaller range in antibody responses, when compared to the other peptide 
expansions, β2(3+YYR+1)L induced antibody titers exceeding 1,000 in 6/7 immunized 
animals.  Similarly, the inverted asymmetrical construct stimulated an immune response in all 
animals.  Seven animals had antibody titers of 1,000 with 6 animals developing titers of 5,000 
and 3 animals exceeding 20,000 [Figure 3.17].  A comparison of median antibody titers at 
week 16 indicated that only the β2(3+YYR+1)L and β2(3+YYR+1)I (p < 0.0049) groups were 
significantly different [Figure 3.18].  
 
3.8  Immunization of Deer and Elk with β2(1+YYR+1)I  and β2(3+YYR+1)I 
 
Following the identification of immunogenic PrP peptide constructs, the opportunity 
arose to test cross-species reactivity in white-tail deer and elk, two very important target species 
for CWD.  Due to the limited number of available animals, a decision was made to test only the 
50 µg vaccine dose.  The chimeric Lkt-peptide vaccines were formulated with 30% Emulsigen-
D and injected SC at 6 week intervals.  Sample collection was complicated due to the use of 
semi-domesticated animals which required careful restraint during blood collection.  
Consequently, some samples are missing at time points when not all the deer or elk were 
captured.         
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Figure 3.14: β2(2+YYR+2)L peptide-specific sheep serum Ab titers for the 50 µg Lkt-
β2(2+YYR+2)L group.  Sheep (n=7) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+2)L epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.15: β2(2+YYR+2)I peptide-specific sheep serum Ab titers for the 50 µg Lkt-
β2(2+YYR+2)I group.  Sheep (n=7) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+2)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.16: β2(3+YYR+1)L peptide-specific sheep serum Ab titers for the 50 µg Lkt-
β2(3+YYR+1)L group.  Sheep (n=5) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(3+YYR+1)L epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.17: β2(3+YYR+1)I peptide-specific sheep serum Ab titers for the 50 µg Lkt-
β2(3+YYR+1)I group.  Sheep (n=5) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(3+YYR+1)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.18: Comparison of peptide-specific titers at week 16 for sheep immunized with 
Lkt-β2(2+YYR+2) and Lkt-β2(3+YYR+1) constructs in their linear and inverted 
orientations.  Sheep were vaccinated SC at 0, 6, and 12 weeks with 50 µg of the indicated Lkt 
chimeric protein formulated in 30% Emulsigen-D.  Each dot represents the titer of individual 
sheep within each group and the horizontal bars indicate group median values.  There was a 
statistically significant difference between the linear and inverted versions of the β2(3+YYR+1) 
epitopes (p < 0.0049). 
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Deer vaccinated with the β2(1+YYR+1)I construct developed peptide-specific antibody 
titers between 0 to 5,000 with titers in only 2/5 animals exceeding the 1,000 threshold [Figure 
3.19].  The expanded construct β2(3+YYR+1)I produced a greater range in antibody responses 
(0-76,000), with 4/5 animals developing titers greater than 1,000 [Figure 3.20].  Both 
constructs induced lower antibody responses in elk.  The β2(1+YYR+1)I construct failed to 
induce antibody responses, with titers greater than 1,000 in any of the animals [Figure 3.21].  
While the expanded construct produced stronger antibody responses, there was not a significant 
difference (p < 0.095) between vaccine groups, and the antibody titers were less than those 
observed in deer.  Two elk developed titers greater than 1,000 [Figure 3.22]. 
A comparison of the two PrP peptide constructs within the two cervid species indicated 
that in both deer and elk, the β2(3+YYR+1)I construct induced higher median titers than 
β2(1+YYR+1)I [Figure 3.23].  Analysis of the median titers at week 18, however, revealed no 
statistically significant difference between the two epitopes in either species [Figure 3.24].  The 
dose of vaccine used in this trial had previously been optimized in sheep for which the average 
female/male weighs 140/160 lbs.  The average weight for a female/male whitetail deer and 
female/male elk is 140/165 and 500/700 lbs, respectively 
(http://www.antelope.org/weights/estimate_weights.htm).  Factors such as body weight, 
vaccine dose, sex and interspecies genetic variation may have a significant impact on vaccine 
immunogenicity (Van Loveren et al., 2001).  Therefore, additional studies such as dose 
titrations in each species should be conducted before making conclusions regarding the 
immunogenicity of individual PrP peptide constructs. 
 
3.9  Addition of Multiple C-Terminal Amino Acids [β2(2+YYR+9)] 
 
 Previous experiments indicated that expansion of the YYR epitope increased 
immunogenicity with enhanced antibody responses.  To further investigate the limits of this 
concept, a much larger YYR epitope was constructed.  Nine amino acids were added to the C-
terminus, extending the amino acid sequence away from the YYR epitope on the α-helix 1, a 
region that had already been examined by other research groups (Muller-Schiffmann and Korth, 
2008).  The goal of this expansion was not only to develop a construct with improved  
 91 
 
 
Figure 3.19: β2(1+YYR+1)I peptide-specific whitetail deer serum Ab titers for the 50 µg 
Lkt-β2(1+YYR+1)I group.  Deer (n=5) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(1+YYR+1)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.20: β2(3+YYR+1)I peptide-specific whitetail deer serum Ab titers for the 50 µg 
Lkt-β2(3+YYR+1)I group.  Deer (n=5) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(3+YYR+1)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.21: β2(1+YYR+1)I peptide-specific elk serum Ab titers for the 50 µg Lkt-
β2(1+YYR+1)I group.  Elk (n=5) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(1+YYR+1)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.22: β2(3+YYR+1)I peptide-specific elk serum Ab titers for the 50 µg Lkt-
β2(3+YYR+1)I group.  Elk (n=5) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(3+YYR+1)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.23: Median β2(1+YYR+1)I and β2(3+YYR+1)I peptide-specific whitetail deer 
and elk serum Ab titers for the 50 µg Lkt-β2(1+YYR+1)I and Lkt-β2(3+YYR+1)I groups.  
Elk (n=10) and deer (n=10) were vaccinated SC at 0, 6, and 12 weeks with 50 µg of the 
indicated Lkt chimeric protein formulated in 30% Emulsigen-D.  Antibodies were detected 
using peptide-specific ELISAs and data is presented as the median values for the four groups.  
Arrows indicate immunization intervals. 
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Figure 3.24: Comparison of peptide-specific serum Ab titers at week 18 for whitetail deer 
and elk immunized with Lkt-β2(1+YYR+1)I and Lkt-β2(3+YYR+1)I constructs.  Deer and 
elk were vaccinated SC at 0, 6, and 12 weeks with 50 µg of the indicated Lkt chimeric protein 
formulated in 30% Emulsigen-D.  Each dot represents the titer of individual animals within 
each group and the horizontal bars indicate group median values. 
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immunogenicity, but also to test the boundaries of the PrPSc-specific epitope.  If the PrP epitope 
was too large, it was hypothesized that specificity for PrPSc would be lost or that PrP-specific T-
reg cells may be invoked, inhibiting antibody responses.  A large trial was conducted to 
compare the new epitope [β2(2+YYR+9)I] with previously tested epitopes.  By week 16, the 
β2(2+YYR+9)I construct induced antibody titers ranging between 5,000 to 246,000 [Figure 
3.25].  Analysis of peptide-specific antibody titers for all PrP epitope constructs revealed the 
week 16 median titers for the β2(2+YYR+9)I group was significantly higher (p < 0.018) than 
all other groups with the exception of the β2(2+YYR+2)L group which had a median titer of 
17,700 [Figure 3.26].  While more robust immune responses had been stimulated, it was 
critical to determine whether specificity for PrPSc had been maintained; these results are 
discussed later. 
To examine whether the significant increase in immunogenicity observed with 
β2(2+YYR+9)I was attributable to the size of the epitope or its unique amino acid sequence, 
another construct was tested.  This PrP epitope was similar in length and molecular weight but 
the amino acid sequence was expanded toward the N-terminus instead [β2(9+YYR+2)I].  Two 
groups of mice (n=8) were vaccinated three times at three-week intervals, with either 10 µg of 
the Lkt-β2(9+YYR+2)I [Figure 3.27] or β2(2+YYR+9)I [Figure 3.28] formulated in 30% 
Emulsigen.  The β2(9+YYR+2)I construct produced a slower antibody response, with titers 
ranging from 10,000 to 100,000 at week 7, versus week 3 for the same magnitude of response 
in the β2(2+YYR+9)I group.  Another difference observed was in the range of individual 
animal antibody responses.  Between weeks three and six, the variation in individual antibody 
responses within the β2(2+YYR+9)I group was less than the other group.  By week 10, the 
antibody titers were significantly different (p < 0.010), with a median titer of 23,000 for the 
β2(9+YYR+2)I group and 63,000 for the β2(2+YYR+9)I group [Figure 3.29].  These results 
provided further evidence that the amino acid sequence significantly affects the 
immunogenicity of PrPC cryptic epitopes.  
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Figure 3.25: β2(2+YYR+9)I peptide-specific sheep serum Ab titers for the 50 µg Lkt-
β2(2+YYR+9)I group.  Sheep (n=7) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+9)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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Figure 3.26: Comparison of peptide-specific sheep serum Ab titers at week 16 for nine 
different YYR constructs.  Sheep were vaccinated SC at 0, 6, and 12 weeks with 50 µg of the 
indicated Lkt chimeric protein formulated in 30% Emulsigen-D.  Each dot represents the titer of 
individual sheep within each group and the horizontal bars indicate group median values. 
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Figure 3.27: β2(9+YYR+2)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(9+YYR+2)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(9+YYR+2)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.28: β2(2+YYR+9)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+9)I.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic fusion to 
the β2(2+YYR+9)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.29: Comparison of peptide-specific murine serum Ab titers at week 10 for the 10 
µg Lkt-β2(9+YYR+2)I and Lkt-β2(2+YYR+9)I groups.  Mice were vaccinated SC at 0, 3, 
and 6 weeks with 10 µg of the indicated Lkt chimeric protein formulated in 30% Emulsigen-D.  
Each dot represents the titer of individual sheep within each group and the horizontal bars 
indicate group median values.  There was a statistically significant difference between the 
median titers of the two groups (p < 0.010). 
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3.9.1  Immunogenicity Analysis of the Region Between Epitopes β2(2+YYR+2) and 
β2(2+YYR+9) 
 
 The data in Figure 3.32 revealed a significant (p < 0.01) increase in immunogenicity 
following a seven amino acid addition to the β2(2+YYR+2)I in the C-terminal direction.  To 
better understand the structural basis for this increased immunogenicity, six new peptide 
epitopes were designed which increased in sized by single amino acid increments from 
β2(2+YYR+3)I, to β2(2+YYR+8)I.  It was anticipated that there would be either an 
incremental increase in immunogenicity with each additional amino acid or the immunogenicity 
of β2(2+YYR+2)I would remain relatively constant until a threshold in peptide size was 
reached and immunogenicity would escalate to the level seen in β2(2+YYR+9)I.  This series of 
constructs, including the original β2(2+YYR+2)I and β2(2+YYR+9)I, were used to vaccinate 
groups of C57BL/6 mice (n=8) twice with a three week interval.  The original β2(2+YYR+2)I 
construct was the least immunogenic, with peptide-specific titers ranging between 400 to 4,000 
at week 6 [Figure 3.30].  The next two constructs, β2(2+YYR+3)I and β2(2+YYR+4)I 
produced significantly greater antibody responses (p < 0.0002), with titers ranging between 
4,500 to 85,000 (median 43,00), and 14,000 to 81,000 (median 55,898), respectively [Figure 
3.31 and 3.32].  All mice immunized with β2(2+YYR+4)I developed high antibody titers that 
were more consistent than antibody responses in any other group.  Interestingly, the titers for 
the next largest epitope, β2(2+YYR+5)I, were significantly weaker (p < 0.0002) than the 
previous two peptides, with a range between 270 to 11,300 and a median value of 906 [Figure 
3.33].  Constructs β2(2+YYR+6)I and β2(2+YYR+7)I had comparable immunogenicity, with 
antibody titers ranging between 30 to 18,600 (median 13,000) and 1,000 to 55,800 (10,902), 
respectively [Figure 3.34 and 3.35].  The final construct, β2(2+YYR+8)I was moderately 
immunogenic with titers ranging between 10,400 to 70,100 (median 18,683) [Figure 3.36].  
Along with β2(2+YYR+2)I, β2(2+YYR+9)I was used as a comparison construct displaying 
titers ranging between 3,700 to 58,000 (median 32,600) [Figure 3.37] a significant difference 
from β2(2+YYR+2), β2(2+YYR+5)I and β2(2+YYR+6)I I (p < 0.0003; p < 0.0006 and p < 
0.040 respectively) [Figure 3.38].  Comparison of titers at week 10 revealed that there was no  
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Figure 3.30: β2(2+YYR+2)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+2)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+2)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.31: β2(2+YYR+3)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+3)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+3)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.32: β2(2+YYR+4)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+4)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+4)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.33: β2(2+YYR+5)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+5)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+5)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals.  
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Figure 3.34: β2(2+YYR+6)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+6)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+6)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.35: β2(2+YYR+7)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+7)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+7)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.36: β2(2+YYR+8)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+8)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+8)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.37: β2(2+YYR+9)I peptide-specific murine serum Ab titers for the 10 µg Lkt-
β2(2+YYR+9)I group.  Mice (n=8) were vaccinated with 10 µg Lkt produced as a genetic 
fusion to the β2(2+YYR+9)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 3 and 6.  Antibodies were detected using peptide-specific ELISAs 
and data presented represents individual animals.  Arrows indicate immunization intervals. 
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Figure 3.38: Comparison of peptide-specific murine serum Ab titers at week 10 for 8 
constructs.  Mice were vaccinated SC at 0, 3, and 6 weeks with 10 µg of the indicated Lkt 
chimeric protein formulated in 30% Emulsigen-D.  Each dot represents the titer of individual 
sheep within each group and the horizontal bars indicate group median values.  Because week 
10 samples for the β2(2+YYR+8)I group were unavailable, values from week 7 were used to 
calculate the median titers. 
 
 
 
 
 
 
 
 
 
 
!2
(2+
YY
R+
2)I
!2
(2+
YY
R+
3)I
!2
(2+
YY
R+
4)I
!2
(2+
YY
R+
5)I
!2
(2+
YY
R+
6)I
!2
(2+
YY
R+
7)I
!2
(2+
YY
R+
8)I
!2
(2+
YY
R+
9)I
10
100
1000
10000
100000
Pe
pt
id
e 
sp
ec
ifi
c 
se
ru
m
 A
b 
Ti
te
r
 113 
statistical difference between the four most immunogenic constructs, β2(2+YYR+3)I, 
β2(2+YYR+4)I, β2(2+YYR+8)I and β2(2+YYR+9)I [Figure 3.38]. 
 
3.10  The α-Helix 1 YYR Epitope 
 
 It was suggested by Muller-Schiffmann and Korth (2008) that the best target for passive 
and active immunization was the region between amino acids 145 and 160.  This is the α-helix 
1 region containing the first of the YYR epitopes.  They argued that these residues stimulate T-
cell proliferation and are also a preferred B-cell epitope, resulting in significant antibody 
production.  In addition, antibodies to this region had anti-prion activity in ScN2a cells (Muller-
Schiffmann and Korth, 2008).  
 Taking this work into consideration, a construct was designed based on the α-helix 1 
YYR region [α1(2+YYR+2)I].  The construct was fused to Lkt and used to vaccinate sheep 
using a 50 µg dose of chimeric protein formulated in 30% Emulsigen.  This vaccine was 
injected at 6 week intervals.  Antibody responses to this construct were very poor.  One animal 
achieved  an antibody titer of 100,000 but the highest titer among the remaining 6 animals was 
1,600, with three animals failing to break 1,000 [Figure 3.39].  In terms of active antibody 
responses, this epitope on the α-helix 1 was poorly immunogenic when compared to both the 
β2(2+YYR+2)I and β2(2+YYR+9)I constructs.  It has also been shown later that the antibodies 
to the α-helix 1 epitope were not PrPSc-specific [Figure 3.41].  Perhaps it would be possible to 
alter the YYR epitope on the α-helix 1 to improve its immunogenicity and PrPSc-specificity as 
was done with the other YYR epitope. 
 
3.11  Presence of Antibody at Sites Pertinent to TSE Infection (Mucosal Surface, Cerebral 
Spinal Fluid) 
 
 Mucosal surfaces (upper respiratory and gastro-intestinal tracts) with the associated 
organized lymphoid tissue (tonsil, Peyer’s patches, and draining lymph nodes) provide critical 
sites for prion entry and amplification (Heggebo et al., 2003), while the brain serves as the final 
prion destination and site of pathology.  Consequently, the main goal of prion vaccination is  
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Figure 3.39: α1(2+YYR+2)I peptide-specific sheep serum Ab titers for the 50 µg Lkt-
α1(2+YYR+2)I group.  Sheep (n=7) were vaccinated with 50 µg Lkt produced as a genetic 
fusion to the α1(2+YYR+2)I epitope.  Vaccines were formulated with 30% Emulsigen-D and 
administered SC at weeks 0, 6 and 12.  Antibodies were detected using peptide-specific 
ELISAs and data presented represents individual animals.  Arrows indicate immunization 
intervals. 
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to neutralize infectious prions before they cross the mucosa or, in cases where an animal is 
already infected, prevent the accumulation of proteinaceous plaques in the brain.  For this to 
happen there must be sufficient PrPSc-specific neutralizing antibodies at mucosal surfaces and 
associated lymphoid tissue, as well as antibody in the CNS.  Due to physiological/anatomical 
constraints like the blood-brain barrier, which has a permeability coefficient of 0.1 x 10-6 
mL/g/s (Poduslo et al., 2001), Ig concentration gradients following SC immunization are 
expected to be: serum > mucosa > CSF.  Altering the vaccination route to a mucosal delivery 
system would markedly shift the Ig concentration in favour of the mucosa.   
 Although the concentration of PrPSc-specific antibody required for disease prevention is 
not known, it was important to determine the distribution of peptide-specific antibody in 
various body fluids following immunization with the Lkt-peptide vaccine system.  At the end of 
the vaccine trial using the β2(2+YYR+9)I construct, five animals were sacrificed.  CSF, serum 
and nasal secretions were collected and analyzed to determine peptide-specific titers.  As 
expected, the serum antibody titers were highest (ranging from 1,000 - 60,000), followed by 
nasal secretions (250 - 20,000) and finally CSF (100 – 650) [Figure 3.40].  Regression analysis 
showed a significant correlation (r2 = 0.95, p < 0.0052) between serum antibody titers and 
antibody concentrations in the CSF.  Achieving high PrPSc-specific antibody titers in serum 
may therefore, may be critical for the prevention of prion plaque deposition in the CNS.  
Interestingly, immunotherapy studies for Alzheimer’s have shown CSF protection against A-
beta plaque formation despite low concentrations of anti-Amyloid β IgG in the CSF (Poduslo et 
al., 2007). 
 Epitope-specific antibody responses were also detected in the mucosal secretions, 
following vaccination. There was, however, no significant correlation (r2 = 0.52, p < 0.17) 
between the mucosal and serum peptide-specific antibody titers.  Because parenteral vaccine 
administration is not an ideal way to stimulate mucosal immunity, this lack of correlation was 
expected. 
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Figure 3.40: Epitope-specific serum, CSF and mucosal Ab titers at week 23.  Sheep (n=5) 
were vaccinated with 50 µg Lkt produced as a genetic fusion to the β2(2+YYR+9)I epitope.  
Vaccines were formulated with 30% Emulsigen-D and administered SC at weeks 0, 6 and 12 
and 21.  Antibodies were detected using peptide-specific ELISAs and data is presented for 
individual animals. 
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3.12  IgG subtype determination 
 
 To better charaterize the types of IgG antibody responses our constructs were 
stimulating we screened mouse immune sera against anti-IgG1,-IgG2a and -IgG2b antibodies.  
Sera from three different groups of mice immunized with either Lkt-β2(2+YYR+2)I, Lkt-
β2(9+YYR+2)I or Lkt-β2(2+YYR+9)I were analyzed using peptide ELISAs specific for the 
different IgG subtypes.  All sera predominantly consisted of IgG1 antibodies with a median titer 
of 54,000 while IgG2a and IgG2b had median titers of 24 and 30 respectively [Figure 3.41].   
 
3.13  Specificity of the Immune Response for PrPC and PrPSc 
 
3.13.1  PrPC ELISA 
 
 The primary reason for investigating YYR epitope alterations was to improve peptide 
immunogenicity without altering antibody specificity for PrPSc.  It was presumed that increased 
antibody responses would be correlated with protective antibody concentrations at appropriate 
sites to achieve prion neutralization.  We hypothesized that an increase in neutralizing antibody 
titer could be achieved without a loss in antibody specificity for PrPSc.  A reduction in 
specificity could result in antibody binding to PrPC and possibly disrupting normal function or 
stimulating inappropriate signalling events in neurons (Solforosi et al., 2004).  Antibody 
specificity was first analyzed by comparing the reactivity of pre-immune and immune sera with 
recombinant PrPC in an ELISAs.  None of the β-strand 2 constructs, in the 65 animals tested, 
induced a detectable antibody reaction with PrPC [Figure 3.42].  One animal in the α-helix 1 
group did, however, have an antibody response that cross-reacted with PrPC.       
 
3.13.2  PrPC and PrPSc Immunoprecipitation 
 
 To further investigate the specificity of the expanded PrP epitopes, PrPSc 
immunoprecipitation assays were performed using uninfected and Rocky Mountain Laboratory 
(RML) Scrapie-infected mouse brain homogenates.  Sera from sheep immunized with 
β2(2+YYR+9)I and β2(2+YYR+2)I only immunoprecipitated PrPSc, whereas sera from animals  
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Figure 3.41: IgG antibody subtype characterization.  Week 10 immune sera from mice 
(n=11) previously vaccinated at week 0, 3 and 6 with 10 µg of either Lkt-β2(2+YYR+2)I, Lkt-
β2(9+YYR+2)I or Lkt-β2(2+YYR+9)I were screened using a peptide ELISA.  The secondary 
antibody used in the ELISA was IgG subtype specific for IgG1, IgG2a or IgG2b.  Each dot 
represents the titer of an indidual mouse and the bars indicate the median titers for each 
different IgG subtype.   
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Figure 3.42: PrPC reactivity of serum from sheep immunized with different β2-strand 
[β2(YYR)I, β2(1+YYR+1)I, β2(2+YYR+2)L, β2(2+YYR+2)I, β2(1+YYR+1)I x 4, 
β2(2+YYR+9)I] and α1 epitopes (2+YYR+2)I.  Sheep (n=65) were divided into groups and 
then vaccinated with individual constructs at 6 week intervals.  Week 0 and 14 sera from the β2 
construct groups was screened while sera from the α1 group were tested at week 0 and 16.  The 
positive control was SAF32, a PrPC mAb. 
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immunized with β2(1+YYR+)I and β2(YYR)L, to a lesser degree, immunoprecipitated both 
PrPSc and PrPC [Figure 3.43].  The presence of two or three bands per lane on the RML gel can 
be explained by the three glycosylation states (non-, mono- and diglycosylation) that exist in 
both cellular and infectious conformation (Aguzzi et al., 2007).   
The results regarding specificity differ from the PrPC ELISA results in that the ELISA 
detected PrPC reactivity only for serum specific for the α1 epitope.  What was consistent, 
however, was that in both experiments, the antisera for the most immunogenic construct, 
β2(2+YYR+9)I, lacked reactivity against PrPC.  This confirms that it is possible to design a PrP 
epitope which induces strong antibody responses and maintains specificity for PrPSc.  
 
3.14  Immunization Using Lkt-PrPC 
 
An immune response to a protein often results in preferential targeting of one or more 
epitopes, also known as the dominant epitopes, by different components of the acquired 
immune system.  Another mechanism exists, known as epitope-spreading, whereby the 
specificity of the immune response broadens over time to include epitopes neighbouring the 
dominant one (Vanderlugt and Miller, 2002).  With the goal of directing an immune response to 
a cryptic epitope on a self protein, epitope-spreading threatens the specificity of the intended 
response by creating alternative epitopes outside the cryptic region, potentially resulting in 
autoimmunity.  To investigate the possible consequence of epitope spreading within the Lkt 
vaccine model, we conducted an experiment with the objective of breaking immune tolerance 
to PrPC.  A recombinant fusion of Lkt and full-length PrPC (Lkt-PrPC) was created, expressed in 
E. coli, and purified.  Sheep (n=7) were immunized three times at 6 week intervals using the 
vaccine formulation and dose utilized for the YYR peptide vaccines.  ELISA was used to 
screen both pre-immune and immune (week 15) sera with recombinant PrPC protein, but we 
were unable to detect a significant change in antibody titers when comparing week 15 Lkt 
control sera and Lkt-PrPC sera (p < 0.23) [Figure 3.44].  This inability to break PrPC tolerance 
led to the conclusion that epitope spreading, in response to vaccination with the Lkt-YYR based 
constructs, would be restricted by immune tolerance. 
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Figure 3.43: Immunoprecipitation of PrPSc and PrPC using serum from sheep vaccinated 
with different YYR Constructs.  Sera from sheep immunized with β2(YYR)L, 
β2(1+YYR+1)I, β2(2+YYR+2)L, β2(2+YYR+2)I, β2(2+YYR+9)I, and α1(2+YYR+2)I three 
times at six week intervals were evaluated for reactivity with PrPSc and PrPC.  Antibodies 
conjugated to magnetic beads were used in immunoprecipitation assays with brain homogenates 
of uninfected (WT) and Scrapie-infected mice (RML).  3 µL of 10% WT or RML brain 
homogenate was used as a PrP control for each blot.  Magnetic beads or magnetic beads coated 
with serum from naïve sheep serve as negative controls while beads coated with 6D11, a 
commercially available mAb which binds both PrPSc and PrPC, serves as a positive control. 
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Figure 3.44: Antibodies to Lkt-PrPC do not break tolerance against recombinant PrPC.  
Scrapie-susceptible sheep (genotype ARQ) were immunized three times with either Lkt carrier 
(Control; n = 4) or Lkt-PrPC (PrPC; n = 7) at six week intervals.  PrPC-specific antibody titers 
were determined by ELISA using recombinant PrPC protein.  Pre-immune serum (W0) and 
serum collected 2 weeks after the third immunization (W15) were screened at a final dilution of 
1/10.  No PrPC-specific cross-reactivity was detected.    
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3.15  Effectiveness of Maternal Ab Protection Following Oral Scrapie Challenge in 
Newborn Lambs. 
 
 A key application of this work is the ability to produce an antibody response capable of 
delaying the onset of Scrapie symptoms following exposure to PrPSc.  Part way through this 
project, we had the opportunity to collaborate with a group of Scrapie immunologists in 
Norway (Drs. Martha Ulvund, Charles Press and Arild Espenes) affiliated with the Norwegian 
School of Veterinary Science.  They have developed an aggressive method of experimental 
Scrapie inoculation which produces symptoms within a four month period.  Their model is able 
to achieve symptoms so quickly because they inoculate the lambs as newborns.  It is in the first 
9 months of life, during development of the gut associated lymphoid tissue, that sheep are most  
susceptible to Scrapie infection (St Rose et al., 2006).  Throughout this period of development, 
the ileal Peyer’s patch possesses an extensive bed of follicular dendritic cells and specialized 
epithelial which are actively engaged in the uptake and transcytosis of macromolecules from 
the gut (Heggebo et al., 2000), thus efficiently facilitating the uptake of Scrapie particles. 
 At the time when this collaboration was established, the most effective vaccine epitope 
tested was Lkt-β2(2+YYR+2)I.  To assess the effectiveness of Abs stimulated by this construct 
pregnant ewes were vaccinated with either Lkt-β2(2+YYR+2)I or just Lkt at 6 and 3 weeks 
prior to delivery.  At birth, the lambs were immediately taken (before receiving their first 
colostrum feed) and inoculated with a 1 g suspension of infectious Scrapie material via a 
feeding tube.  The lambs were returned to their mother and sibling(s) and monitored via 24 h 
video surveillance for signs of infection which is indicated by spontaneous scratching of the 
head, tail root, back, flanks and feet (Ersdal et al., 2005).   
 The Lkt control group (n=4) were the first to demonstrate signs of illness, with two 
sheep presenting at 103 days post infection and the remaining two at 132 days [Figure 3.45].  
In the Lkt-β2(2+YYR+2)I vaccinated group (n=3) two sheep became ill at 138 days and the 
third at 139 days [Figure 3.45].  Despite the small sample size, a comparison of the median 
onset of symptoms 117.5 day for the Lkt control group and 138 days for the vaccinated group 
demonstrated a statistically significant (p < 0.019) delay in symptoms for the vaccinated group. 
This suggested that the maternal IgG antibodies produced, in the Lkt-β2(2+YYR+2)I  
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Figure 3.45: Symptoms onset following oral Scrapie challenge of newborn labs while 
nursing from mothers vaccinated with either Lkt or Lkt-β2(2+YYR+2)I.  Two Pregnant 
ewes were vaccinated with Lkt and two with Lkt-β2(2+YYR+2)I.  Vaccines were formulated 
with Emulsigen-D and administered SC at 6 and 4 weeks prior to delivery of their lambs.  At 
birth, and prior to the first feeding, all lambs were inoculated with a 4 mL PBS suspension 
containing 1 g of Scrapie infected brain material, administered using a stomach tube.  Lambs 
were continuously monitored via 24 h video surveillance for the onset of Scrapie symptoms.     
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vaccinated sheep, were transferred passively to the nursing lambs and interfered with the uptake 
of PrPSc material.  This resulted in a delay of disease onset. 
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4.0  DISCUSSION 
 
4.1  LKT as a Carrier Molecule   
 
 Prion diseases provide unique challenges for the development of immunotherapeutic 
strategies.  Typical infectious agents are composed almost exclusively of biomolecules which 
are foreign to the body and presents developers of therapeutic agents or vaccines with a broad 
range of potential targets.  Successful progression of prion disease is completely reliant on the 
presence of a ubiquitously expressed protein for which the body has developed significant 
immunological anergy or tolerance (Griffin and Cashman, 2005).  Because the major 
pathogenic agent is a misfolded endogenous protein, researchers have been unable to detect 
PrPSc-specific immune responses at any point during disease manifestation (Bockman and 
Kingsbury, 1988).  It has been suggested that PrPSc is too similar (immunogenically) to PrPC 
and that tolerance mechanisms suppress an immune response, or alternatively that PrPSc is 
present all the time at concentrations too low to stimulate disease but high enough to establish 
self-tolerance (Muller-Schiffmann and Korth, 2008).  This is in contrast to Alzheimer’s disease 
research, which has shown successful immunization using the Aβ peptide in animal and human 
models (Orgogozo et al., 2003; Schenk et al., 1999), indicating that epitopes of oligomeric or 
multimeric Aβ are indeed immunogenic.        
Immunotherapeutic strategies using full-length PrPC have had limited success and 
generate legitimate concerns regarding the potential consequences of circulating anti-PrPC 
antibodies.  Examples of such potential outcomes are: complement-dependent lysis of cells, 
autoimmunity, impairment of PrPC function, apoptosis of neurons, inappropriate activation of 
cell signalling pathways, or suppression of T-cell activation of human lymphocytes (Cashman 
and Caughey, 2004).   
More recent methodologies have enlisted the use of specific PrP peptide fragments to 
stimulate anti-PrPSc antibody responses.  While this may appear to be a safer strategy, due to 
the reduced risk of producing anti-PrPC related effects, poor immunogenicity remains a 
significant challenge.  Efforts to enhance immunogenicity have included the experimentation 
with different adjuvants and carrier systems.  Although numerous adjuvants have been 
investigated, few have been licensed for use in commercial vaccine formulations (Ertl and 
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Lanzavecchia, 2010).  For this project, we utilized a commercially available veterinary adjuvant 
‘Emulsigen–D’ which is an oil-in-water emulsion containing the additive 
dimethyldioctadecylammonium bromide (a known T-cell activator) for increased 
immunostimulation with weak antigens.   
The main function of a hapten carrier system is to stimulate T helper cell activity which 
can interact with hapten-specific B-cells.  This is achieved when hapten-specific B-cells take up 
the entire protein complex and present T-cell epitopes from the carrier protein, in the context of 
major histocompatibility complex II molecules (Potter and Manns, 2000).  To facilitate the 
immunogenic presentation of PrP peptides produced here, a Lkt carrier system was adapted.  
The Lkt carrier has previously been used to deliver self-peptide hormones such as GnRH to a 
variety of species (Robbins et al., 2004).  It was hypothesized that this system may be 
sufficiently immunogenic to effectively break PrP tolerance and stimulate an anti-PrP antibody 
response.   
To validate this system a comparison was first made between the Lkt chimeric protein 
and the peptide chemically conjugated to the KLH delivery system.  While this clearly was not 
an exhaustive analysis of all available carriers, based on literature searches, KLH was one of 
the most widely used carrier molecules in prion research.  The results in mice supported the 
hypothesis that Lkt was a more immunogenic carrier system than KLH.  The 10 µg Lkt 
construct was significantly more immunogenic than the 100 µg KLH model and also produced 
more consistent responses within the group of vaccinated mice.  We also observed a dose-
dependent carrier activity with Lkt, a trait that may actually prove challenging when designing 
a delivery strategy for wild animals.  While trying to deliver a specific dose of prion vaccine 
orally in the wild is outside the objectives of this project, it is worth being aware of potential 
downstream complications in vaccine development.  An initial strategy for addressing such a 
challenge might be drawn from research done in the 1980’s which demonstrated the successful 
delivery of an oral rabies vaccine to wild fox populations (Engel, 1986).  They used modified 
live rabies virus which they injected into a sponge, coated it with wax and placed in plastic 
pouches containing bait.  The pouches could then be dropped by low-flying airplanes in areas 
where rabies was endemic.  Because an oral PrP vaccine delivery system is likely the most 
feasible method of delivery for wild animal populations, it is likely that a different carrier or 
expression model will need to be adapted in the future.  For the purposes of this study where we 
 128 
are more interested in studying the characteristics of different PrP epitopes, the Lkt carrier 
system is perfectly suitable.   
The dose dependent nature of Lkt carrier activity was investigated in both mice and 
sheep.  As further experiments were conducted, using optimized vaccine formulations for each 
animal model, it became apparent that the Lkt constructs were between 3 and 6-fold more 
immunogenic in sheep than in mice.  Although not directly investigated, one could rationalise 
this difference based on the knowledge that Lkt is derived from a common ruminant pathogen 
P. haemolytica (Poulsen et al., 2006) and therefore may more efficiently induce an 
immunological response.  As an example of the prevalence of pre-experimental exposure to P. 
haemolytica we screened 35 sheep at day 0 for Lkt peptide-specific titers and found that all 35 
animals displayed titers ranging from 5000 to 270,000 (data not shown).  It is possible that 
recognition of the PrP peptides is influenced by the pre-existing T-cell repertoire in each host 
species.   
 
4.2  Significance of Epitope Design and Orientation on Immunogenicity 
 
 Although there has been no detectable immune response to either natural or 
experimental prion infection (Bockman and Kingsbury, 1988), extensive research has 
investigated the potential of PrPC in its entirety or as smaller fragments to stimulate antibody 
production.  Souan et al. isolated residues 131-150 and 211-230, because those regions 
contained a MHC II binding motif, which are potential T-cell epitopes.  They used these 
fragments to vaccinate mice and later observed high T-cell proliferation.  They also split PrPC 
into 20mer peptides and used them in murine immunogenicity studies.  Results showed that the 
regions containing the MHC II motif were again the most immunogenic, as were two other 
slightly less effective epitopes 31-50 and 151-170.  They followed up with experiments which 
showed that antibodies to the 131-150 region cleared PrPSc in ScNa2 cells (Souan et al., 2001).  
Another group created 30mer peptides and identified residues 143-172 and 156-187 as having 
strong T-cell proliferative effects in knock-out mice (Gregoire et al., 2004).  Regions extending 
from 145-190, encompassing the α-helix 1, β-strand 2 and α-helix 2 secondary structures, were 
able to stimulate both B-cell and T-cell proliferation in both PrP-knockout and wild-type mice 
(Muller-Schiffmann and Korth, 2008). 
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 In a typical hapten-carrier system, the carrier molecule contains T-cell epitopes specific 
for a different protein than that to which the B-cell epitopes are derived.  Although this 
combination of T and B-cell epitopes facilitates the induction of an antibody response, a 
limiting factor is the lack of a memory T-cell response to the protein containing the B-cell 
epitope.  If, however, there are both T and B-cell epitopes on the hapten, as is suggested might 
be the case for the region encompassed by the β2(2+YYR+9)I construct (Muller-Schiffmann 
and Korth, 2008), then memory T-cells may be stimulated.  This may help prolong the 
effectiveness of the vaccine by lengthening the interval of time required between booster 
immunizations.  This would be especially beneficial for the immunization efforts in wild animal 
populations.   
The PrP region which served as the starting point for this research was the YYR (amino 
acids 165-168) epitope located on the β-strand 2.  It had been demonstrated previously that it 
was possible to generate antibodies to this region and that those antibodies were specific for the 
infectious PrPSc conformation (Paramithiotis et al., 2003).  The potential therapeutic value of 
this residue, however, was limited by poor immunogenicity.  Using a vaccine delivery system 
unique to prion research, different epitope presentation methods, and epitope sequence 
manipulation, many vaccine constructs were created in an effort to increase the immunogenicity 
of the YYR epitope while maintaining its specificity for PrPSc. 
As previously mentioned, an ideal vaccine epitope sequence would contain both a B and 
T-cell epitope to facilitate robust immune responses.  In order to target a specific cryptic 
epitope on PrP, the sequence of the epitope being designed must directly represent the sequence 
at the cryptic region.  In situations where multiple cryptic epitopes exist, the immunogenic 
potential of each may influence the decision regarding its inclusion/exclusion during vaccine 
design.  Epitope design is further complicated by the lack of structural data for PrPSc.  Although 
all of the expanded β-strand 2 constructs were significantly more immunogenic than the core 
YYR epitope [Figure 3.26], it was difficult to anticipate the effect of additional amino acid 
residues.  For example, the asymmetrical expansion β2(2+YYR+9)I, which according to PrPC 
structural modelling studies extends outside of the cryptic region to a surface-exposed area 
(DeMarco et al., 2006), was designed to induce PrPC antibodies.  Interestingly, not only was it 
the most immunogenic construct, but it also retained PrPSc specificity.  Perhaps such sequences 
need to lose structure in addition to being surface exposed for there to be a loss in specificity.  
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Upon dissecting the β2(2+YYR+9)I epitope by single amino acid residues, it was demonstrated 
that expanding the β2(2+YYR+2)I and β2(2+YYR+4)I epitopes by one amino acid produced a 
48-fold increase and 62-fold decrease in immunogenicity, respectively [Figure 3.38].  This 
provided evidence that subtle changes in epitope sequence can have a marked effect on 
immunogenicity, a characteristic also observed in anti-cancer peptide vaccine development 
(Lazoura and Apostolopoulos, 2005).  It is likely that the differing chemical and physical 
properties of individual amino acid’s such as hydophobicity/hydrophilicity, positive or negative 
charge, presence/absence of bulky side-chains, influence the affinity between the epitope and 
B-cell receptor.  The addition of an amino acid which improves the epitope/receptor affinity 
increases the strength of stimulating signal received by the immune cell, resulting in a more 
robust immune response (Partidos et al., 1992).    
 Peptide presentation likely plays an important role in the stimulation of an immune 
response to a given epitope.  Several groups have reported that creating tandem peptide repeats 
induced antigen processing more efficiently, resulting in stronger immunogenicity and 
increased production of neutralising antibodies (Meloen et al., 1994; Qi et al., 2009; Silva-
Flannery et al., 2009).  Epitope presentations in this work consisted of either linear or inverted 
tandem repeats.  Inverted repeats were initially used in order to replicate the YYR epitope 
presentation used in the paper by Paramithiotis et al (2003).  They hypothesized that binding of 
the YYR mAb is dependent on the terminal arginine residue.  Consequently, the 
CYYRRYYRYY sequence was used because arginine flanks the PrP bi-tyrosine motif at both 
the N and C-terminus (Paramithiotis et al., 2003).  As we expanded the epitopes and maintained 
the inverted formula, the original rationale was no longer applicable [Figure 4.1a].  
Comparisons of linear vs. inverted orientation for β2(1+YYR+1), β2(2+YYR+2), and 
β2(3+YYR+1) epitopes demonstrated that the inverted presentations were equal to or 
significantly more immunogenic than the linear version.  Consequently, follow-up constructs 
were designed primarily in the inverted form. 
A possible explanation for the increased immunogenicity of the inverted constructs 
[using β2(2+YYR+9) as an example] may have to do with a longer consecutive sequence of 
hydrophilic amino acids (8) versus the linear construct (5) [Figure 4.1b].  Because B-cell  
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a) 
 
b) 
 
 
 
Figure 4.1: Illustration of linear vs. inverted epitope presentation.  a) The top construct 
demonstrates the linear version containing two repeated epitopes in the same forward 
orientation.  The bottom construct demonstrates the inverted version where there is one epitope 
in the forward orientation followed by two epitopes which are identical to the first except for 
their backwards orientation.  b) The top β2(2+YYR+9) sequence represents the amino acids 
present in the linear construct while the bottom is the sequence of the inverted construct.  The 
red letters indicate hydrophilic amino acid residues.      
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epitopes are generally composed of hydrophilic amino acids (Kindt et al., 2007), the inverted 
presentation may be more efficient in stimulating an epitope-specific B-cell response.  
Analyzing the linear and inverted epitope using Bepipred Linear Epitope Prediction software 
suggests that the linear construct contains one B-cell epitope at amino acid 7-22 while the 
inverted construct contains the same B-cell epitope at position 7-22 and an additional one at 27-
36 (Larsen et al., 2006).  It may be that the later epitope is more immunogenic than the shared 
one or that the ELISA detects the additive effect of two different B-cell clones, one producing 
Ab to the linear epitope and another for the unique inverted epitope.  Because the peptide used 
in the ELISA contains both sequences, it is possible that if the two different Abs do not 
interfere with each others binding, their additive effect produces a stronger signal.       
 Antibodies typically recognize either sequential or discontinuous/conformational 
epitopes.  Sequential epitopes represent a linear sequence of amino acids which are correlated 
to a protein’s primary structure.  Discontinuous epitopes are composed of amino acid residues 
from different parts of the sequence which are brought together by folding of the protein into its 
native conformation.  It is suggested that the conformational epitopes make up 90% of the total 
epitope repertoire recognized by antibodies (Barlow et al., 1986).  Because the peptide 
sequences generated for this research project ranged in length, it is likely that the Ab epitopes 
also varied between linear and conformational.  It would be of interest to evaluate the strongly 
and weakly immunogenic constructs [eg. anti-β2(2+YYR+9)I and β2(YYR1)L)] to determine 
whether the epitopes of the induced antibodies are sequential or conformational.  Because the 
transformation from PrPC to PrPSc requires a conformational shift, it would make sense that the 
most effective antibodies are recognizing a conformationally specific sequence.  
 The quantity of specific Ab induced by an epitope following vaccination directly 
influences the amount of Ab which accumulates in relevant body compartments such as 
mucosal surfaces and CSF.  Due to the small molecular size of IgG (150 kilodaltons), it easily 
diffuses out of the blood and into neighbouring tissues (Janeway et al., 2001).  Diffusion to the 
CNS is limited, however, by the blood-brain barrier which prevents most molecules greater 
than 400 daltons from passing through (Boado et al., 2010).  We evaluated the serum, mucosal 
and CNS titers from 5 animals vaccinated with the β2(2+YYR+9)I epitope.  In each animal, the 
titers were greatest in the serum and lowest in the CNS, with an overall positive correlation 
between serum and CSF titers [Figure 3.40].  Because such a small fraction of the serum Ab 
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enters the CNS, achieving high body titers for as long as possible is essential and may be 
confounded by the presence of peripheral amyloid deposits which can act as Ab sponges 
(Kokjohn and Roher, 2009).  There is a lack of data, however, defining what antibody titer 
would be sufficient for protection.  Making comparisons of Ab magnitude between different 
researchers is difficult because there is no standardized method of presenting Ab levels.  Some 
groups report Ab levels as ELISA optical densities at varying serum concentrations, others 
report Ab levels in µg/mL, while a third method assigns the Ab quantities a titer value. 
An Alzheimer’s immunotherapy study reported by Hu et al. (2008) may help provide 
some perspective for our results.  Using an AD transgenic mouse model which develops disease 
at 6 months, the authors vaccinated mice with one of three different peptides, Aβ1-15, Aβ36-42 
and Aβ42 at 5 months of age.  The initial vaccination consisted of 10-16 subcutaneous injections 
on the back of each mouse followed by weekly boosts beginning at seven months using an 
inhaled vaccine administered into the nostrils.  The titers for all groups peaked at 210 days with 
median values of 9,600 (Aβ1-15), 7,771 (Aβ36-42) and 12,000 (Aβ42) (Hu et al., 2008).  Clinical 
outcome was assessed by grading the performance of the mice in a water maze as well as post-
mortem histological examination of the brains.  All three vaccinated groups displayed 
performance improvements over the non-vaccinated control group, however the Aβ1-15 and 
Aβ42 were superior in their ability to prevent senile plaque formation which coincided with 
better cognitive function (Hu et al., 2008).  In comparison, our most immunogenic construct 
[β2(2+YYR+9)] achieved median titers of 63,000 in mice [Figure 3.28] and 100,000 in sheep 
[Figure 3.25].  While there are pathophysiologic differences between Alzheimer’s and prion 
diseases, the results reported by Hu et al. suggest that our construct may be immunogenically 
adequate.   
 While titer magnitude is an important criteria for assessing potential epitopes, the Ab 
isotype also has implications for the ability of a humoral immune response to protect against 
prion disease.  Although there are five different isotypes of antibodies present in the body (IgA, 
IgM, IgG, IgE and IgD) IgA and IgG are the most relevant for this discussion.  Despite IgA 
representing 10-15% of the circulating immunoglobulin in serum, it is the primary form present 
in secretions such as tears, saliva, milk and mucus from the digestive, genitourinary and 
bronchial tracts (Kindt et al., 2007).  Production of secretory IgA by plasma cells lining the 
mucosal membranes can reach as high as 15 g per day in humans, more than any other isotype.  
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Because prion diseases are transmitted primarily by the oral route in animals (Beekes and 
McBride, 2007), the ability to neutralise PrPSc in the gut mucosa may play an important role in 
delaying disease onset (Goni et al., 2005).   
 The other relevant class of Ab is IgG which represents 80% of the total serum 
immunoglobulin.  This class can be further divided into 4 subtypes IgG1, IgG2, IgG3 and IgG4.  
IgG1 and IgG3 have the greatest affinity for Fc receptors on phagocytic cells, and are better 
complement activators in comparison to the other two.  Also, IgG1 and IgG3 are the only 
immunoglobulins able to cross the placenta and therefore play a role in protecting the human 
fetus (Kindt et al., 2007).  The production of PrP-specific IgG Abs has been shown by several 
laboratories to be effective in delaying symptoms for peripheral Scrapie infections in mice 
(Goni et al., 2008; Pilon et al., 2007).   
 To better characterise the immune responses to our YYR based epitopes we conducted 
isotype specific ELISAs on serum from animals vaccinated with the different constructs.  
Regardless of the epitope used, all of the antibodies produced were predominantly IgG1 
[Figure 3.41].  Immunization studies in AD demonstrated that IgG1 antibodies had stronger 
affinity for Aβ plaques but were less efficient at clearing plaques than IgG2a antibodies (Bard 
et al., 2003).  Should the same be true for prion disease, an IgG1 dominant response with high 
affinity for PrPSc amyloid would be advantageous for the neutralization of infectious particles 
and prevention of PrP isoform conversion.  Although creating antibodies to clear plaques seems 
like an ideal strategy in neurodegenerative disease, AD research has produced conflicting 
results.  For example, one study demonstrated a decline in plaque burden was accompanied by 
increased cognitive function (Janus et al., 2000), whereas, a contrasting study described 
patients displaying cognitive improvements following vaccination without a corresponding 
clearance of amyloid plaques (Dodart et al., 2002).  Consequently, with uncertainty 
surrounding the relationship between amyloid accumulation and clinical symptoms, the type of 
IgG Ab produced by our constructs seems suitable for our downstream therapeutic goals which 
include preventing: the uptake of orally ingested PrPSc, the transition from peripheral PrPSc 
amplification to neuroinvasion, and excretion of PrPSc into the environment. 
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4.3  Consequence of Epitope Selection on Specificity 
  
 The identification of a cryptic epitope on PrPC which becomes exposed when refolded 
into the infectious conformation presents an opportunity for targeted immunotherapy 
(Paramithiotis et al., 2003).  It has been suggested that stimulation of PrPSc-specific antibodies 
may lead to destruction and uptake of infectious particles by tingible body macrophages prior to 
the development of protease resistance in PrPSc.  Isoform specific antibodies may also disrupt 
the interaction between PrPC and PrPSc, thus preventing template-based misfolding of PrPC.  
Experiments have shown that isoform conversion occurs close to or at the cell surface, 
indicating the potential for antibody-PrPSc interaction (Borchelt et al., 1990; Caughey and 
Raymond, 1991).  Successful interruption in the isoform conversion process would suggest that 
immunoprophylaxis for the prevention of disease onset in PrPSc exposed animals may be 
possible.  In animals already infected, the presence of PrPSc-specific antibodies may slow 
disease progression and prevent/reduce the shedding of infectious prion material into the 
environment, thereby disrupting its natural transmission cycle.  The epitopes designed for this 
project utilized prion amino acid sequences which are highly conserved across relevant species 
such as mice, cattle, deer, elk and humans.  Consequently, an effective epitope may have a 
protective application across multiple species once vaccine dose and formulation have been 
optimized.  Subtle species differences do exist however.  For example at residue 174 Elk, Mule 
deer and Whitetail deer have asparagine while other species including sheep, mice and human, 
have a serine residue.  This difference may influence peptide immunogenicity.  Should a single 
amino acid difference be shown to negatively affect immunogenicity, then it would be possible 
to customize epitope composition for each target species.    
Designing an epitope with the ability to induce antibodies discriminating between one 
prion isoform and another was an integral objective of this research.  As is the case for most 
TSEs, where aggregation of the misfolded proteins makes structural analysis impossible, 
predictions of epitope architecture on the PrPSc molecule are challenging.  In the absence of 
such data, decisions can be made based on biophysical models of protein misfolding (as was 
done for this project), simulations of different patterns of exposure, panels of randomly selected 
epitopes and computer modeling.  Because modeling cannot accurately anticipate in vivo 
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scenarios, antibodies produced by each construct must be screened using ELISA and 
immunoprecipitation experiments to determine antibody specificity for either PrPC or PrPSc.  
The YY motif present on α-helix 1 was also shown to be surface-exposed upon 
conversion from PrP to PrPSc (Paramithiotis et al., 2003).  Although only briefly examined in 
this thesis work, many researchers have suggested that because this region is thought to have a 
key role in the conversion process, it is an ideal target for immunotherapy.  The mAb 6H4, 
specific for amino acids 144-52 (in the bovine sequence) was able to protect against Scrapie 
infection in both Scrapie susceptible cells N2a and transgenic mice expressing a fragment 
antigen-binding region of 6H4 (Enari et al., 2001; Heppner et al., 2001).  Interestingly, our 
results following vaccination with α1(2+YYR+2)I demonstrated both weak immunogenicity 
[Figure 3.39] and in one animal no PrPSc-specificity [Figure 3.42].  Because mAb 6H4 binds 
to both the infectious and cellular versions of PrP and overlaps with the α1(2+YYR+2)I 
epitope, is was not surprising that one animal produced an immune response lacking 
conformational specificity.  Also in the same region, just 2 amino acids closer to the N-teminus, 
an Ab called 15B3-1 was described that, in contrast to the previous two epitopes, is PrPSc-
specific (Korth et al., 1997).  A comparison of these neighbouring/overlapping α-helix 1 
epitopes suggest that subtle changes in amino acid composition can have a marked effect on 
specificity [Figure 4.2].       
While the specificity of an antibody response is significant from a prion 
immunotherapeutic perspective, there are also important implications for use in disease 
detection.  Current diagnosis involves post-mortem analysis of brain and lymphoid tissues using 
immunohistochemistry or an ELISA to detect the PrPSc isoform.  While these tests are accurate, 
there is a great need for a reliable pre-mortem diagnostic tools.  The ability to diagnose prion 
disease from samples such as CSF, blood or urine would be ideal, but has proven challenging 
due to the low levels of PrPSc present in the different fluids of infected animals and the inability 
of current diagnostic antibodies to differentiate between PrPC and PrPSc (Herbst et al., 2009).  
The identification of an epitope [β2(2+YYR+9)I] which is not only immunogenic but PrPSc-
specific, allows for its potential application as an immunotherapeutic agent as well as a 
diagnostic tool.  
 An example of a potential diagnostic application for PrPSc-specific Abs has been 
demonstrated by Madampage et al. (2010).  They have utilized nanopore technology consisting  
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Figure 4.2: The portion of the α-helix 1 and β-strand 2 from Bovine PrP illustrating the 
location of the 15B3-1, 6H4, α1(2+YYR+2) and β2(2+YYR+9) epitopes in relation to each 
other.  Only the 15B3-1 and β2(2+YYR+9) epitopes are specific for the PrPSc conformation.   
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of a lipid bilayer that creates a membrane barrier between two chambers filled with buffer and 
the toxin α-hemolysin which inserts into the membrane creating a channel.  By passing a 
charge across the channel they can monitor the current created by ions as they pass through.  If 
a large molecule is in close proximity to the channel or passes through it, characteristic changes 
in the current are detectable and are defined as “bumping” and “translocation” events, 
respectively (Madampage et al., 2010).  They demonstrated that PrPC can pass through the 
channel despite the presence of α-helices, β-hairpins and disulphide bonds.  The addition of Ab 
specific for a portion of the PrP molecule, when bound, prevents the translocation of PrP 
through the channel (Madampage et al., 2010).  Because structural elements of PrP are 
maintained in this type of analysis, conformation-specific Abs may be able to detect PrPSc at 
pre-clinical levels from pre-mortem serum, saliva, milk or urine samples allowing time for 
appropriate intervention. 
 
4.4  Peptide Vaccination followed by In Vivo Scrapie Challenge 
 
 Although demonstrating immunogenicity and specificity are critical variables in the 
development of a prion vaccine, they become irrelevant (from a public health perspective) if 
there is no impact on parameters such as disease transmission, onset of symptoms or disease 
progression.  Given the physiological nature of PrPSc, challenge trials require special level three 
facilities and elaborate decontamination protocols, making experiments in large species like 
sheep, cattle and deer costly and labour intensive.  Despite this, these type of trials are essential 
for evaluating the therapeutic potential of constructs that have been shown to be both 
immunogenic and PrPSc-specific in vaccination trials.   
Although the challenge experiment conducted in Norway was limited by sample size, it 
provided critical information necessary for the planning of future experiments.  Most 
importantly, the results demonstrated that our YYR-based vaccine was able to delay the onset 
of symptoms in all three vaccinated animals.  While the results were statistically significant, 
one may question whether a median 20 day delay of symptoms would have any detectable 
impact in a population of animals.  It should be noted, however, that the epitope used in this 
particular experiment has since been altered through selective amino acid expansion 
[(β2(2+YYR+9)I] to achieve significant improvements in immunogenicity.  As it has been 
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previously demonstrated that the magnitude of Ab response has a direct relationship to the level 
of protection provided (Goni et al., 2008; Sigurdsson et al., 2002), this new expanded epitope 
may achieve a better level of protection than the one originally tested. 
Important information that would complement the results of this trial would be the Ab 
titers from the pregnant ewe’s serum and colostrum at the time of delivery, as well as serum 
IgG and gut IgA Ab titers from the lambs a few days after delivery to determine the degree of 
maternal transfer.  This would help in understanding the relationship between titer magnitude 
and delay in symptom onset.  Immunohistochemistry analysis of gut lymphoid tissue as well as 
representative CNS material would facilitate a comparison of PrPSc accumulation between the 
vaccinated and non-vaccinated groups.  It would also be of interest to monitor urine and 
excrement to see if vaccination has any impact on prion shedding during infection.  Shedding of 
infectious material has a significant impact on both the spread of disease between members of a 
herd but also has implications on land use.  Because PrPSc can survive for extended periods of 
time in the soil, contaminated land can be unusable for grazing purposes for as long as 16 years 
(Georgsson et al., 2006).   
 
4.5  Peptide-based vaccines in cancer immunotherapy 
 
 The development of cancer cells is a complicated process and is thought to be initiated 
by two different mechanisms: viral infection (eg. human T-cell lymphotropic virus and Epstein-
Barr virus have been linked to T-cell leukemia and Burkitt’s lymphoma respectively); and 
genetic mutations attributed to environmental insults (Lazoura and Apostolopoulos, 2005).  The 
majority of tumor antigens identified (eg. Her2/neu, and MAGE2/3) are expressed on both 
normal and cancer cells, however the expression levels are much higher on the cancer cells.  
Because self-peptides are the target of cancer immunotherapeutic strategies, the induced 
immune responses can potentially initiate unwanted autoimmune reactions, as is the case for 
prion vaccines (Lazoura and Apostolopoulos, 2005).   
 The branch of the immune system most involved in the eradication of tumor cells are 
the cytotoxic T-cell lymphocytes (CTLs).  Initially researchers focused on attaining high 
affinity T-cell epitopes derived from tumor associated antigens believing that these would be 
the most successful in producing a robust CTL response.  However, In vivo studies indicated 
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these epitopes were ineffective because T-cells recognizing high affinity epitopes had been 
eliminated/silenced by host tolerance mechanisms.  As a result lower affinity epitopes produced 
more effective immune responses (Lazoura and Apostolopoulos, 2005).  The major 
complication arising from this discovery was that low affinity epitopes are much more difficult 
to screen for due to their inherently weak immunogenicity.  
 A surprising link between PrPSc-specific antibodies and cancer cells was made by 
Cashman et al in 2010.  They discovered that prion proteins are misfolded on the surface of 
certain cancer cells, suggesting that there may be potential for prion antibodies to aid in 
treatment of cancer (http://www.vchri.ca/s/NewsReleases.asp?ReportID=410543).  The idea of 
specifically targeting cancer cells without the toxic side effects produced by many commonly 
used chemotherapeutic agents is highly attractive.    
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5.0  CONCLUSIONS 
 
 Research done as a component of this thesis project, identified a highly immunogenic 
cryptic PrP epitope which produces PrPSc-specific titers in the serum, mucosal surfaces and 
CSF, a requirement which may be critical for successful immunotherapy.  Endogenous peptides 
are inherently difficult to vaccinate against due to tolerance and the potential repercussions of 
an improper immune response resulting in autoimmunity.  While there does not seem to be a 
straight forward methodology that can be used for developing a vaccine to endogenous 
proteins, a few key concepts have been identified.  First, knowledge of protein structure helps 
to identify regions of the self protein that make suitable targets for an immune response.  
Experiments which demonstrated that bi-tyrosine motifs are exposed during the misfolding of 
the prion protein provided a starting point for this project.  However, because there is an 
incomplete understanding of the PrPSc structure, anticipating which amino acid expansions 
would increase immunogenicity and yet retain specificity was challenging.  This problem may 
be unique to misfolding diseases which involve protein aggregation, because determining 
crystal structure is not possible unless single protein molecules can be isolated.   
 Second, with the abundance of bioinformatic tools available, it may seem logical to 
analyse the prion protein amino acid sequence and use whatever antigenic epitope predictions 
are calculated in the vaccine.  These programs operate on the logic that the most antigenic 
regions of a protein are surface exposed residues and predict these regions using parameters 
such as hydrophilicity, accessibility and flexibility (Kolaskar and Tongaonkar, 1990).  This 
approach makes sense for proteins foreign to the immune system.  For endogenous proteins, 
however, it is precisely these predicted surface exposed residues that are likely to invoke the 
strongest tolerance.  Furthermore, in misfolding diseases, the epitope prediction software 
cannot predict what residues would be exposed in the disease conformation because its 
calculations are based on the amino acid sequence which is identical for PrPC and PrPSc.  
Consequently single amino acid manipulations, once a general epitope of interest has been 
identified, seems to be the most effective way to optimize an epitope for immunogenicity and 
specificity.                    
Finally, the true therapeutic value of a vaccine construct can only be determined 
following extensive in vivo challenge experimentation.  Regarding the epitope identified in this 
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work, factors such as symptom progression, prion shedding, and time of death as a result of 
prion disease challenge must be evaluated.  While these experiments have begun in sheep, trials 
will eventually have to be carried out in the target species of interest, such as cervids.  Building 
on the results from the Norway challenge trial, a new in vivo sheep challenge study has begun.  
Animals received vaccinations with the [β2(2+YYR+9)I] construct followed by an oral Scrapie 
challenge.  Key parameters to be followed are the length of peripheral amplification, 
duration/severity of CNS symptoms and overall lifespan of the infected animals.  Success of the 
vaccine would be defined as a statistically significant delay in mortality of the experimental 
groups compared to controls and it would need to be established what the mechanism of this 
delay was.  Is the production of PrPSc-specific antibodies interfering with key pathological 
processes like prion uptake in the gastrointestinal tract, peripheral amplification, progression to 
the CNS or the mechanism of CNS toxicity?  Other important future studies should examine 
methods of vaccination.  Because wild cervids are the most common prion infected species in 
Alberta and Saskatchewan, vaccination administration would have to be capable of reaching 
these populations, likely as an oral formulation.  Dose titrations would need to be conducted in 
both deer and elk as it appears that Lkt behaves in a dose-dependent manner.  Because the PrP 
amino acid sequence in cervids differs by a few residues from the sheep sequences used in this 
project, creating “cervidized” constructs may further enhance immunogenicity and should be 
evaluated.     
Despite the considerable factors that still need addressing, this work outlines the 
important considerations for stimulating immune responses specific for misfolded prion protein.  
Strategies identified here may be relevant in the search for immunotherapeutic vaccines against 
other protein misfolding diseases such as Alzheimer’s, ALS, Huntington’s, and Parkinson’s 
Disease.   
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7.0     APPENDIX A 
 
Tables describing the amino acid and nucleotide sequence for all constructs designed as a 
part of the thesis work. 
 
 
Construct β2(YYR)I 
Amino Acid 
Sequence 
GSYYRRYYRYYSGSYYRRYYRYYGSSYYRRYYRYYSGSYYR
RYYRYYGSSHHHHHH 
Nucleotide 
Sequence 
GGA TCC TAC TAT CGT CGC TAT TAC CGT TAT TAC AGC 
GGT TCT TAC TAT CGC CGC TAT TAC CGT TAT TAC GGC 
TCT AGC TAC TAT CGT CGC TAT TAC CGT TAT TAC AGC 
GGT AGC TAC TAT CGC CGC TAT TAC CGT TAT TAC GGT 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
 
 
 
Construct β2(1+YYR+1)L 
Amino Acid 
Sequence 
GSVYYRPSGSVYYRPGSSVYYRPSGSVYYRPSGSVYYRPGSSVY
YRPSGSVYYRPSGSVYYRPGSSHHHHHH 
Nucleotide 
Sequence 
GGA TCC GTT TAC TAT CGT CCT AGC GGT TCT GTG TAC 
TAT CGC CCG GGC TCT AGC GTT TAC TAT CGT CCG AGC 
GGT AGC GTC TAC TAT CGC CCT AGC GGT TCT GTC TAC 
TAT CGT CCG GGC TCT AGC GTT TAC TAT CGC CCT AGC 
GGT TCT GTT TAC TAT CGT CCG AGC GGT TCT GTC TAC TAT 
CGC CCT GGT TCT AGC CAC CAC CAC CAC CAC CAC TGA 
CCA TGG 
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Construct β2(1+YYR+1)I 
Amino Acid 
Sequence 
GSVYYRPPRYYVPRYYVSGSVYYRPPRYYVPRYYVGSSVYYRP
PRYYVPRYYVSGSVYYRPPRYYVPRYYVGSSHHHHHH 
Nucleotide 
Sequence 
GGA TCC GTT TAC TAT CGT CCT CCG CGC TAT TAC GTT CCT 
CGC TAT TAC GTG AGC GGT TCT GTG TAC TAT CGC CCG 
CCT CGC TAT TAC GTG CCG CGC TAT TAC GTT GGC TCT 
AGC GTT TAC TAT CGT CCT CCG CGC TAT TAC GTT CCT CGC 
TAT TAC GTG AGC GGT AGC GTG TAC TAT CGC CCG CCT 
CGC TAT TAC GTG CCG CGC TAT TAC GTT GGT TCT AGC 
CAC CAC CAC CAC CAC CAC TGA CCA TGG 
 
 
 
Construct β2(2+YYR+2)L 
Amino Acid 
Sequence 
GSQVYYRPVSGSQVYYRPVGSSQVYYRPVSGSQVYYRPVGSSQ
VYYRPVSGSQVYYRPVGSSQVYYRPVSGSQVYYRPVGSSHHHH
HH 
Nucleotide 
Sequence 
GGA TCC CAA GTT TAC TAT CGT CCT GTT AGC GGT TCT 
CAA GTT TAC TAT CGT CCT GTT GGT TCT AGC CAA GTT 
TAC TAT CGT CCT GTT AGC GGT TCT CAA GTT TAC TAT CGT 
CCT GTT GGT TCT AGC CAA GTT TAC TAT CGT CCT GTT AGC 
GGT TCT CAA GTT TAC TAT CGT CCT GTT GGT TCT AGC 
CAA GTT TAC TAT CGT CCT GTT AGC GGT TCT CAA GTT 
TAC TAT CGT CCT GTT GGT TCT AGC CAC CAC CAC CAC 
CAC CAC TGA CCA TGG  
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Construct β2(2+YYR+2)I 
Amino Acid 
Sequence 
GSQVYYRPVVPRYYVQVPRYYVQSGSQVYYRPVVPRYYVQVP
RYYVQGSSQVYYRPVVPRYYVQVPRYYVQSGSQVYYRPVVPR
YYVQVPRYYVQGSSHHHHHH 
Nucleotide 
Sequence 
GGA TCC CAA GTT TAC TAT CGT CCT GTT GTC CCT CGT TAT 
TAC GTT CAA GTT CCT CGT TAT TAC GTT CAA AGC GGT 
TCT CAA GTT TAC TAT CGT CCT GTT GTC CCT CGT TAT TAC 
GTT CAA GTT CCT CGT TAT TAC GTT CAA GGT TCT AGC 
CAA GTT TAC TAT CGT CCT GTT GTC CCT CGT TAT TAC GTT 
CAA GTT CCT CGT TAT TAC GTT CAA AGC GGT TCT CAA 
GTT TAC TAT CGT CCT GTT GTC CCT CGT TAT TAC GTT CAA 
GTT CCT CGT TAT TAC GTT CAA GGT TCT AGC CAC CAC 
CAC CAC CAC CAC TGA CCA TGG 
 
 
 
Construct β2(3+YYR+1)L 
Amino Acid 
Sequence 
GSNQVYYRPSGSNQVYYRPGSSNQVYYRPSGSNQVYYRPGSSN
QVYYRPSGSNQVYYRPGSSNQVYYRPSGSNQVYYRPGSSHHHH
HH 
Nucleotide 
Sequence 
GGA TCC AAT CAA GTT TAC TAT CGT CCT AGC GGT TCT 
AAT CAA GTT TAC TAT CGT CCT GGT TCT AGC AAT CAA 
GTT TAC TAT CGT CCT AGC GGT TCT AAT CAA GTT TAC TAT 
CGT CCT GGT TCT AGC AAT CAA GTT TAC TAT CGT CCT 
AGC GGT TCT AAT CAA GTT TAC TAT CGT CCT GGT TCT 
AGC AAT CAA GTT TAC TAT CGT CCT AGC GGT TCT AAT 
CAA GTT TAC TAT CGT CCT GGT TCT AGC CAC CAC CAC 
CAC CAC CAC TGA CCA TGG 
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Construct β2(3+YYR+1)I 
Amino Acid 
Sequence 
GSNQVYYRPPRYYVQNPRYYVQNSGSNQVYYRPPRYYVQNPR
YYVQNGSSNQVYYRPPRYYVQNPRYYVQNSGSNQVYYRPPRY
YVQNPRYYVQNGSSHHHHHH 
Nucleotide 
Sequence 
GGA TCC AAT CAA GTT TAC TAT CGT CCT CCG CGT TAT 
TAC GTT CAA AAT CCT CGT TAT TAC GTT CAA AAT AGC 
GGT TCT AAT CAA GTT TAC TAT CGT CCT CCG CGT TAT 
TAC GTT CAA AAT CCT CGT TAT TAC GTT CAA AAT GGT 
TCT AGC AAT CAA GTT TAC TAT CGT CCT CCG CGT TAT 
TAC GTT CAA AAT CCT CGT TAT TAC GTT CAA AAT AGC 
GGT TCT AAT CAA GTT TAC TAT CGT CCT CCG CGT TAT 
TAC GTT CAA AAT CCT CGT TAT TAC GTT CAA AAT GGT 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
 
 
 
Construct β2(2+YYR+3)I 
Amino Acid 
Sequence 
GSQVYYRPVDDVPRYYVQDVPRYYVQSGSQVYYRPVDDVPRY
YVQDVPRYYVQGSSQVYYRPVDDVPRYYVQDVPRYYVQSGSQ
VYYRPVDDVPRYYVQDVPRYYVQSGSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC CAA GTT TAC TAT CGT CCT GTT GAT GAT GTA 
CCG CGC TAT TAC GTT CAG GAT GTC CCT CGC TAT TAC 
GTG CAG AGC GGT TCT CAA GTG TAC TAT CGC CCG GTC 
GAT GAT GTA CCT CGC TAT TAC GTG CAA GAT GTT CCG 
CGC TAT TAC GTT CAG GGC TCT AGC CAG GTT TAC TAT 
CGT CCT GTC GAT GAT GTG CCG CGC TAT TAC GTT CAG 
GAT GTA CCT CGC TAT TAC GTG CAA AGC GGT AGC CAG 
GTG TAC TAT CGC CCG GTC GAT GAT GTT CCT CGC TAT 
TAC GTG CAA GAT GTA CCG CGC TAT TAC GTT CAG GGT 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
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Construct β2(2+YYR+4)I 
Amino Acid 
Sequence 
GSQVYYRPVDQQDVPRYYVQQDVPRYYVQSGSQVYYRPVDQ
QDVPRYYVQQDVPRYYVQGSSQVYYRPVDQQDVPRYYVQQD
VPRYYVQSGSQVYYRPVDQQDVPRYYVQQDVPRYYVQGSSHH
HHHH 
Nucleotide 
Sequence 
GGA TCC  CAA GTT TAC TAT CGT CCT GTT GAT CAG CAG 
GAT GTA CCG CGC TAT TAC GTT CAG CAG GAT GTC CCT 
CGC TAT TAC GTG CAG AGC GGT TCT CAA GTG TAC TAT 
CGC CCG GTC GAT CAG CAG GAT GTA CCT CGC TAT TAC 
GTG CAA CAG GAT GTT CCG CGC TAT TAC GTT CAG GGC 
TCT AGC CAG GTT TAC TAT CGT CCT GTC GAT CAG CAG 
GAT GTG CCG CGC TAT TAC GTT CAG CAG GAT GTA CCT 
CGC TAT TAC GTG CAA AGC GGT AGC CAG GTG TAC TAT 
CGC CCG GTC GAT CAG CAG GAT GTT CCT CGC TAT TAC 
GTG CAA CAG GAT GTA CCG CGC TAT TAC GTT CAG GGT 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
 
 
 
Construct β2(2+YYR+5)I 
Amino Acid 
Sequence 
GSQVYYRPVDQYYQDVPRYYVQYQDVPRYYVQSGSQVYYRPV
DQYYQDVPRYYVQYQDVPRYYVQGSSQVYYRPVDQYYQDVPR
YYVQYQDVPRYYVQSGSQVYYRPVDQYYQDVPRYYVQYQDV
PRYYVQGSSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC CAA GTT TAC TAT CGT CCT GTT GAT CAG TAT TAT 
CAG GAT GTA CCG CGC TAT TAC GTT CAG TAT CAG GAT 
GTC CCT CGC TAT TAC GTG CAG AGC GGT TCT CAA GTG 
TAC TAT CGC CCG GTC GAT CAG TAT TAT CAG GAT GTA 
CCT CGC TAT TAC GTG CAA TAT CAG GAT GTT CCG CGC 
TAT TAC GTT CAG GGC TCT AGC CAG GTT TAC TAT CGT CCT 
GTC GAT CAG TAT TAT CAG GAT GTG CCG CGC TAT TAC 
GTT CAG TAT CAG GAT GTA CCT CGC TAT TAC GTG CAA 
AGC GGT AGC CAG GTG TAC TAT CGC CCG GTC GAT CAG 
TAT TAT CAG GAT GTT CCT CGC TAT TAC GTG CAA TAT 
CAG GAT GTA CCG CGC TAT TAC GTT CAG GGT TCT AGC 
CAC CAC CAC CAC CAC CAC TGA CCA TGG 
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Construct β2(2+YYR+6)I 
Amino Acid 
Sequence 
GSQVYYRPVDQYSSYQDVPRYYVQSYQDVPRYYVQSGSQVYY
RPVDQYSSYQDVPRYYVQSYQDVPRYYVQGSSQVYYRPVDQY
SSYQDVPRYYVQSYQDVPRYYVQSGSQVYYRPVDQYSSYQDV
PRYYVQSYQDVPRYYVQGSSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC CAA GTT TAC TAT CGT CCT GTT GAT CAG TAT 
AGT AGT TAT CAG GAT GTA CCG CGC TAT TAC GTT CAG 
AGT TAT CAG GAT GTC CCT CGC TAT TAC GTG CAG AGC 
GGT TCT CAA GTG TAC TAT CGC CCG GTC GAT CAG TAT 
AGT AGT TAT CAG GAT GTA CCT CGC TAT TAC GTG CAA 
AGT TAT CAG GAT GTT CCG CGC TAT TAC GTT CAG GGC 
TCT AGC CAG GTT TAC TAT CGT CCT GTC GAT CAG TAT 
AGT AGT TAT CAG GAT GTG CCG CGC TAT TAC GTT CAG 
AGT TAT CAG GAT GTA CCT CGC TAT TAC GTG CAA AGC 
GGT AGC CAG GTG TAC TAT CGC CCG GTC GAT CAG TAT 
AGT AGT TAT CAG GAT GTT CCT CGC TAT TAC GTG CAA 
AGT TAT CAG GAT GTA CCG CGC TAT TAC GTT CAG GGT 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
 
 
 
Construct β2(2+YYR+7)I 
Amino Acid 
Sequence 
GSQVYYRPVDQYSNNSYQDVPRYYVQNSYQDVPRYYVQSGSQ
VYYRPVDQYSNNSYQDVPRYYVQNSYQDVPRYYVQGSSQVYY
RPVDQYSNNSYQDVPRYYVQNSYQDVPRYYVQSGSQVYYRPV
DQYSNNSYQDVPRYYVQNSYQDVPRYYVQGSSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC CAA GTT TAC TAT CGT CCT GTT GAT CAG TAT 
AGT AAC AAC AGT TAT CAG GAT GTA CCG CGC TAT TAC 
GTT CAG AAC AGT TAT CAG GAT GTC CCT CGC TAT TAC 
GTG CAG AGC GGT TCT CAA GTG TAC TAT CGC CCG GTC 
GAT CAG TAT AGT AAC AAC AGT TAT CAG GAT GTA CCT 
CGC TAT TAC GTG CAA AAC AGT TAT CAG GAT GTT CCG 
CGC TAT TAC GTT CAG GGC TCT AGC CAG GTT TAC TAT 
CGT CCT GTC GAT CAG TAT AGT AAC AAC AGT TAT CAG 
GAT GTG CCG CGC TAT TAC GTT CAG AAC AGT TAT CAG 
GAT GTA CCT CGC TAT TAC GTG CAA AGC GGT AGC CAG 
GTG TAC TAT CGC CCG GTC GAT CAG TAT AGT AAC AAC 
AGT TAT CAG GAT GTT CCT CGC TAT TAC GTG CAA AAC 
AGT TAT CAG GAT GTA CCG CGC TAT TAC GTT CAG GGT 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
 
 
 
 172 
 
Construct β2(2+YYR+8)I 
Amino Acid 
Sequence 
GSQVYYRPVDQYSNQQNSYQDVPRYYVQQNSYQDVPRYYVQS
GSQVYYRPVDQYSNQQNSYQDVPRYYVQQNSYQDVPRYYVQG
SSQVYYRPVDQYSNQQNSYQDVPRYYVQQNSYQDVPRYYVQS
GSQVYYRPVDQYSNQQNSYQDVPRYYVQQNSYQDVPRYYVQG
SSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC CAA GTT TAC TAT CGT CCT GTT GAT CAG TAT 
AGT AAC CAG CAG AAC AGT TAT CAG GAT GTA CCG CGC 
TAT TAC GTT CAG CAG AAC AGT TAT CAG GAT GTC CCT 
CGC TAT TAC GTG CAG AGC GGT TCT CAA GTG TAC TAT 
CGC CCG GTC GAT CAG TAT AGT AAC CAG CAG AAC AGT 
TAT CAG GAT GTA CCT CGC TAT TAC GTG CAA CAG AAC 
AGT TAT CAG GAT GTT CCG CGC TAT TAC GTT CAG GGC 
TCT AGC CAG GTT TAC TAT CGT CCT GTC GAT CAG TAT 
AGT AAC CAG CAG AAC AGT TAT CAG GAT GTG CCG CGC 
TAT TAC GTT CAG CAG AAC AGT TAT CAG GAT GTA CCT 
CGC TAT TAC GTG CAA AGC GGT AGC CAG GTG TAC TAT 
CGC CCG GTC GAT CAG TAT AGT AAC CAG CAG AAC AGT 
TAT CAG GAT GTT CCT CGC TAT TAC GTG CAA CAG AAC 
AGT TAT CAG GAT GTA CCG CGC TAT TAC GTT CAG GGT 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG  
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Construct β2(2+YYR+9)I 
Amino Acid 
Sequence 
GSQVYYRPVDQYSNQNNQNSYQDVPRYYVQNQNSYQDVPRY
YVQSGSQVYYRPVDQYSNQNNQNSYQDVPRYYVQNQNSYQD
VPRYYVQGSSQVYYRPVDQYSNQNNQNSYQDVPRYYVQNQNS
YQDVPRYYVQSGSQVYYRPVDQYSNQNNQNSYQDVPRYYVQ
NQNSYQDVPRYYVQSGSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC CAA GTA TAT TAT CGT CCG GTG GAT CAG TAT 
AGC AAC CAG AAC AAC CAG AAC AGC TAC CAG GAT GTG 
CCG CGT TAC TAC GTT CAG AAC CAG AAC TCT TAT CAA 
GAT GTA CCG CGT TAC TAC GTG CAG TCC GGC AGC CAA 
GTG TAC TAC CGC CCG GTT GAT CAG TAC AGC AAC CAA 
AAC AAC CAG AAC AGC TAT CAA GAC GTA CCG CGT TAT 
TAC GTT CAA AAC CAG AAC TCC TAC CAG GAT GTA CCG 
CGT TAC TAC GTT CAG GGT TCC TCT CAG GTG TAT TAT 
CGT CCG GTT GAC CAG TAT TCT AAC CAA AAC AAC CAG 
AAT TCT TAC CAG GAC GTG CCG CGC TAC TAC GTA CAG 
AAT CAG AAC TCC TAC CAG GAC GTG CCG CGC TAT TAC 
GTT CAG TCT GGT TCC CAG GTG TAC TAT CGT CCA GTG 
GAC CAG TAC TCC AAC CAG AAC AAC CAG AAT TCT TAC 
CAG GAT GTT CCG CGC TAC TAC GTT CAG AAT CAG AAC 
AGC TAC CAG GAC GTT CCA CGT TAT TAT GTT CAG GGT 
TCT AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
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Construct β2(9+YYR+2)I 
Amino Acid 
Sequence 
GSNMYRYPNQVYYRPVVPRYYVQNPYRYMNVPRYYVQNPYR
YMNSGSNMYRYPNQVYYRPVVPRYYVQNPYRYMNVPRYYVQ
NPYRYMNGSSNMYRYPNQVYYRPVVPRYYVQNPYRYMNVPR
YYVQNPYRYMNSGSNMYRYPNQVYYRPVVPRYYVQNPYRYM
NVPRYYVQNPYRYMNSGSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC AAC ATG TAC CGT TAC CCT AAC CAG GTG TAT 
TAT CGT CCG GTA GTT CCA CGT TAC TAT GTG CAG AAC 
CCG TAT CGC TAC ATG AAT GTT CCG CGT TAC TAT GTC 
CAG AAC CCA TAC CGT TAC ATG AAC TCT GGT TCC AAT 
ATG TAC CGT TAC CCG AAC CAG GTC TAC TAC CGT CCG 
GTT GTG CCA CGT TAC TAC GTG CAG AAT CCG TAC CGC 
TAC ATG AAC GTA CCT CGT TAC TAC GTT CAG AAC CCG 
TAT CGT TAT ATG AAC GGC AGC TCT AAC ATG TAC CGT 
TAT CCG AAC CAG GTT TAT TAC CGT CCG GTA GTT CCG 
CGC TAT TAC GTA CAA AAC CCG TAT CGT TAC ATG AAC 
GTC CCG CGC TAC TAT GTT CAG AAC CCG TAC CGT TAT 
ATG AAC TCC GGT TCT AAC ATG TAC CGC TAT CCG AAC 
CAG GTT TAC TAC CGC CCT GTG GTT CCG CGC TAT TAC GTT 
CAG AAC CCA TAT CGC TAC ATG AAC GTG CCG CGT TAT 
TAC GTA CAA AAT CCG TAC CGT TAC ATG AAC GGT TCT 
AGC CAC CAC CAC CAC CAC CAC TGA CCA TGG 
 
 
 
Construct α1(2+YYR+2)I 
Amino Acid 
Sequence 
GSDRYYRENNERYYRDNERYYRDSGSDRYYRENNERYYRDNE
RYYRDGSSDRYYRENNERYYRDNERYYRDSGSDRYYRENNER
YYRDNERYYRDGSSHHHHHH 
 
Nucleotide 
Sequence 
GGA TCC GAT CGT TAC TAT CGC GAA AAC AAT GAG CGT 
TAC TAC CGT GAC AAC GAA CGC TAT TAC CGT GAT TCT 
GGC TCC GAC CGT TAC TAT CGT GAA AAC AAC GAA CGT 
TAC TAT CGT GAT AAC GAG CGC TAC TAC CGC GAC GGT 
AGC TCT CAT GAT CGT TAC TAT CGC GAA AAC AAT GAG 
CGT TAC TAC CGT GAC AAC GAA CGC TAT TAC CGT GAT 
TCT GGC TCC GAC CGT TAC TAT CGT GAA AAC AAC GAA 
CGT TAC TAT CGT GAT AAC GAG CGC TAC TAC CGC GAC 
GGT AGC TCT CAT CAC CAC CAC CAC CAC TGA CCA TGG 
 
 
